TL1A-binding antibody and method of use

Abstract

Tumor necrosis factor (TNF)-like cytokine 1A (TL1A) is a transmembrane protein that is part of the TNF superfamily and is expressed by bone marrow mononuclear cells and endothelial cells. TL1A-binding proteins (e.g., antibodies that bind to TL1A) and methods of use are provided herein. Aspects of this disclosure relate to compositions comprising the TL1A-binding proteins described herein and pharmaceutically acceptable carriers. Aspects of this disclosure relate to isolated nucleic acids encoding the TL1A-binding proteins described herein. Aspects of this disclosure relate to recombinant host cells comprising isolated nucleic acids.

Description

[Technical Field]

[0001] Cross-references to related applications This application is a compilation of the following U.S. Provisional Patent Applications, filed on 11 August 2023 (No. 63 / 519,056), filed on 23 October 2023 (No. 63 / 592,535), filed on 16 November 2023 (No. 63 / 599,923), and filed on 29 November 2023 (No. 63 / 60), the entire contents of which are incorporated herein by reference. This application claims the benefits and priority of U.S. Patent Provisional Application No. 4,104; U.S. Patent Provisional Application No. 63 / 554,897 filed on 16 February 2024; U.S. Patent Provisional Application No. 63 / 554,916 filed on 16 February 2024; U.S. Patent Provisional Application No. 63 / 559,060 filed on 28 February 2024; and U.S. Patent Provisional Application No. 63 / 559,071 filed on 28 February 2024.

[0002] Sequence List This application is filed electronically in XML format and includes a sequence listing, which is incorporated by reference in its entirety. The XML copy created on August 8, 2024, is called 220703-010508_PCT_SL.xml and has a size of 2,191,11 3 It is Ito. [Background technology]

[0003] background Tumor necrosis factor (TNF)-like cytokine 1A (TL1A) is a transmembrane protein that is part of the TNF superfamily and is expressed by bone marrow mononuclear cells and endothelial cells. TL1A interacts with its receptors, death receptor 3 (DR3) and decoy receptor 3 (DcR3), to induce signaling. TL1A is elevated in individuals with inflammatory diseases, including Crohn's disease and ulcerative colitis, and DR3 expression is upregulated in inflammatory tissues. Therefore, TL1A, along with other members of the TNF superfamily, is being investigated as a therapeutic target for treating inflammatory diseases, including inflammatory bowel disease. Current biologics targeting TNF are associated with serious side effects, highlighting the need for improved therapies targeting TL1A. [Overview of the project]

[0004] Summary of this disclosure Essential TL1A-binding proteins, a) (i) CDR1 having the amino acid sequence described in SEQ ID NO: 5, or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 5, (ii) SEQ ID NO: 1 5 CDR2 or SEQ ID NO: 1 having the amino acid sequence described above. 5 CDR2 having one to two amino acid substitutions compared to the sequence, and (iii) Sequence ID 25 CDR3 or SEQ ID NO: having the amino acid sequence described above 25 The heavy chain variable region (VH) containing CDR3 with one to two amino acid substitutions compared to the sequence, and b)(i) Sequence ID 35 CDR1 or SEQ ID NO: having the amino acid sequence described above 35 CDR1, which has one to two amino acid substitutions compared to the sequence, (ii) Sequence ID 45 CDR2 or SEQ ID NO: having the amino acid sequence described above 45 CDR2 having one to two amino acid substitutions compared to the sequence, and (iii) Sequence ID 55 CDR3 or SEQ ID NO: having the amino acid sequence described above 55This specification describes TL1A-binding proteins comprising a light chain variable region (VL) containing a CDR3 having one to two amino acid substitutions compared to the sequence of (1). In some embodiments, the TL1A-binding protein comprises a)(i) a CDR1 having the amino acid sequence described in SEQ ID NO: 5, and (ii) SEQ ID NO: 1 5 CDR2 having the amino acid sequence described above, and (iii) Sequence ID 25 A heavy chain variable region (VH) containing CDR3 having the amino acid sequence described above, and b)(i) Sequence ID 35 CDR1 having the amino acid sequence described above, (ii) Sequence ID 45 CDR2 having the amino acid sequence described above, and (iii) Sequence ID 55 The TL1A-binding protein includes a light chain variable region (VL) containing CDR3 having the amino acid sequence described above. In some embodiments, the TL1A-binding protein includes an immunoglobulin Fc domain. In some embodiments, the Fc domain includes amino acid modified L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0005] TL1A-binding proteins, a) (i) CDR1 having the amino acid sequence described in SEQ ID NO: 6, or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 6, (ii) SEQ ID NO: 1 6 CDR2 or SEQ ID NO: 1 having the amino acid sequence described above. 6 CDR2 having one to two amino acid substitutions compared to the sequence, and (iii) Sequence ID 26 CDR3 or SEQ ID NO: having the amino acid sequence described above 26 The heavy chain variable region (VH) containing CDR3 with one to two amino acid substitutions compared to the sequence, and b)(i) Sequence ID 36 CDR1 or SEQ ID NO: having the amino acid sequence described above 36 CDR1, which has one to two amino acid substitutions compared to the sequence, (ii) Sequence ID 46 CDR2 or SEQ ID NO: having the amino acid sequence described above 46 CDR2 having one to two amino acid substitutions compared to the sequence, and (iii) Sequence ID56 CDR3 having the amino acid sequence set forth in or SEQ ID NO: 56 Disclosed herein is a TL1A-binding protein comprising a light chain variable region (VL) comprising a CDR3 having 1 to 2 amino acid substitutions as compared to the sequence of . In some embodiments, the TL1A-binding protein comprises: a) (i) CDR1 having the amino acid sequence set forth in SEQ ID NO: 6, (ii) SEQ ID NO: 1 6 CDR2 having the amino acid sequence set forth in, and (iii) SEQ ID NO: 26 a heavy chain variable region (VH) comprising CDR3 having the amino acid sequence set forth in, and b) (i) SEQ ID NO: 36 CDR1 having the amino acid sequence set forth in, (ii) SEQ ID NO: 46 CDR2 having the amino acid sequence set forth in, and (iii) SEQ ID NO: 56 a light chain variable region (VL) comprising CDR3 having the amino acid sequence set forth in. In some embodiments, the TL1A-binding protein comprises an immunoglobulin Fc domain. In some embodiments, the Fc domain comprises amino acid modifications L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0006] A TL1A-binding protein, comprising: a) (i) CDR1 having the amino acid sequence set forth in SEQ ID NO: 7 or CDR1 having 1 to 2 amino acid substitutions as compared to the sequence of SEQ ID NO: 7, (ii) SEQ ID NO: 1 7 CDR2 having the amino acid sequence set forth in or SEQ ID NO: 1 7 CDR2 having 1 to 2 amino acid substitutions as compared to the sequence of, and (iii) SEQ ID NO: 27 CDR3 having the amino acid sequence set forth in or SEQ ID NO: 27 a heavy chain variable region (VH) comprising CDR3 having 1 to 2 amino acid substitutions as compared to the sequence of, and b) (i) SEQ ID NO: 37 CDR1 having the amino acid sequence set forth in or SEQ ID NO: 37 CDR1 having 1 to 2 amino acid substitutions as compared to the sequence of, (ii) SEQ ID NO: 47 CDR2 having the amino acid sequence set forth in or SEQ ID NO:47 a CDR2 having 1 to 2 amino acid substitutions compared to the sequence, and (iii) SEQ ID NO: 57 a CDR3 having the amino acid sequence set forth in or SEQ ID NO: 57 a light chain variable region (VL) comprising a CDR3 having 1 to 2 amino acid substitutions compared to the sequence of are described herein. In some embodiments, the TL1A-binding protein comprises a) (i) a CDR1 having the amino acid sequence set forth in SEQ ID NO: 7, (ii) SEQ ID NO: 1 7 a CDR2 having the amino acid sequence set forth in, and (iii) SEQ ID NO: 27 a heavy chain variable region (VH) comprising a CDR3 having the amino acid sequence set forth in, and (i) SEQ ID NO: 37 a CDR1 having the amino acid sequence set forth in, (ii) SEQ ID NO: 47 a CDR2 having the amino acid sequence set forth in, and (iii) SEQ ID NO: 57 a light chain variable region (VL) comprising a CDR3 having the amino acid sequence set forth in. In some embodiments, the TL1A-binding protein comprises an immunoglobulin Fc domain. In some embodiments, the Fc domain comprises amino acid modifications L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0007] A TL1A-binding protein, wherein a) (i) a CDR1 having the amino acid sequence set forth in SEQ ID NO: 8 or a CDR1 having 1 to 2 amino acid substitutions compared to the sequence of SEQ ID NO: 8, (ii) SEQ ID NO: 1 8 a CDR2 having the amino acid sequence set forth in or SEQ ID NO: 1 8 a CDR2 having 1 to 2 amino acid substitutions compared to the sequence of, and (iii) SEQ ID NO: 2 8 a CDR3 having the amino acid sequence set forth in or SEQ ID NO: 2 8 a heavy chain variable region (VH) comprising a CDR3 having 1 to 2 amino acid substitutions compared to the sequence of, and b) (i) SEQ ID NO: 38 a CDR1 having the amino acid sequence set forth in or SEQ ID NO: 38CDR1, which has one to two amino acid substitutions compared to the sequence, (ii) Sequence ID 48 CDR2 or SEQ ID NO: having the amino acid sequence described above 48 CDR2 having one to two amino acid substitutions compared to the sequence, and (iii) Sequence ID 58 CDR3 or SEQ ID NO: having the amino acid sequence described above 58 This specification describes TL1A-binding proteins comprising a light chain variable region (VL) containing a CDR3 having one to two amino acid substitutions compared to the sequence of (1). In some embodiments, the TL1A-binding protein comprises a)(i) a CDR1 having the amino acid sequence described in SEQ ID NO: 8, and (ii) SEQ ID NO: 1 8 CDR2 having the amino acid sequence described above, and (iii) SEQ ID NO: 2 8 A heavy chain variable region (VH) containing CDR3 having the amino acid sequence described above, and (i) Sequence ID 38 CDR1 having the amino acid sequence described above, (ii) Sequence ID 48 CDR2 having the amino acid sequence described above, and (iii) Sequence ID 58 The TL1A-binding protein includes a light chain variable region (VL) containing CDR3 having the amino acid sequence described above. In some embodiments, the TL1A-binding protein includes an immunoglobulin Fc domain. In some embodiments, the Fc domain includes amino acid modified L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0008] This specification describes a TL1A-binding protein comprising: a) a heavy chain variable region (VH) including (i) a CDR1 having the amino acid sequence described in SEQ ID NO: 9 or a CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 9; (ii) a CDR2 having the amino acid sequence described in SEQ ID NO: 19 or a CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 19; and (iii) a light chain variable region (VL) including (i) a CDR1 having the amino acid sequence described in SEQ ID NO: 39 or a CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 39; (ii) a CDR2 having the amino acid sequence described in SEQ ID NO: 49 or a CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 49; and (iii) a light chain variable region (VL) including a CDR3 having the amino acid sequence described in SEQ ID NO: 59 or a CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 59. In some embodiments, the TL1A-binding protein comprises a heavy chain variable region (VH) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 9, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 19, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 29, and a light chain variable region (VL) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 39, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 49, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 59. In some embodiments, the TL1A-binding protein comprises an immunoglobulin Fc domain. In some embodiments, the Fc domain comprises amino acid modified L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0009] This specification describes a TL1A-binding protein comprising: a) a heavy chain variable region (VH) including (i) a CDR1 having the amino acid sequence described in SEQ ID NO: 10 or a CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 10; (ii) a CDR2 having the amino acid sequence described in SEQ ID NO: 20 or a CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 20; and (iii) a light chain variable region (VL) including (i) a CDR1 having the amino acid sequence described in SEQ ID NO: 40 or a CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 40; (ii) a CDR2 having the amino acid sequence described in SEQ ID NO: 50 or a CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 50; and (iii) a light chain variable region (VL) including a CDR3 having the amino acid sequence described in SEQ ID NO: 60 or a CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 60. In some embodiments, the TL1A-binding protein includes a heavy chain variable region (VH) comprising (i) CDR1 having the amino acid sequence described in SEQ ID NO: 10, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 20, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 30, and a light chain variable region (VL) comprising (i) CDR1 having the amino acid sequence described in SEQ ID NO: 40, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 50, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 60. In some embodiments, the TL1A-binding protein includes an immunoglobulin Fc domain. In some embodiments, the Fc domain includes amino acid modified L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0010] This specification describes a TL1A-binding protein comprising: a) a heavy chain variable region (VH) including (i) a CDR1 having the amino acid sequence described in SEQ ID NO: 1 or a CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 1, (ii) a CDR2 having the amino acid sequence described in SEQ ID NO: 11 or a CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 11, and (iii) a heavy chain variable region (VL) including (i) a CDR1 having the amino acid sequence described in SEQ ID NO: 31 or a CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 31, (ii) a CDR2 having the amino acid sequence described in SEQ ID NO: 41 or a CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 41, and (iii) a light chain variable region (VL) including a CDR3 having the amino acid sequence described in SEQ ID NO: 51 or a CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 51. In some embodiments, the TL1A-binding protein comprises a) a heavy chain variable region (VH) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 1, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 11, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 21, and b) a light chain variable region (VL) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 31, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 41, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 51. In some embodiments, the TL1A-binding protein comprises an immunoglobulin Fc domain. In some embodiments, the Fc domain comprises amino acid modified L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0011] This specification describes a TL1A-binding protein comprising: a) a heavy chain variable region (VH) including (i) a CDR1 having the amino acid sequence described in SEQ ID NO: 2 or a CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 2; (ii) a CDR2 having the amino acid sequence described in SEQ ID NO: 12 or a CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 12; and (iii) a light chain variable region (VL) including (i) a CDR1 having the amino acid sequence described in SEQ ID NO: 32 or a CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 32; (ii) a CDR2 having the amino acid sequence described in SEQ ID NO: 42 or a CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 42; and (iii) a CDR3 having the amino acid sequence described in SEQ ID NO: 52 or a CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 52. In some embodiments, the TL1A-binding protein includes a) a heavy chain variable region (VH) comprising (i) CDR1 having the amino acid sequence described in SEQ ID NO: 2, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 12, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 22, and b) a light chain variable region (VL) comprising (i) CDR1 having the amino acid sequence described in SEQ ID NO: 32, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 42, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 52. In some embodiments, the TL1A-binding protein includes an immunoglobulin Fc domain. In some embodiments, the Fc domain includes amino acid modified L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0012] A TL1A-binding protein is described herein, comprising a) a heavy chain variable region (VH) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 3 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 3, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 13 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 13, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 23 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 23; and a light chain variable region (VL) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 33 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 33, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 43 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 43, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 53 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 53. In some embodiments, the TL1A-binding protein comprises a) a heavy chain variable region (VH) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 3, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 13, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 23, and b) a light chain variable region (VL) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 33, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 43, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 53. In some embodiments, the TL1A-binding protein comprises an immunoglobulin Fc domain. In some embodiments, the Fc domain comprises amino acid modified L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0013] This specification describes a TL1A-binding protein comprising: a) a heavy chain variable region (VH) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 4 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 4; (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 14 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 14; and (iii) a light chain variable region (VL) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 34 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 34; (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 44 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 44; and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 54 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 54. In some embodiments, the TL1A-binding protein includes a) a heavy chain variable region (VH) comprising (i) CDR1 having the amino acid sequence described in SEQ ID NO: 4, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 14, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 24, and b) a light chain variable region (VL) comprising (i) CDR1 having the amino acid sequence described in SEQ ID NO: 34, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 44, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 54. In some embodiments, the TL1A-binding protein includes an immunoglobulin Fc domain. In some embodiments, the Fc domain includes amino acid modified L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0014] A TL1A-binding protein comprising a)(i) CDR1 having the amino acid sequence described in SEQ ID NO: 321 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 321, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 430 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 430, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 539 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 539, and (i) This specification describes TL1A-binding proteins comprising (ii) a light chain variable region (VL) including (ii) a CDR1 having the amino acid sequence described in SEQ ID NO: 648 or a CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 648, (ii) a CDR2 having the amino acid sequence described in SEQ ID NO: 757 or a CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 757, and (iii) a light chain variable region (VL) including a CDR3 having the amino acid sequence described in SEQ ID NO: 866 or a CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 866. In some embodiments, the TL1A-binding protein comprises a) a heavy chain variable region (VH) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 321, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 430, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 539, and b) a light chain variable region (VL) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 648, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 757, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 866. In some embodiments, the TL1A-binding protein comprises an immunoglobulin Fc domain. In some embodiments, the Fc domain comprises amino acid modified L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0015] A TL1A-binding protein comprising a)(i) a heavy chain variable region (VH) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 341 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 341, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 450 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 450, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 559 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 559, and b)(i This specification describes TL1A-binding proteins comprising (ii) a CDR1 having the amino acid sequence described in SEQ ID NO: 668 or a CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 668, (ii) a CDR2 having the amino acid sequence described in SEQ ID NO: 777 or a CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 777, and (iii) a light chain variable region (VL) comprising a CDR3 having the amino acid sequence described in SEQ ID NO: 886 or a CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 886. In some embodiments, the TL1A-binding protein comprises a) a heavy chain variable region (VH) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 341, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 450, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 559, and b) a light chain variable region (VL) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 668, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 777, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 886. In some embodiments, the TL1A-binding protein comprises an immunoglobulin Fc domain. In some embodiments, the Fc domain comprises amino acid modified L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0016] A TL1A-binding protein comprising a)(i) a heavy chain variable region (VH) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 345 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 345, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 454 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 454, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 563 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 563, and b)(i This specification describes TL1A-binding proteins comprising (ii) a CDR1 having the amino acid sequence described in SEQ ID NO: 672 or a CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 672, (ii) a CDR2 having the amino acid sequence described in SEQ ID NO: 781 or a CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 781, and (iii) a light chain variable region (VL) comprising a CDR3 having the amino acid sequence described in SEQ ID NO: 890 or a CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 890. In some embodiments, the TL1A-binding protein comprises a) a heavy chain variable region (VH) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 345, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 454, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 563, and b) a light chain variable region (VL) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 672, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 781, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 890. In some embodiments, the TL1A-binding protein comprises an immunoglobulin Fc domain. In some embodiments, the Fc domain comprises amino acid modified L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0017] A TL1A-binding protein comprising a)(i) a heavy chain variable region (VH) including (i) a CDR1 having the amino acid sequence described in SEQ ID NO: 349 or a CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 349, (ii) a CDR2 having the amino acid sequence described in SEQ ID NO: 458 or a CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 458, and (iii) a CDR3 having the amino acid sequence described in SEQ ID NO: 567 or a CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 567, and b)(i This specification describes a TL1A-binding protein comprising (ii) a CDR1 having the amino acid sequence described in SEQ ID NO: 676 or a CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 676, (ii) a CDR2 having the amino acid sequence described in SEQ ID NO: 785 or a CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 785, and (iii) a light chain variable region (VL) comprising a CDR3 having the amino acid sequence described in SEQ ID NO: 894 or a CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 894. In some embodiments, the TL1A-binding protein comprises a) a heavy chain variable region (VH) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 349, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 458, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 567, and b) a light chain variable region (VL) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 676, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 785, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 894. In some embodiments, the TL1A-binding protein comprises an immunoglobulin Fc domain. In some embodiments, the Fc domain comprises amino acid modified L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0018] A TL1A-binding protein comprising a)(i) a heavy chain variable region (VH) including (i) a CDR1 having the amino acid sequence described in SEQ ID NO: 351 or a CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 351, (ii) a CDR2 having the amino acid sequence described in SEQ ID NO: 460 or a CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 460, and (iii) a CDR3 having the amino acid sequence described in SEQ ID NO: 569 or a CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 569, and b)(i This specification describes TL1A-binding proteins comprising (ii) a CDR1 having the amino acid sequence described in SEQ ID NO: 678 or a CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 678, (ii) a CDR2 having the amino acid sequence described in SEQ ID NO: 787 or a CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 787, and (iii) a light chain variable region (VL) comprising a CDR3 having the amino acid sequence described in SEQ ID NO: 896 or a CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 896. In some embodiments, the TL1A-binding protein comprises a) a heavy chain variable region (VH) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 351, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 460, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 569, and b) a light chain variable region (VL) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 678, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 787, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 896. In some embodiments, the TL1A-binding protein comprises an immunoglobulin Fc domain. In some embodiments, the Fc domain comprises amino acid modified L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0019] A TL1A-binding protein comprising a)(i) a heavy chain variable region (VH) having the amino acid sequence described in SEQ ID NO: 354 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 354, (ii) a CDR2 having the amino acid sequence described in SEQ ID NO: 463 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 463, and (iii) a heavy chain variable region (VH) having the amino acid sequence described in SEQ ID NO: 572 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 572, and b)(i This specification describes TL1A-binding proteins comprising (ii) a CDR1 having the amino acid sequence described in SEQ ID NO: 681 or a CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 681, (ii) a CDR2 having the amino acid sequence described in SEQ ID NO: 790 or a CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 790, and (iii) a light chain variable region (VL) comprising a CDR3 having the amino acid sequence described in SEQ ID NO: 899 or a CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 899. In some embodiments, the TL1A-binding protein comprises a) a heavy chain variable region (VH) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 354, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 463, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 572, and b) a light chain variable region (VL) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 681, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 790, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 899. In some embodiments, the TL1A-binding protein comprises an immunoglobulin Fc domain. In some embodiments, the Fc domain comprises amino acid modified L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0020] A TL1A-binding protein comprising a)(i) a heavy chain variable region (VH) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 365 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 365, (ii) a CDR2 having the amino acid sequence described in SEQ ID NO: 474 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 474, and (iii) a heavy chain variable region (VH) including (i) This specification describes TL1A-binding proteins comprising (ii) a light chain variable region (VL) including (ii) a CDR1 having the amino acid sequence described in SEQ ID NO: 692 or a CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 692, (ii) a CDR2 having the amino acid sequence described in SEQ ID NO: 801 or a CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 801, and (iii) a CDR3 having the amino acid sequence described in SEQ ID NO: 910 or a CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 910. In some embodiments, the TL1A-binding protein comprises a) a heavy chain variable region (VH) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 365, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 474, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 583, and b) a light chain variable region (VL) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 692, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 801, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 910. In some embodiments, the TL1A-binding protein comprises an immunoglobulin Fc domain. In some embodiments, the Fc domain comprises amino acid modified L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0021] A TL1A-binding protein comprising a)(i) a heavy chain variable region (VH) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 371 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 371, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 480 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 480, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 589 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 589, and b)(i This specification describes TL1A-binding proteins comprising (ii) a CDR1 having the amino acid sequence described in SEQ ID NO: 698 or a CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 698, (ii) a CDR2 having the amino acid sequence described in SEQ ID NO: 807 or a CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 807, and (iii) a light chain variable region (VL) comprising a CDR3 having the amino acid sequence described in SEQ ID NO: 916 or a CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 916. In some embodiments, the TL1A-binding protein comprises a) a heavy chain variable region (VH) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 371, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 480, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 589, and b) a light chain variable region (VL) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 698, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 807, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 916. In some embodiments, the TL1A-binding protein comprises an immunoglobulin Fc domain. In some embodiments, the Fc domain comprises amino acid modified L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0022] A TL1A-binding protein comprising a)(i) CDR1 having the amino acid sequence described in SEQ ID NO: 372 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 372, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 481 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 481, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 590 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 590, and b)(i) SEQ ID NO: 69 9 CDR1 or SEQ ID NO: 69 having the amino acid sequence described above 9 This specification describes a TL1A-binding protein comprising a light chain variable region (VL) comprising (ii) CDR1 having one to two amino acid substitutions compared to the sequence of (ii) SEQ ID NO: 808, or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 808, and (iii) CDR3 having the amino acid sequence of (iii) SEQ ID NO: 917, or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 917. In some embodiments, the TL1A-binding protein comprises a) a heavy chain variable region (VH) comprising (i) CDR1 having the amino acid sequence of (ii) SEQ ID NO: 372, (ii) CDR2 having the amino acid sequence of (iii) CDR3 having the amino acid sequence of (iii) SEQ ID NO: 590, and b) (i) SEQ ID NO: 69 9 The TL1A-binding protein comprises a light chain variable region (VL) including (ii) CDR1 having the amino acid sequence described in (ii) 808, and (iii) CDR3 having the amino acid sequence described in 917. In some embodiments, the TL1A-binding protein comprises an immunoglobulin Fc domain. In some embodiments, the Fc domain comprises amino acid modified L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0023] A TL1A-binding protein comprising a)(i) a CDR1 having the amino acid sequence described in SEQ ID NO: 373 or a CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 373, (ii) a CDR2 having the amino acid sequence described in SEQ ID NO: 482 or a CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 482, and (iii) a heavy chain variable region (VH) having the amino acid sequence described in SEQ ID NO: 591 or a CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 591, and (i) This specification describes TL1A-binding proteins comprising (ii) a light chain variable region (VL) including (ii) a CDR1 having the amino acid sequence described in SEQ ID NO: 700 or a CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 700, (ii) a CDR2 having the amino acid sequence described in SEQ ID NO: 809 or a CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 809, and (iii) a CDR3 having the amino acid sequence described in SEQ ID NO: 918 or a CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 918. In some embodiments, the TL1A-binding protein comprises a) a heavy chain variable region (VH) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 373, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 482, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 591, and b) a light chain variable region (VL) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 700, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 809, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 918. In some embodiments, the TL1A-binding protein comprises an immunoglobulin Fc domain. In some embodiments, the Fc domain comprises amino acid modified L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0024] A TL1A-binding protein comprising a)(i) CDR1 having the amino acid sequence described in SEQ ID NO: 388 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 388, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 497 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 497, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 606 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 606, and (i) This specification describes TL1A-binding proteins comprising (ii) a light chain variable region (VL) including (ii) a CDR1 having the amino acid sequence described in SEQ ID NO: 715 or a CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 715, (ii) a CDR2 having the amino acid sequence described in SEQ ID NO: 824 or a CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 824, and (iii) a CDR3 having the amino acid sequence described in SEQ ID NO: 933 or a CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 933. In some embodiments, the TL1A-binding protein comprises a) a heavy chain variable region (VH) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 388, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 497, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 606, and b) a light chain variable region (VL) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 715, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 824, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 933. In some embodiments, the TL1A-binding protein comprises an immunoglobulin Fc domain. In some embodiments, the Fc domain comprises amino acid modified L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0025] A TL1A-binding protein comprising a)(i) a heavy chain variable region (VH) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 394 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 394, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 503 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 503, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 612 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 612, and b)(i This specification describes TL1A-binding proteins comprising (ii) a CDR1 having the amino acid sequence described in SEQ ID NO: 721 or a CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 721, (ii) a CDR2 having the amino acid sequence described in SEQ ID NO: 830 or a CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 830, and (iii) a light chain variable region (VL) comprising a CDR3 having the amino acid sequence described in SEQ ID NO: 939 or a CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 939. In some embodiments, the TL1A-binding protein comprises a) a heavy chain variable region (VH) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 394, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 503, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 612, and b) a light chain variable region (VL) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 721, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 830, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 939. In some embodiments, the TL1A-binding protein comprises an immunoglobulin Fc domain. In some embodiments, the Fc domain comprises amino acid modified L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0026] A TL1A-binding protein comprising a)(i) a heavy chain variable region (VH) including (i) a CDR1 having the amino acid sequence described in SEQ ID NO: 400 or a CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 400, (ii) a CDR2 having the amino acid sequence described in SEQ ID NO: 509 or a CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 509, and (iii) a CDR3 having the amino acid sequence described in SEQ ID NO: 618 or a CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 618, and b)(i This specification describes TL1A-binding proteins comprising (ii) a CDR1 having the amino acid sequence described in SEQ ID NO: 727 or a CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 727, (ii) a CDR2 having the amino acid sequence described in SEQ ID NO: 836 or a CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 836, and (iii) a light chain variable region (VL) comprising a CDR3 having the amino acid sequence described in SEQ ID NO: 945 or a CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 945. In some embodiments, the TL1A-binding protein comprises a) a heavy chain variable region (VH) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 400, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 509, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 618, and b) a light chain variable region (VL) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 727, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 836, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 945. In some embodiments, the TL1A-binding protein comprises an immunoglobulin Fc domain. In some embodiments, the Fc domain comprises amino acid modified L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0027] Aspects of this disclosure relate to TL1A-binding antibodies that specifically bind to epitopes of TL1A polypeptides recognized by antibodies disclosed herein. Aspects of this disclosure relate to TL1A-binding antibodies that specifically bind to epitopes of TL1A polypeptides recognized by antibodies 1, 2, 3, 4, 6, 8, 10, 47, 49, 63, or 69 disclosed herein.

[0028] Aspects of this disclosure relate to TL1A-binding antibodies that specifically bind to any one of the amino acid residues Val 101, Val 102, Arg 103, Gln 104, Thr 105, Pro 106, Thr 107, Gln 108, His 109, Phe 110, Lys 111, His 118, Trp 119, Glu 120, Glu 122, Leu 123, Gly 124, Lys 137, Arg 156, Gly 157, Met 158, Ser 231, Asp 232, Ile 233, Ser 234, Tyr 238, Thr 239, Lys 240, and Lys 243 of the TL1A polypeptide, including SEQ ID NO: 2493. In some embodiments, the TL1A-binding antibody specifically binds to 10 or more amino acid residues selected from Val 102, Arg 103, Gln 104, Thr 105, Thr 107, Gln 108, His 118, Trp 119, Glu 120, Glu 122, Leu 123, Gly 124, Lys 137, Arg 156, Gly 157, Met 158, Ser 231, Asp 232, Ile 233, Ser 234, Leu 235, Val 236, Asp 237, Tyr 238, Thr 239, Lys 240, and Lys 243 in the TL1A sequence.

[0029] Aspects of this disclosure relate to TL1A-binding antibodies that specifically bind to any one of the following amino acid residues: Val 102, Arg 103, Gln 104, Thr 105, Thr 107, Gln 108, His 118, Trp 119, Glu 120, Glu 122, Leu 123, Gly 124, Lys 137, Arg 156, Gly 157, Met 158, Ser 234, Tyr 238, and Thr 239, to the TL1A polypeptide including SEQ ID NO: 2493. In some embodiments, the TL1A-binding antibody specifically binds to the TL1A sequence at the amino acid residues Val 102, Arg 103, Gln 104, Thr 105, Thr 107, Gln 108, His 118, Trp 119, Glu 120, Glu 122, Leu 123, Gly 124, Lys 137, Arg 156, Gly 157, Met 158, Ser 234, Tyr 238, and Thr 239.

[0030] A part of this disclosure is a)(i) Sequence ID 5 ~ 10 Having the amino acid sequence described in any one of the following, or the sequence number 5 ~ 10 CDR1 having an amino acid sequence having one or two amino acid substitutions compared to any one of the following, (ii) Sequence ID 15 ~ 20 Having the amino acid sequence described in any one of the following, or the sequence number 15 ~ 20 CDR2 having an amino acid sequence having one or two amino acid substitutions compared to any one of the following, and (iii) Sequence ID 25 ~ 30 Having the amino acid sequence described in any one of the following, or the sequence number 25 ~ 30 A heavy chain variable region (VH) containing a CDR3 having an amino acid sequence having one or two amino acid substitutions compared to any one of the following, and b)(i) Sequence ID 35 ~ 40 Having the amino acid sequence described in any one of the following, or the sequence number 35 ~ 40CDR1 having an amino acid sequence having one or two amino acid substitutions compared to any one of the following, (ii) Sequence ID 45 ~ 50 Having the amino acid sequence described in any one of the following, or the sequence number 45 ~ 50 CDR2 having an amino acid sequence having one or two amino acid substitutions compared to any one of the following, and (iii) Sequence ID 55 ~ 60 Having the amino acid sequence described in any one of the following, or the sequence number 55 ~ 60 This relates to a TL1A-binding protein containing a light chain variable region (VL) that includes a CDR3 having an amino acid sequence having one or two amino acid substitutions compared to any one of the following.

[0031] In some embodiments, the TL1A-binding protein is SEQ ID NO: 1 85 ~1 90 VH containing a sequence having at least 80% sequence identity with respect to any one of the amino acid sequences, and Sequence ID No. 1 95 ~ 200 It includes a VL containing a sequence having at least 80% sequence identity with respect to any one of the amino acid sequences.

[0032] In some embodiments, VH is sequence number 1 85 The sequence contains at least 80% sequence identity with respect to the amino acid sequence of the sequence number 1, and VL is sequence number 1 95 It contains a sequence that has at least 80% sequence identity with respect to the amino acid sequence.

[0033] In some embodiments, VH is sequence number 1 86 The sequence contains at least 80% sequence identity with respect to the amino acid sequence of the sequence number 1, and VL is sequence number 1 96 It contains a sequence that has at least 80% sequence identity with respect to the amino acid sequence.

[0034] In some embodiments, VH is sequence number 1 87The sequence contains at least 80% sequence identity with respect to the amino acid sequence of the sequence number 1, and VL is sequence number 1 97 It contains a sequence that has at least 80% sequence identity with respect to the amino acid sequence.

[0035] In some embodiments, VH is sequence number 1 88 The sequence contains at least 80% sequence identity with respect to the amino acid sequence of the sequence number 1, and VL is sequence number 1 98 It contains a sequence that has at least 80% sequence identity with respect to the amino acid sequence.

[0036] In some embodiments, VH is sequence number 1 89 The sequence contains at least 80% sequence identity with respect to the amino acid sequence of the sequence number 1, and VL is sequence number 1 99 It contains a sequence that has at least 80% sequence identity with respect to the amino acid sequence.

[0037] In some embodiments, VH is sequence number 1 90 The sequence contains at least 80% sequence identity with respect to the amino acid sequence, and VL is sequence number 200 It contains a sequence that has at least 80% sequence identity with respect to the amino acid sequence.

[0038] TL1A-binding protein, a)(i) Sequence ID 5 CDR1 or SEQ ID NO: having the amino acid sequence described above 5 CDR1, which has one to two amino acid substitutions compared to the sequence, (ii) Sequence ID 15 CDR2 or SEQ ID NO: having the amino acid sequence described above 15 CDR2 having one to two amino acid substitutions compared to the sequence, and (iii) Sequence ID 25 CDR3 or SEQ ID NO: having the amino acid sequence described above 25 The heavy chain variable region (VH) containing CDR3 with one to two amino acid substitutions compared to the sequence, and b)(i) Sequence ID 35 CDR1 or SEQ ID NO: having the amino acid sequence described above 35CDR1, which has one to two amino acid substitutions compared to the sequence, (ii) Sequence ID 45 CDR2 or SEQ ID NO: having the amino acid sequence described above 45 CDR2 having one to two amino acid substitutions compared to the sequence, and (iii) Sequence ID 55 CDR3 or SEQ ID NO: having the amino acid sequence described above 55 TL1A-binding proteins are described herein that include a light chain variable region (VL) containing a CDR3 having one to two amino acid substitutions compared to the sequence. In some embodiments, the TL1A-binding protein is a)(i) Sequence ID 5 CDR1 having the amino acid sequence described above, (ii) Sequence ID 15 CDR2 having the amino acid sequence described above, and (iii) Sequence ID 25 A heavy chain variable region (VH) containing CDR3 having the amino acid sequence described above, and b)(i) Sequence ID 35 CDR1 having the amino acid sequence described above, (ii) Sequence ID 45 CDR2 having the amino acid sequence described above, and (iii) Sequence ID 55 The TL1A-binding protein includes a light chain variable region (VL) containing CDR3 having the amino acid sequence described above. In some embodiments, the TL1A-binding protein includes an immunoglobulin Fc domain. In some embodiments, the Fc domain includes amino acid modified L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE). 。

[0039] TL1A-binding proteins, a) (i) CDR1 having the amino acid sequence described in SEQ ID NO: 6, or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 6, (ii) SEQ ID NO: 1 6 CDR2 or SEQ ID NO: 1 having the amino acid sequence described above. 6 CDR2 having one to two amino acid substitutions compared to the sequence, and (iii) Sequence ID 26 CDR3 or SEQ ID NO: having the amino acid sequence described above 26The heavy chain variable region (VH) containing CDR3 with one to two amino acid substitutions compared to the sequence, and b)(i) Sequence ID 36 CDR1 or SEQ ID NO: having the amino acid sequence described above 36 CDR1, which has one to two amino acid substitutions compared to the sequence, (ii) Sequence ID 46 CDR2 or SEQ ID NO: having the amino acid sequence described above 46 CDR2 having one to two amino acid substitutions compared to the sequence, and (iii) Sequence ID 56 CDR3 or SEQ ID NO: having the amino acid sequence described above 56 This specification describes TL1A-binding proteins comprising a light chain variable region (VL) containing a CDR3 having one to two amino acid substitutions compared to the sequence of (1). In some embodiments, the TL1A-binding protein comprises a)(i) a CDR1 having the amino acid sequence described in SEQ ID NO: 6, and (ii) SEQ ID NO: 1 6 CDR2 having the amino acid sequence described above, and (iii) Sequence ID 26 A heavy chain variable region (VH) containing CDR3 having the amino acid sequence described above, and b)(i) Sequence ID 36 CDR1 having the amino acid sequence described above, (ii) Sequence ID 46 CDR2 having the amino acid sequence described above, and (iii) Sequence ID 56 The TL1A-binding protein includes a light chain variable region (VL) containing CDR3 having the amino acid sequence described above. In some embodiments, the TL1A-binding protein includes an immunoglobulin Fc domain. In some embodiments, the Fc domain includes amino acid modified L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0040] TL1A-binding proteins, a) (i) CDR1 having the amino acid sequence described in SEQ ID NO: 7 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 7, (ii) SEQ ID NO: 1 7 CDR2 or SEQ ID NO: 1 having the amino acid sequence described above. 7 CDR2 having one to two amino acid substitutions compared to the sequence, and (iii) Sequence ID27 CDR3 or SEQ ID NO: having the amino acid sequence described above 27 The heavy chain variable region (VH) containing CDR3 with one to two amino acid substitutions compared to the sequence, and b)(i) Sequence ID 37 CDR1 or SEQ ID NO: having the amino acid sequence described above 37 CDR1, which has one to two amino acid substitutions compared to the sequence, (ii) Sequence ID 47 CDR2 or SEQ ID NO: having the amino acid sequence described above 47 CDR2 having one to two amino acid substitutions compared to the sequence, and (iii) Sequence ID 57 CDR3 or SEQ ID NO: having the amino acid sequence described above 57 This specification describes TL1A-binding proteins comprising a light chain variable region (VL) containing a CDR3 having one to two amino acid substitutions compared to the sequence of (1). In some embodiments, the TL1A-binding protein comprises a)(i) a CDR1 having the amino acid sequence described in SEQ ID NO: 7, and (ii) SEQ ID NO: 1 7 CDR2 having the amino acid sequence described above, and (iii) Sequence ID 27 A heavy chain variable region (VH) containing CDR3 having the amino acid sequence described above, b) (i) Sequence ID 37 CDR1 having the amino acid sequence described above, (ii) Sequence ID 47 CDR2 having the amino acid sequence described above, and (iii) Sequence ID 57 The TL1A-binding protein includes a light chain variable region (VL) containing CDR3 having the amino acid sequence described above. In some embodiments, the TL1A-binding protein includes an immunoglobulin Fc domain. In some embodiments, the Fc domain includes amino acid modified L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0041] This specification describes a TL1A-binding protein comprising: a) a heavy chain variable region (VH) including (i) a CDR1 having the amino acid sequence described in SEQ ID NO: 8 or a CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 8; (ii) a CDR2 having the amino acid sequence described in SEQ ID NO: 18 or a CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 18; and (iii) a light chain variable region (VL) including (i) a CDR1 having the amino acid sequence described in SEQ ID NO: 38 or a CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 38; (ii) a CDR2 having the amino acid sequence described in SEQ ID NO: 48 or a CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 48; and (iii) a light chain variable region (VL) including a CDR3 having the amino acid sequence described in SEQ ID NO: 58 or a CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 58. In some embodiments, the TL1A-binding protein includes a) a heavy chain variable region (VH) comprising (i) CDR1 having the amino acid sequence described in SEQ ID NO: 8, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 18, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 28, and b) a light chain variable region (VL) comprising (i) CDR1 having the amino acid sequence described in SEQ ID NO: 38, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 48, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 58. In some embodiments, the TL1A-binding protein includes an immunoglobulin Fc domain. In some embodiments, the Fc domain includes amino acid modified L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0042] This specification describes a TL1A-binding protein comprising: a) a heavy chain variable region (VH) including (i) a CDR1 having the amino acid sequence described in SEQ ID NO: 9 or a CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 9; (ii) a CDR2 having the amino acid sequence described in SEQ ID NO: 19 or a CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 19; and (iii) a light chain variable region (VL) including (i) a CDR1 having the amino acid sequence described in SEQ ID NO: 39 or a CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 39; (ii) a CDR2 having the amino acid sequence described in SEQ ID NO: 49 or a CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 49; and (iii) a light chain variable region (VL) including a CDR3 having the amino acid sequence described in SEQ ID NO: 59 or a CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 59. In some embodiments, the TL1A-binding protein comprises a heavy chain variable region (VH) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 9, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 19, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 29, and a light chain variable region (VL) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 39, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 49, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 59. In some embodiments, the TL1A-binding protein comprises an immunoglobulin Fc domain. In some embodiments, the Fc domain comprises amino acid modified L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0043] TL1A-binding protein, a)(i) Sequence ID 10 CDR1 or SEQ ID NO: having the amino acid sequence described above 10 CDR1, which has one to two amino acid substitutions compared to the sequence, (ii) Sequence ID 20 CDR2 or SEQ ID NO: having the amino acid sequence described above 20 CDR2 having one to two amino acid substitutions compared to the sequence, and (iii) Sequence ID 30 CDR3 or SEQ ID NO: having the amino acid sequence described above 30 The heavy chain variable region (VH) containing CDR3 with one to two amino acid substitutions compared to the sequence, and b)(i) Sequence ID 40 CDR1 or SEQ ID NO: having the amino acid sequence described above 40 CDR1, which has one to two amino acid substitutions compared to the sequence, (ii) Sequence ID 50 CDR2 or SEQ ID NO: having the amino acid sequence described above 50 CDR2 having one to two amino acid substitutions compared to the sequence, and (iii) Sequence ID 60 CDR3 or SEQ ID NO: having the amino acid sequence described above 60 TL1A-binding proteins are described herein that include a light chain variable region (VL) containing a CDR3 having one to two amino acid substitutions compared to the sequence. In some embodiments, the TL1A-binding protein is a)(i) Sequence ID 10 CDR1 having the amino acid sequence described above, (ii) Sequence ID 20 CDR2 having the amino acid sequence described above, and (iii) Sequence ID 30 A heavy chain variable region (VH) containing CDR3 having the amino acid sequence described above, and (i) Sequence ID 40 CDR1 having the amino acid sequence described above, (ii) Sequence ID 50 CDR2 having the amino acid sequence described above, and (iii) Sequence ID 60The TL1A-binding protein includes a light chain variable region (VL) containing CDR3 having the amino acid sequence described above. In some embodiments, the TL1A-binding protein includes an immunoglobulin Fc domain. In some embodiments, the Fc domain includes amino acid modified L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE). In some embodiments, the TL1A-binding protein or TL1A-binding antibody contains TL1A with a K concentration of less than about 0.5 nanomolar (nM) D They are joined together.

[0044] (i) Sequence ID 5 ~ 10 Having the amino acid sequence described in any one of the following, or the sequence number 5 ~ 10 CDR1 having an amino acid sequence with one or two amino acid substitutions compared to any one of the following; (ii) Sequence ID 15 ~ 20 Having the amino acid sequence described in any one of the following, or the sequence number 15 ~ 20 CDR2 having an amino acid sequence having one or two amino acid substitutions compared to any one of the following; and (ii) Sequence ID 25 ~ 30 Having the amino acid sequence described in any one of the following, or the sequence number 25 ~ 30 This specification describes TL1A-binding proteins that include a heavy chain variable region (VH) containing a CDR3 having an amino acid sequence having one or two amino acid substitutions compared to any one of the above.

[0045] (i) Sequence ID 35 ~ 40 Having the amino acid sequence described in any one of the following, or the sequence number 35 ~ 40 CDR1 having an amino acid sequence with one or two amino acid substitutions compared to any one of the following; (i) Sequence ID 45 ~ 50 Having the amino acid sequence described in any one of the following, or the sequence number 45 ~50 CDR2 having an amino acid sequence having one or two amino acid substitutions compared to any one of the following; and (iii) Sequence ID 55 ~ 60 Having the amino acid sequence described in any one of the following, or the sequence number 55 ~ 60 This specification describes TL1A-binding proteins that include a light chain variable region (VL) containing a CDR3 having an amino acid sequence having one or two amino acid substitutions compared to any one of the above.

[0046] A method for obtaining an antibody that specifically binds to a particular epitope portion of a TL1A sequence containing SEQ ID NO: 2493 is described herein, the method comprising the steps of: evaluating whether the antibody specifically binds to a particular epitope portion, wherein the particular epitope portion has the amino acid residues Val 102, Arg 103, Gln 104, Thr 105, Thr 107, Gln 108, His 118, Trp 119, Glu 120, Glu 122, Leu 123, Gly 124, Lys 137, Arg 156, Gly 157, Met 158, Ser 227, Tyr 231, and Thr 232 of SEQ ID NO: 2493; and isolating or selecting an antibody that binds to a particular epitope portion.

[0047] Also described herein are TL1A-binding proteins that specifically bind to TL1A polypeptides, including sequence numbers 2493 or 2494, wherein the TL1A-binding protein is an antibody.

[0048] a) A heavy chain variable region (VH) comprising (i) CDR1 having an amino acid sequence described in any one of SEQ ID NOs: 1-4 and 313-421, or an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NOs: 1-4 and 313-421; (ii) CDR2 having an amino acid sequence described in any one of SEQ ID NOs: 11-14 and 422-530, or an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NOs: 11-14 and 422-530; and (iii) CDR3 having an amino acid sequence described in any one of SEQ ID NOs: 21-24 and 531-639, or an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NOs: 21-24 and 531-639; and b) (i) SEQ ID NOs: 31-34 This specification describes TL1A-binding proteins comprising a light chain variable region (VL) including (ii) CDR1 having an amino acid sequence described in any one of SEQ ID NOs: 1-4 and 313-421, or an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NOs: 41-44 and 749-857, or an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NOs: 41-44 and 749-857, and (iii) CDR3 having an amino acid sequence described in any one of SEQ ID NOs: 51-54 and 858-966, or an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NOs: 51-54 and 858-966.

[0049] In some embodiments, VH includes a sequence having at least 80% sequence identity with one of the amino acid sequences of SEQ ID NOs. 181-184 and 2275-2383, and VL includes a sequence having at least 80% sequence identity with one of the amino acid sequences of SEQ ID NOs. 191-194 and 2384-2492.

[0050] In some embodiments, VH includes a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 181, and VL includes a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 191.

[0051] In some embodiments, VH includes a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 182, and VL includes a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 192.

[0052] In some embodiments, VH includes a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 183, and VL includes a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 193.

[0053] In some embodiments, VH includes a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 184, and VL includes a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 194.

[0054] In some embodiments, VH includes a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2283, and VL includes a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2392.

[0055] In some embodiments, VH includes a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2303, and VL includes a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2412.

[0056] In some embodiments, VH includes a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2307, and VL includes a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2416.

[0057] In some embodiments, VH includes a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2311, and VL includes a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2420.

[0058] In some embodiments, VH includes a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2313, and VL includes a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2422.

[0059] In some embodiments, VH includes a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2316, and VL includes a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2425.

[0060] In some embodiments, VH includes a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2327, and VL includes a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2436.

[0061] In some embodiments, VH includes a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2333, and VL includes a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2442.

[0062] In some embodiments, VH includes a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2334, and VL includes a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2443.

[0063] In some embodiments, VH includes a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2335, and VL includes a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2444.

[0064] In some embodiments, VH includes a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2350, and VL includes a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2459.

[0065] In some embodiments, VH includes a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2356, and VL includes a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2465.

[0066] In some embodiments, VH includes a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2362, and VL includes a sequence having at least 80% sequence identity with SEQ ID NO: 2471.

[0067] This specification describes a TL1A-binding protein comprising: a) a heavy chain variable region (VH) including (i) a CDR1 having the amino acid sequence described in SEQ ID NO: 1 or a CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 1, (ii) a CDR2 having the amino acid sequence described in SEQ ID NO: 11 or a CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 11, and (iii) a heavy chain variable region (VL) including (i) a CDR1 having the amino acid sequence described in SEQ ID NO: 31 or a CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 31, (ii) a CDR2 having the amino acid sequence described in SEQ ID NO: 41 or a CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 41, and (iii) a light chain variable region (VL) including a CDR3 having the amino acid sequence described in SEQ ID NO: 51 or a CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 51. In some embodiments, the TL1A-binding protein comprises a) a heavy chain variable region (VH) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 1, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 11, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 21, and b) a light chain variable region (VL) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 31, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 41, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 51. In some embodiments, the TL1A-binding protein comprises an immunoglobulin Fc domain. In some embodiments, the Fc domain comprises amino acid modified L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0068] This specification describes a TL1A-binding protein comprising: a) a heavy chain variable region (VH) including (i) a CDR1 having the amino acid sequence described in SEQ ID NO: 2 or a CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 2; (ii) a CDR2 having the amino acid sequence described in SEQ ID NO: 12 or a CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 12; and (iii) a light chain variable region (VL) including (i) a CDR1 having the amino acid sequence described in SEQ ID NO: 32 or a CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 32; (ii) a CDR2 having the amino acid sequence described in SEQ ID NO: 42 or a CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 42; and (iii) a CDR3 having the amino acid sequence described in SEQ ID NO: 52 or a CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 52. In some embodiments, the TL1A-binding protein includes a) a heavy chain variable region (VH) comprising (i) CDR1 having the amino acid sequence described in SEQ ID NO: 2, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 12, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 22, and b) a light chain variable region (VL) comprising (i) CDR1 having the amino acid sequence described in SEQ ID NO: 32, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 42, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 52. In some embodiments, the TL1A-binding protein includes an immunoglobulin Fc domain. In some embodiments, the Fc domain includes amino acid modified L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0069] A TL1A-binding protein is described herein, comprising a) a heavy chain variable region (VH) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 3 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 3, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 13 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 13, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 23 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 23; and a light chain variable region (VL) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 33 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 33, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 43 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 43, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 53 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 53. In some embodiments, the TL1A-binding protein comprises a) a heavy chain variable region (VH) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 3, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 13, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 23, and b) a light chain variable region (VL) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 33, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 43, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 53. In some embodiments, the TL1A-binding protein comprises an immunoglobulin Fc domain. In some embodiments, the Fc domain comprises amino acid modified L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0070] This specification describes a TL1A-binding protein comprising: a) a heavy chain variable region (VH) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 4 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 4; (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 14 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 14; and (iii) a light chain variable region (VL) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 34 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 34; (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 44 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 44; and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 54 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 54. In some embodiments, the TL1A-binding protein includes a) a heavy chain variable region (VH) comprising (i) CDR1 having the amino acid sequence described in SEQ ID NO: 4, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 14, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 24, and b) a light chain variable region (VL) comprising (i) CDR1 having the amino acid sequence described in SEQ ID NO: 34, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 44, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 54. In some embodiments, the TL1A-binding protein includes an immunoglobulin Fc domain. In some embodiments, the Fc domain includes amino acid modified L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0071] A TL1A-binding protein comprising a)(i) CDR1 having the amino acid sequence described in SEQ ID NO: 321 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 321, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 430 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 430, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 539 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 539, and (i) This specification describes TL1A-binding proteins comprising (ii) a light chain variable region (VL) including (ii) a CDR1 having the amino acid sequence described in SEQ ID NO: 648 or a CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 648, (ii) a CDR2 having the amino acid sequence described in SEQ ID NO: 757 or a CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 757, and (iii) a light chain variable region (VL) including a CDR3 having the amino acid sequence described in SEQ ID NO: 866 or a CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 866. In some embodiments, the TL1A-binding protein comprises a) a heavy chain variable region (VH) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 321, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 430, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 539, and b) a light chain variable region (VL) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 648, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 757, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 866. In some embodiments, the TL1A-binding protein comprises an immunoglobulin Fc domain. In some embodiments, the Fc domain comprises amino acid modified L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0072] A TL1A-binding protein comprising a)(i) a heavy chain variable region (VH) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 341 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 341, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 450 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 450, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 559 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 559, and b)(i This specification describes TL1A-binding proteins comprising (ii) a CDR1 having the amino acid sequence described in SEQ ID NO: 668 or a CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 668, (ii) a CDR2 having the amino acid sequence described in SEQ ID NO: 777 or a CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 777, and (iii) a light chain variable region (VL) comprising a CDR3 having the amino acid sequence described in SEQ ID NO: 886 or a CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 886. In some embodiments, the TL1A-binding protein comprises a) a heavy chain variable region (VH) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 341, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 450, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 559, and b) a light chain variable region (VL) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 668, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 777, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 886. In some embodiments, the TL1A-binding protein comprises an immunoglobulin Fc domain. In some embodiments, the Fc domain comprises amino acid modified L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0073] A TL1A-binding protein comprising a)(i) a heavy chain variable region (VH) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 345 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 345, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 454 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 454, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 563 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 563, and b)(i This specification describes TL1A-binding proteins comprising (ii) a CDR1 having the amino acid sequence described in SEQ ID NO: 672 or a CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 672, (ii) a CDR2 having the amino acid sequence described in SEQ ID NO: 781 or a CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 781, and (iii) a light chain variable region (VL) comprising a CDR3 having the amino acid sequence described in SEQ ID NO: 890 or a CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 890. In some embodiments, the TL1A-binding protein comprises a) a heavy chain variable region (VH) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 345, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 454, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 563, and b) a light chain variable region (VL) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 672, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 781, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 890. In some embodiments, the TL1A-binding protein comprises an immunoglobulin Fc domain. In some embodiments, the Fc domain comprises amino acid modified L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0074] A TL1A-binding protein comprising a)(i) a heavy chain variable region (VH) including (i) a CDR1 having the amino acid sequence described in SEQ ID NO: 349 or a CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 349, (ii) a CDR2 having the amino acid sequence described in SEQ ID NO: 458 or a CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 458, and (iii) a CDR3 having the amino acid sequence described in SEQ ID NO: 567 or a CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 567, and b)(i This specification describes a TL1A-binding protein comprising (ii) a CDR1 having the amino acid sequence described in SEQ ID NO: 676 or a CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 676, (ii) a CDR2 having the amino acid sequence described in SEQ ID NO: 785 or a CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 785, and (iii) a light chain variable region (VL) comprising a CDR3 having the amino acid sequence described in SEQ ID NO: 894 or a CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 894. In some embodiments, the TL1A-binding protein comprises a) a heavy chain variable region (VH) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 349, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 458, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 567, and b) a light chain variable region (VL) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 676, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 785, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 894. In some embodiments, the TL1A-binding protein comprises an immunoglobulin Fc domain. In some embodiments, the Fc domain comprises amino acid modified L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0075] A TL1A-binding protein comprising a)(i) a heavy chain variable region (VH) including (i) a CDR1 having the amino acid sequence described in SEQ ID NO: 351 or a CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 351, (ii) a CDR2 having the amino acid sequence described in SEQ ID NO: 460 or a CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 460, and (iii) a CDR3 having the amino acid sequence described in SEQ ID NO: 569 or a CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 569, and b)(i This specification describes TL1A-binding proteins comprising (ii) a CDR1 having the amino acid sequence described in SEQ ID NO: 678 or a CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 678, (ii) a CDR2 having the amino acid sequence described in SEQ ID NO: 787 or a CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 787, and (iii) a light chain variable region (VL) comprising a CDR3 having the amino acid sequence described in SEQ ID NO: 896 or a CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 896. In some embodiments, the TL1A-binding protein comprises a) a heavy chain variable region (VH) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 351, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 460, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 569, and b) a light chain variable region (VL) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 678, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 787, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 896. In some embodiments, the TL1A-binding protein comprises an immunoglobulin Fc domain. In some embodiments, the Fc domain comprises amino acid modified L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0076] A TL1A-binding protein comprising a)(i) a heavy chain variable region (VH) having the amino acid sequence described in SEQ ID NO: 354 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 354, (ii) a CDR2 having the amino acid sequence described in SEQ ID NO: 463 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 463, and (iii) a heavy chain variable region (VH) having the amino acid sequence described in SEQ ID NO: 572 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 572, and b)(i This specification describes TL1A-binding proteins comprising (ii) a CDR1 having the amino acid sequence described in SEQ ID NO: 681 or a CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 681, (ii) a CDR2 having the amino acid sequence described in SEQ ID NO: 790 or a CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 790, and (iii) a light chain variable region (VL) comprising a CDR3 having the amino acid sequence described in SEQ ID NO: 899 or a CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 899. In some embodiments, the TL1A-binding protein comprises a) a heavy chain variable region (VH) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 354, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 463, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 572, and b) a light chain variable region (VL) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 681, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 790, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 899. In some embodiments, the TL1A-binding protein comprises an immunoglobulin Fc domain. In some embodiments, the Fc domain comprises amino acid modified L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0077] A TL1A-binding protein comprising a)(i) a heavy chain variable region (VH) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 365 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 365, (ii) a CDR2 having the amino acid sequence described in SEQ ID NO: 474 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 474, and (iii) a heavy chain variable region (VH) including (i) This specification describes TL1A-binding proteins comprising (ii) a light chain variable region (VL) including (ii) a CDR1 having the amino acid sequence described in SEQ ID NO: 692 or a CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 692, (ii) a CDR2 having the amino acid sequence described in SEQ ID NO: 801 or a CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 801, and (iii) a CDR3 having the amino acid sequence described in SEQ ID NO: 910 or a CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 910. In some embodiments, the TL1A-binding protein comprises a) a heavy chain variable region (VH) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 365, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 474, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 583, and b) a light chain variable region (VL) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 692, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 801, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 910. In some embodiments, the TL1A-binding protein comprises an immunoglobulin Fc domain. In some embodiments, the Fc domain comprises amino acid modified L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0078] A TL1A-binding protein comprising a)(i) a heavy chain variable region (VH) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 371 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 371, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 480 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 480, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 589 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 589, and b)(i This specification describes TL1A-binding proteins comprising (ii) a CDR1 having the amino acid sequence described in SEQ ID NO: 698 or a CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 698, (ii) a CDR2 having the amino acid sequence described in SEQ ID NO: 807 or a CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 807, and (iii) a light chain variable region (VL) comprising a CDR3 having the amino acid sequence described in SEQ ID NO: 916 or a CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 916. In some embodiments, the TL1A-binding protein comprises a) a heavy chain variable region (VH) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 371, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 480, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 589, and b) a light chain variable region (VL) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 698, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 807, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 916. In some embodiments, the TL1A-binding protein comprises an immunoglobulin Fc domain. In some embodiments, the Fc domain comprises amino acid modified L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0079] A TL1A-binding protein comprising a)(i) CDR1 having the amino acid sequence described in SEQ ID NO: 372 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 372, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 481 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 481, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 590 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 590, and b)(i) SEQ ID NO: 69 9 CDR1 or SEQ ID NO: 69 having the amino acid sequence described above 9 This specification describes a TL1A-binding protein comprising a light chain variable region (VL) comprising (ii) CDR1 having one to two amino acid substitutions compared to the sequence of (ii) SEQ ID NO: 808, or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 808, and (iii) CDR3 having the amino acid sequence of (iii) SEQ ID NO: 917, or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 917. In some embodiments, the TL1A-binding protein comprises a) a heavy chain variable region (VH) comprising (i) CDR1 having the amino acid sequence of (ii) SEQ ID NO: 372, (ii) CDR2 having the amino acid sequence of (iii) CDR3 having the amino acid sequence of (iii) SEQ ID NO: 590, and b) (i) SEQ ID NO: 69 9 The TL1A-binding protein comprises a light chain variable region (VL) including (ii) CDR1 having the amino acid sequence described in (ii) 808, and (iii) CDR3 having the amino acid sequence described in 917. In some embodiments, the TL1A-binding protein comprises an immunoglobulin Fc domain. In some embodiments, the Fc domain comprises amino acid modified L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0080] A TL1A-binding protein comprising a)(i) a CDR1 having the amino acid sequence described in SEQ ID NO: 373 or a CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 373, (ii) a CDR2 having the amino acid sequence described in SEQ ID NO: 482 or a CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 482, and (iii) a heavy chain variable region (VH) having the amino acid sequence described in SEQ ID NO: 591 or a CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 591, and (i) This specification describes TL1A-binding proteins comprising (ii) a light chain variable region (VL) including (ii) a CDR1 having the amino acid sequence described in SEQ ID NO: 700 or a CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 700, (ii) a CDR2 having the amino acid sequence described in SEQ ID NO: 809 or a CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 809, and (iii) a CDR3 having the amino acid sequence described in SEQ ID NO: 918 or a CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 918. In some embodiments, the TL1A-binding protein comprises a) a heavy chain variable region (VH) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 373, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 482, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 591, and b) a light chain variable region (VL) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 700, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 809, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 918. In some embodiments, the TL1A-binding protein comprises an immunoglobulin Fc domain. In some embodiments, the Fc domain comprises amino acid modified L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0081] A TL1A-binding protein comprising a)(i) CDR1 having the amino acid sequence described in SEQ ID NO: 388 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 388, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 497 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 497, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 606 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 606, and (i) This specification describes TL1A-binding proteins comprising (ii) a light chain variable region (VL) including (ii) a CDR1 having the amino acid sequence described in SEQ ID NO: 715 or a CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 715, (ii) a CDR2 having the amino acid sequence described in SEQ ID NO: 824 or a CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 824, and (iii) a CDR3 having the amino acid sequence described in SEQ ID NO: 933 or a CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 933. In some embodiments, the TL1A-binding protein comprises a) a heavy chain variable region (VH) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 388, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 497, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 606, and b) a light chain variable region (VL) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 715, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 824, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 933. In some embodiments, the TL1A-binding protein comprises an immunoglobulin Fc domain. In some embodiments, the Fc domain comprises amino acid modified L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0082] A TL1A-binding protein comprising a)(i) a heavy chain variable region (VH) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 394 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 394, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 503 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 503, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 612 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 612, and b)(i This specification describes TL1A-binding proteins comprising (ii) a CDR1 having the amino acid sequence described in SEQ ID NO: 721 or a CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 721, (ii) a CDR2 having the amino acid sequence described in SEQ ID NO: 830 or a CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 830, and (iii) a light chain variable region (VL) comprising a CDR3 having the amino acid sequence described in SEQ ID NO: 939 or a CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 939. In some embodiments, the TL1A-binding protein comprises a) a heavy chain variable region (VH) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 394, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 503, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 612, and b) a light chain variable region (VL) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 721, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 830, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 939. In some embodiments, the TL1A-binding protein comprises an immunoglobulin Fc domain. In some embodiments, the Fc domain comprises amino acid modified L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0083] A TL1A-binding protein comprising a)(i) a heavy chain variable region (VH) including (i) a CDR1 having the amino acid sequence described in SEQ ID NO: 400 or a CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 400, (ii) a CDR2 having the amino acid sequence described in SEQ ID NO: 509 or a CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 509, and (iii) a CDR3 having the amino acid sequence described in SEQ ID NO: 618 or a CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 618, and b)(i This specification describes TL1A-binding proteins comprising (ii) a CDR1 having the amino acid sequence described in SEQ ID NO: 727 or a CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 727, (ii) a CDR2 having the amino acid sequence described in SEQ ID NO: 836 or a CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 836, and (iii) a light chain variable region (VL) comprising a CDR3 having the amino acid sequence described in SEQ ID NO: 945 or a CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 945. In some embodiments, the TL1A-binding protein comprises a) a heavy chain variable region (VH) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 400, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 509, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 618, and b) a light chain variable region (VL) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 727, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 836, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 945. In some embodiments, the TL1A-binding protein comprises an immunoglobulin Fc domain. In some embodiments, the Fc domain comprises amino acid modified L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0084] This specification describes TL1A-binding proteins comprising a heavy chain variable region (VH) including: (i) CDR1 having an amino acid sequence described in any one of SEQ ID NOs: 1-4 and 313-421, or an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NOs: 1-4 and 313-421; (ii) CDR2 having an amino acid sequence described in any one of SEQ ID NOs: 11-14 and 422-530, or an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NOs: 11-14 and 422-530; and (iii) CDR3 having an amino acid sequence described in any one of SEQ ID NOs: 21-24 and 531-639, or an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NOs: 21-24 and 531-639.

[0085] This specification describes TL1A-binding proteins comprising a light chain variable region (VL) including (i) CDR1 having an amino acid sequence described in any one of SEQ ID NOs. 31-34 and 640-748, or an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NOs. 1-4 and 313-421; (ii) CDR2 having an amino acid sequence described in any one of SEQ ID NOs. 41-44 and 749-857, or an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NOs. 41-44 and 749-857; and (iii) CDR3 having an amino acid sequence described in any one of SEQ ID NOs. 51-54 and 858-966, or an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NOs. 51-54 and 858-966.

[0086] Aspects of this disclosure relate to compositions comprising the TL1A-binding protein and a pharmaceutically acceptable carrier described herein. Aspects of this disclosure relate to liquid compositions for injection comprising the TL1A-binding protein and a pharmaceutically acceptable carrier described herein.

[0087] Aspects of this disclosure relate to isolated nucleic acids encoding TL1A-binding proteins as described herein.

[0088] Aspects of this disclosure relate to recombinant host cells containing isolated nucleic acids.

[0089] A method for producing a TL1A-binding protein that specifically binds to a TL1A polypeptide containing SEQ ID NO: 2493 or 2494, wherein the TL1A antigen-binding protein is an antibody, is described herein.

[0090] Aspects of the present disclosure relate to a method for obtaining an antibody that specifically binds to a particular epitope portion of a TL1A sequence containing SEQ ID NO: 2493, the method comprising the step of evaluating whether the antibody specifically binds to a particular epitope portion, wherein the particular epitope portion is the amino acid residues of SEQ ID NO: 2493: Val 101, Val 102, Arg 103, Gln 104, Thr 105, Pro 106, Thr 107, Gln 108, His 109, Phe 110, Lys 111, His 118, Trp 119, Glu 120, Glu 122, Leu 123, Gly 124, Lys 137, Arg 156, Gly 157, Met 158, Ser 234, Tyr 238, and Thr The present invention relates to a method comprising the steps of: having 10 or more amino acid residues selected from 239; and isolating or selecting an antibody that binds to a particular epitope moiety.

[0091] Aspects of the present disclosure relate to a method for obtaining an antibody that specifically binds to a particular epitope portion of a TL1A sequence containing SEQ ID NO: 2493, the method comprising the steps of: evaluating whether the antibody specifically binds to a particular epitope portion, wherein the particular epitope portion has the amino acid residues Val 102, Arg 103, Gln 104, Thr 105, Thr 107, Gln 108, His 118, Trp 119, Glu 120, Glu 122, Leu 123, Gly 124, Lys 137, Arg 156, Gly 157, Met 158, Ser 234, Tyr 238, and Thr 239 of SEQ ID NO: 2493; and isolating or selecting an antibody that binds to a particular epitope portion.

[0092] Aspects of this disclosure relate to a method for producing a TL1A-binding protein that specifically binds to a TL1A polypeptide containing SEQ ID NO: 2493 at one of the amino acid residues in Tables 12, 13, or 14, wherein the TL1A antigen-binding protein is an antibody. In some embodiments, the TL1A-binding antibody specifically binds to a TL1A polypeptide containing SEQ ID NO: 2493 at one of the amino acid residues Lys240, Thr239, Tyr238, Asp237, Val236, Leu235, Ser234, Gln104, and Arg103. In some embodiments, the TL1A-binding antibody specifically binds to a TL1A polypeptide containing SEQ ID NO: 2493 at one of the amino acid residues Val 102, Arg 103, Gln 104, Glu 120, Glu 122, Leu 123, and Arg 156.

[0093] Aspects of the present disclosure relate to a method for obtaining an antibody that specifically binds to a particular epitope portion of a TL1A sequence including SEQ ID NO: 2493 or SEQ ID NO: 2494, the method comprising the steps of: evaluating whether the antibody specifically binds to a particular epitope portion; and isolating or selecting an antibody that binds to a particular epitope portion, wherein the particular epitope portion is recognized by the antibody described herein; or having the amino acid residues Val 102, Arg 103, Gln 104, Glu 120, Glu 122, Leu 123, and Arg 156 of SEQ ID NO: 2493; or having the amino acid residues Lys 240, Thr 239, Tyr 238, Asp 237, Val 236, Leu 235, Ser 234, Gln 104, and Arg 103 of SEQ ID NO: 2493.

[0094] Aspects of this disclosure relate to a method for obtaining an antibody that specifically binds to a particular epitope portion of TL1A by competitively inhibiting the binding of an antibody disclosed herein, for example, antibodies 1, 2, 3, 4, 6, 8, 10, 47, 49, 63, or 69 disclosed herein.

[0095] Aspects of this disclosure relate to a method for treating gastrointestinal inflammatory disease in a patient requiring treatment for the gastrointestinal inflammatory disease, the method comprising subcutaneously or intravenously administering an effective amount of the TL1A-binding protein described herein to the patient. In some embodiments, the administration of the TL1A-binding protein is subcutaneous. In some embodiments, the administration of the TL1A-binding protein is intravenous. In some embodiments, the method comprises the step of administering the TL1A-binding protein to the patient two or more times at intervals of about two weeks to about twelve weeks or longer.

[0096] Aspects of this disclosure relate to a method for treating inflammatory bowel disease in a patient requiring treatment for inflammatory bowel disease, the method comprising subcutaneously or intravenously administering an effective amount of the TL1A-binding protein described herein to the patient. The inflammatory bowel disease is Crohn's disease or ulcerative colitis. In some embodiments, the administration of the TL1A-binding protein is subcutaneous. In some embodiments, the administration of the TL1A-binding protein is intravenous. In some embodiments, the method comprises the step of administering the TL1A-binding protein to the patient two or more times at intervals of about two weeks to about twelve weeks or longer.

[0097] Aspects of this disclosure relate to a method for treating an inflammatory disease in a patient requiring treatment for the inflammatory disease, the method comprising subcutaneously or intravenously administering an effective amount of the TL1A-binding protein described herein to the patient. In some embodiments, the inflammatory disease is psoriasis, psoriatic arthritis, or hidradenitis suppurativa.

[0098] In some embodiments, the administration of the TL1A-binding protein is subcutaneous. In some embodiments, the administration of the TL1A-binding protein is intravenous. In some embodiments, the method includes the step of administering the TL1A-binding protein to a patient two or more times at intervals ranging from about two weeks to about twelve weeks or longer. [Brief explanation of the drawing]

[0099] [Figure 1] Figure 1 is a graph showing the TL1A-binding antibody (Antibody 10) described herein and various comparative antibodies that bind to membrane TL1A. Comparative antibody 1 has substantially the same amino acid sequence as RVT-3101 and is referred to herein as RVT-3101; comparative antibody 2 has substantially the same amino acid sequence as MK-7240 and is referred to herein as MK-7240; and comparative antibody 3 has substantially the same amino acid sequence as TEV-48574 and is referred to herein as TEV-48574.

[0100] [Figure 2A] Figures 2A and 2B show the binding of various comparative antibodies to TL1A monomers and trimers compared to the TL1A-binding antibodies disclosed herein. [Figure 2B] Same as above.

[0101] [Figure 3A] Figures 3A-3D show the apoptosis inhibition of various comparator antibodies compared to the TL1A-binding antibodies disclosed herein. [Figure 3B] Same as above. [Figure 3C] Same as above. [Figure 3D] Same as above.

[0102] [Figure 4A] Figures 4A–4E show the half-lives of the TL1A-binding antibodies disclosed herein in non-human primates. Figure 4F shows the half-lives of the TL1A-binding antibodies disclosed herein in Tg276 mice expressing human FcRn. [Figure 4B] Same as above. [Figure 4C] Same as above. [Figure 4D] Same as above. [Figure 4E] Same as above. [Figure 4F] Same as above.

[0103] [Figure 5A] Figures 5A and 5B show the inhibition of TL1A-induced apoptosis in response to various comparative antibodies and TL1A-binding antibodies described herein. [Figure 5B] Same as above.

[0104] [Figure 6A] Figures 6A-6C show formulation data of the TL1A-binding antibodies described herein compared with various comparator antibodies. [Figure 6B] Same as above. [Figure 6C] Same as above.

[0105] [Figure 7A] Figures 7A-7F show the chemical and pharmacokinetic data of the TL1A-binding antibodies described herein, compared to various comparator antibodies. [Figure 7B] Same as above. [Figure 7C] Same as above. [Figure 7D] Same as above. [Figure 7E] Same as above. [Figure 7F] Same as above.

[0106] [Figure 8A] Figure 8A shows the CryoEM image of the epitope against the control TL1A-binding antibody. Figure 8B shows the CryoEM image of the epitope against TL1A-binding antibody 10. [Figure 8B] Same as above. [Modes for carrying out the invention]

[0107] Detailed explanation It should be understood that both the general statements above and the detailed statements below are illustrative and merely explanatory, and do not limit this disclosure.

[0108] Headings used in this specification are for structural purposes only and should not be construed as limiting the subjects described herein.

[0109] All documents or parts of documents cited in this application, including but not limited to patents, patent applications, articles, books, and scholarly works, are thus explicitly incorporated by reference in their entirety for any purpose.

[0110] definition Unless otherwise specified, all technical terms used herein have the same meanings as those commonly understood by those skilled in the art in which the present invention pertains. Unless otherwise specified or as is clear from the context, the following terms have the following meanings:

[0111] As used herein, unless otherwise specified, the term “antibody” means an intact antibody (e.g., an intact monoclonal antibody), or a fragment thereof, e.g., an Fc fragment of an antibody (e.g., an Fc fragment of a monoclonal antibody), or an antigen-binding fragment of an antibody (e.g., an antigen-binding fragment of a monoclonal antibody), and is understood to include modified, engineered, or chemically conjugated intact antibodies, antigen-binding fragments, or Fc fragments. Generally, an antibody is a multimeric protein containing four polypeptide chains. Two of these polypeptide chains are called immunoglobulin heavy chains (H chains), and two of these polypeptide chains are called immunoglobulin light chains (L chains). The immunoglobulin heavy and light chains are linked by interchain disulfide bonds. The immunoglobulin heavy chains are linked by interchain disulfide bonds. The light chains consist of one variable region (VL) and one constant region (CL). The heavy chain consists of one variable region (VH) and at least three constant regions (CH1, CH2, and CH3). The variable region determines the antibody's binding specificity. Each variable region contains three hypervariable regions known as complementarity-determining regions (CDRs), flanked by four relatively conserved regions known as framework regions (FRs). The ranges of the FRs and CDRs are defined (Kabat et al. (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, US Department of Health and Human Services, NIH Publication No. 91-3242; and Chothia, C. et al. (1987) J. Mol. Biol. 196:901-917). The three CDRs are referred to as CDR1, CDR2, and CDR3, and contribute to the antibody's binding specificity. Naturally occurring antibodies are used as starting materials for engineered antibodies such as chimeric antibodies and humanized antibodies.Examples of antibody-based antigen-binding fragments include Fab, Fab', (Fab')2, Fv, single-chain antibodies (e.g., scFv), minibodies, and diabodies. Examples of modified or engineered antibodies include chimeric antibodies, humanized antibodies, and multispecific antibodies (e.g., bispecific antibodies). An example of a chemically conjugated antibody is an antibody conjugated with a toxin moiety.

[0112] The terms “variable domain” and “variable region” are used interchangeably and refer to a portion of an antibody or immunoglobulin domain that exhibits variability in its sequence and is involved in determining the specificity and binding affinity of a particular antibody. The variability is not uniformly distributed throughout the entire variable domain of the antibody, but is concentrated in the respective subdomains of the heavy chain variable region and the light chain variable region. These subdomains are referred to as “hypervariable regions” or “complementarity-determining regions” (CDRs). The more conserved (i.e., non-hypervariable) portions of the variable domain are called “framework” regions (FRMs or FRs) and provide a scaffold for the six CDRs to form antigen-binding surfaces in three-dimensional space.

[0113] When used herein, the “Fc polypeptide” of dimer Fc refers to one of the two polypeptides that form the dimer Fc domain, i.e., the polypeptide containing the C-terminal constant region of an immunoglobulin heavy chain that is stably self-associable. For example, the Fc polypeptide of dimer IgG Fc contains the IgG CH2 and IgG CH3 constant domain sequences. Fc can be Fc of classes IgA, IgD, IgE, IgG, and IgM. These classes are also denoted as α, δ, ε, γ, and μ, respectively. Some of these can be further divided into subclasses (isotypes), e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2.

[0114] The terms “Fc receptor” and “FcR” are used to describe receptors that bind to the Fc region of an antibody. For example, an FcR may be a human FcR with its native sequence. Generally, FcRs are those that bind to IgG antibodies (gamma receptors), and include the FcγRI, FcγRII, and FcγRIII subclasses of receptors, encompassing allele variants and alternative spliced ​​forms of these receptors. FcγRII receptors include FcγRIIA ("activating receptor") and FcγRIIB ("inhibitory receptor"), which have similar amino acid sequences and differ primarily in their cytoplasmic domains. Certain FcRs may also bind to other isotypes of immunoglobulins (see, for example, Janeway et al., Immuno Biology: the immune system in health and disease, (Elsevier Science Ltd., NY) (4th ed., 1999)). The activating receptor FcγRIIA contains an immunoreceptor-activating tyrosine motif (ITAM) in its cytoplasmic domain. The inhibitory receptor FcγRIIB contains an immunoreceptor-suppressing tyrosine motif (ITIM) in its cytoplasmic domain (Daeron, Annu. Rev. Immunol. 15:203-234 (1997)). FcRs are outlined in Ravetch and Kinet, Annu. Rev. Immunol 9:457-92 (1991); Capel et al., Immunomethods 4:25-34 (1994); and de Haas et al., J. Lab. Clin. Med. 126:330-41 (1995). Other FcRs, including those to be identified in the future, are also included in the term "FcR" as used herein. This term also encompasses the neonatal receptor FcRn, which is involved in the transfer of maternal IgG to the fetus (Guyer et al., J. Immunol. 117:587 (1976); and Kim et al., J. Immunol. 24:249 (1994)).

[0115] The terms “recipient,” “individual,” “subject,” “host,” and “patient” are used interchangeably herein and, in some embodiments, refer to any mammalian subject, particularly humans, to whom diagnosis, treatment, or therapy is desired. “Mammal” means, for the purpose of treatment, any animal classified as a mammal, including humans, domestic and agricultural animals, and laboratory animals, zoo animals, sports animals, or pets, such as dogs, horses, cats, cattle, sheep, goats, pigs, mice, rats, rabbits, guinea pigs, and monkeys. In some embodiments, mammal is human. None of these terms require medical supervision.

[0116] As used herein, the term “effective dose” means an amount of a compound (e.g., a compound of this disclosure) sufficient to produce a beneficial or desired result. An effective dose may be administered in one or more doses, applications, or dosages and is not limited to a specific formulation or route of administration. As used herein, the term “treating” includes any effect that results in improvement of a condition, disease, disorder, etc., such as relief, reduction, modulation, improvement or elimination, or improvement of its symptoms.

[0117] As used herein, the term “pharmaceutical composition” refers to a combination of an active agent and an inactive or active carrier that constitutes a composition particularly suitable for diagnostic or therapeutic use in vivo or ex vivo.

[0118] As used herein, the term “pharmaceutically acceptable carrier” refers to any of the standard pharmaceutically acceptable carriers, such as phosphate-buffered saline, water, emulsions (e.g., oil / water or water / oil emulsions), and various types of wetting agents. The composition may also include stabilizers and preservatives. For examples of carriers, stabilizers, and adjuvants, see, for example, Martin, Remington's Pharmaceutical Sciences, 15th Ed., Mack Publ. Co., Easton, PA (1975).

[0119] The terms “a” and “an” as used herein mean “one or more” and include multiple terms unless otherwise inappropriate from the context.

[0120] Where used herein, all numbers or numerical ranges include integers that fall within or encompass such a range, and fractions of values ​​or integers that fall within or encompass such a range, unless the context explicitly indicates otherwise. Thus, for example, a reference to the range 90–100% includes 91%, 92%, 93%, 94%, 95%, 95%, 96%, 97%, etc., as well as 91.1%, 91.2%, 91.3%, 91.4%, 91.5%, etc., and 92.1%, 92.2%, 92.3%, 92.4%, 92.5%, etc. In another example, references to the range of 1 to 5,000 times include 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 times, as well as 1.1, 1.2, 1.3, 1.4, 1.5 times, 2.1, 2.2, 2.3, 2.4, 2.5 times, etc.

[0121] When used herein, "approximately" refers to a range that includes the number and extends from less than 10% of that number to more than 10% of that number. The "approximately" range extends from less than 10% of the lower limit of that range to more than 10% of the upper limit of that range.

[0122] "Percent (%) identity" refers to the degree to which two sequences (nucleotides or amino acids) have the same residues at the same aligned position. For example, "an amino acid sequence is X% identical to sequence number Y" refers to the % identity of that amino acid sequence to sequence number Y, and explains that X% of the residues in that amino acid sequence are identical to the residues in the sequence disclosed in sequence number Y. Generally, computer programs are used for such calculations. Exemplary programs for comparing and aligning pairs of sequences include ALIGN (Myers and Miller, 1988), FASTA (Pearson and Lipman, 1988; Pearson, 1990), and gapped BLAST (Altschul et al., 1997), BLASTP, BLASTN, or GCG (Devereux et al., 1984).

[0123] Throughout this description, where a composition is described as having, including, or comprising a particular component, or where a process and method is described as having, including, or comprising a particular step, it is intended that there exist compositions of the Disclosure that are essentially composed of or consist of the described components, and that there exist processes and methods of the Disclosure that are essentially composed of or consist of the described process steps.

[0124] Generally speaking, for compositions where percentages are specified, they are based on weight unless otherwise specified. Furthermore, if a variable is not defined, its previous definition applies. TL1A-binding protein

[0125] Compositions, systems, and methods comprising TL1A-binding proteins are provided herein. The TL1A-binding proteins described herein may bind to TL1A monomers, TL1A trimers, or both; may have picomolar potency to TL1A monomers, TL1A trimers, or both; and may have an extended half-life (e.g., compared to known antibodies targeting TL1A); or a combination thereof. In some embodiments, the TL1A-binding proteins described herein enable subcutaneous administration. In some embodiments, the TL1A-binding proteins described herein enable administration, for example, every 8 weeks, every 12 weeks, or at longer intervals. The TL1A-binding proteins described herein may also have improved specificity. The TL1A-binding proteins described herein may have specificity for monomeric TL1A and trimeric TL1A, but may not have specificity for related TNF superfamily proteins such as TNF, FasL, TRAIL, or LIGHT.

[0126] TL1A-binding protein, a)(i) Sequence ID 5 CDR1 or SEQ ID NO: having the amino acid sequence described above 5 CDR1, which has one to two amino acid substitutions compared to the sequence, (ii) Sequence ID 15 CDR2 or SEQ ID NO: having the amino acid sequence described above 15 CDR2 having one to two amino acid substitutions compared to the sequence, and (iii) Sequence ID 25 CDR3 or SEQ ID NO: having the amino acid sequence described above 25 The heavy chain variable region (VH) containing CDR3 with one to two amino acid substitutions compared to the sequence, and b)(i) Sequence ID 35 CDR1 or SEQ ID NO: having the amino acid sequence described above 35 CDR1, which has one to two amino acid substitutions compared to the sequence, (ii) Sequence ID 45CDR2 or SEQ ID NO: having the amino acid sequence described above 45 CDR2 having one to two amino acid substitutions compared to the sequence, and (iii) Sequence ID 55 CDR3 or SEQ ID NO: having the amino acid sequence described above 55 TL1A-binding proteins are described herein that include a light chain variable region (VL) containing a CDR3 having one to two amino acid substitutions compared to the sequence. In some embodiments, the TL1A-binding protein is a)(i) Sequence ID 5 CDR1 having the amino acid sequence described above, (ii) Sequence ID 15 CDR2 having the amino acid sequence described above, and (iii) Sequence ID 25 A heavy chain variable region (VH) containing CDR3 having the amino acid sequence described above, and b)(i) Sequence ID 35 CDR1 having the amino acid sequence described above, (ii) Sequence ID 45 CDR2 having the amino acid sequence described above, and (iii) Sequence ID 55 The TL1A-binding protein includes a light chain variable region (VL) containing CDR3 having the amino acid sequence described above. In some embodiments, the TL1A-binding protein includes an immunoglobulin Fc domain. In some embodiments, the Fc domain includes amino acid modified L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE). 。

[0127] TL1A-binding proteins, a) (i) CDR1 having the amino acid sequence described in SEQ ID NO: 6, or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 6, (ii) SEQ ID NO: 1 6 CDR2 or SEQ ID NO: 1 having the amino acid sequence described above. 6 CDR2 having one to two amino acid substitutions compared to the sequence, and (iii) Sequence ID 26 CDR3 or SEQ ID NO: having the amino acid sequence described above 26 The heavy chain variable region (VH) containing CDR3 with one to two amino acid substitutions compared to the sequence, and b)(i) Sequence ID 36CDR1 or SEQ ID NO: having the amino acid sequence described above 36 CDR1, which has one to two amino acid substitutions compared to the sequence, (ii) Sequence ID 46 CDR2 or SEQ ID NO: having the amino acid sequence described above 46 CDR2 having one to two amino acid substitutions compared to the sequence, and (iii) Sequence ID 56 CDR3 or SEQ ID NO: having the amino acid sequence described above 56 This specification describes TL1A-binding proteins comprising a light chain variable region (VL) containing a CDR3 having one to two amino acid substitutions compared to the sequence of (1). In some embodiments, the TL1A-binding protein comprises a)(i) a CDR1 having the amino acid sequence described in SEQ ID NO: 6, and (ii) SEQ ID NO: 1 6 CDR2 having the amino acid sequence described above, and (iii) Sequence ID 26 A heavy chain variable region (VH) containing CDR3 having the amino acid sequence described above, and b)(i) Sequence ID 36 CDR1 having the amino acid sequence described above, (ii) Sequence ID 46 CDR2 having the amino acid sequence described above, and (iii) Sequence ID 56 The TL1A-binding protein includes a light chain variable region (VL) containing CDR3 having the amino acid sequence described above. In some embodiments, the TL1A-binding protein includes an immunoglobulin Fc domain. In some embodiments, the Fc domain includes amino acid modified L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0128] TL1A-binding proteins, a) (i) CDR1 having the amino acid sequence described in SEQ ID NO: 7 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 7, (ii) SEQ ID NO: 1 7 CDR2 or SEQ ID NO: 1 having the amino acid sequence described above. 7 CDR2 having one to two amino acid substitutions compared to the sequence, and (iii) Sequence ID 27 CDR3 or SEQ ID NO: having the amino acid sequence described above 27The heavy chain variable region (VH) containing CDR3 with one to two amino acid substitutions compared to the sequence, and b)(i) Sequence ID 37 CDR1 or SEQ ID NO: having the amino acid sequence described above 37 CDR1, which has one to two amino acid substitutions compared to the sequence, (ii) Sequence ID 47 CDR2 or SEQ ID NO: having the amino acid sequence described above 47 CDR2 having one to two amino acid substitutions compared to the sequence, and (iii) Sequence ID 57 CDR3 or SEQ ID NO: having the amino acid sequence described above 57 This specification describes TL1A-binding proteins comprising a light chain variable region (VL) containing a CDR3 having one to two amino acid substitutions compared to the sequence of (1). In some embodiments, the TL1A-binding protein comprises a)(i) a CDR1 having the amino acid sequence described in SEQ ID NO: 7, and (ii) SEQ ID NO: 1 7 CDR2 having the amino acid sequence described above, and (iii) Sequence ID 27 A heavy chain variable region (VH) containing CDR3 having the amino acid sequence described above, b) (i) Sequence ID 37 CDR1 having the amino acid sequence described above, (ii) Sequence ID 47 CDR2 having the amino acid sequence described above, and (iii) Sequence ID 57 The TL1A-binding protein includes a light chain variable region (VL) containing CDR3 having the amino acid sequence described above. In some embodiments, the TL1A-binding protein includes an immunoglobulin Fc domain. In some embodiments, the Fc domain includes amino acid modified L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0129] This specification describes a TL1A-binding protein comprising: a) a heavy chain variable region (VH) including (i) a CDR1 having the amino acid sequence described in SEQ ID NO: 8 or a CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 8; (ii) a CDR2 having the amino acid sequence described in SEQ ID NO: 18 or a CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 18; and (iii) a light chain variable region (VL) including (i) a CDR1 having the amino acid sequence described in SEQ ID NO: 38 or a CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 38; (ii) a CDR2 having the amino acid sequence described in SEQ ID NO: 48 or a CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 48; and (iii) a light chain variable region (VL) including a CDR3 having the amino acid sequence described in SEQ ID NO: 58 or a CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 58. In some embodiments, the TL1A-binding protein includes a) a heavy chain variable region (VH) comprising (i) CDR1 having the amino acid sequence described in SEQ ID NO: 8, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 18, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 28, and b) a light chain variable region (VL) comprising (i) CDR1 having the amino acid sequence described in SEQ ID NO: 38, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 48, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 58. In some embodiments, the TL1A-binding protein includes an immunoglobulin Fc domain. In some embodiments, the Fc domain includes amino acid modified L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0130] This specification describes a TL1A-binding protein comprising: a) a heavy chain variable region (VH) including (i) a CDR1 having the amino acid sequence described in SEQ ID NO: 9 or a CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 9; (ii) a CDR2 having the amino acid sequence described in SEQ ID NO: 19 or a CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 19; and (iii) a light chain variable region (VL) including (i) a CDR1 having the amino acid sequence described in SEQ ID NO: 39 or a CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 39; (ii) a CDR2 having the amino acid sequence described in SEQ ID NO: 49 or a CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 49; and (iii) a light chain variable region (VL) including a CDR3 having the amino acid sequence described in SEQ ID NO: 59 or a CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 59. In some embodiments, the TL1A-binding protein comprises a heavy chain variable region (VH) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 9, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 19, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 29, and a light chain variable region (VL) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 39, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 49, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 59. In some embodiments, the TL1A-binding protein comprises an immunoglobulin Fc domain. In some embodiments, the Fc domain comprises amino acid modified L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0131] TL1A-binding protein, a)(i) Sequence ID 10 CDR1 or SEQ ID NO: having the amino acid sequence described above10 CDR1, which has one to two amino acid substitutions compared to the sequence, (ii) Sequence ID 20 CDR2 or SEQ ID NO: having the amino acid sequence described above 20 CDR2 having one to two amino acid substitutions compared to the sequence, and (iii) Sequence ID 30 CDR3 or SEQ ID NO: having the amino acid sequence described above 30 The heavy chain variable region (VH) containing CDR3 with one to two amino acid substitutions compared to the sequence, and b)(i) Sequence ID 40 CDR1 or SEQ ID NO: having the amino acid sequence described above 40 CDR1, which has one to two amino acid substitutions compared to the sequence, (ii) Sequence ID 50 CDR2 or SEQ ID NO: having the amino acid sequence described above 50 CDR2 having one to two amino acid substitutions compared to the sequence, and (iii) Sequence ID 60 CDR3 or SEQ ID NO: having the amino acid sequence described above 60 TL1A-binding proteins are described herein that include a light chain variable region (VL) containing a CDR3 having one to two amino acid substitutions compared to the sequence. In some embodiments, the TL1A-binding protein is a)(i) Sequence ID 10 CDR1 having the amino acid sequence described above, (ii) Sequence ID 20 CDR2 having the amino acid sequence described above, and (iii) Sequence ID 30 A heavy chain variable region (VH) containing CDR3 having the amino acid sequence described above, and (i) Sequence ID 40 CDR1 having the amino acid sequence described above, (ii) Sequence ID 50 CDR2 having the amino acid sequence described above, and (iii) Sequence ID 60 The TL1A-binding protein includes a light chain variable region (VL) containing CDR3 having the amino acid sequence described above. In some embodiments, the TL1A-binding protein includes an immunoglobulin Fc domain. In some embodiments, the Fc domain includes amino acid modified L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0132] In some embodiments, the TL1A-binding antibody specifically binds to the epitope of the TL1A polypeptide recognized by the antibody disclosed herein. In some embodiments, the TL1A-binding antibody specifically binds to the epitope of the TL1A polypeptide recognized by antibody 1, 2, 3, 4, 6, 8, 10, 47, 49, 63, or 69 disclosed herein.

[0133] In some embodiments, the TL1A-binding antibody specifically binds to the TL1A polypeptide containing SEQ ID NO: 2493 at one of the following amino acid residues: Val 101, Val 102, Arg 103, Gln 104, Thr 105, Pro 106, Thr 107, Gln 108, His 109, Phe 110, Lys 111, His 118, Trp 119, Glu 120, Glu 122, Leu 123, Gly 124, Lys 137, Arg 156, Gly 157, Met 158, Ser 231, Asp 232, Ile 233, Ser 234, Tyr 238, Thr 239, Lys 240, and Lys 243. In some embodiments, the TL1A-binding antibody specifically binds to the TL1A sequence at 10 or more amino acid residues selected from Val 102, Arg 103, Gln 104, Thr 105, Thr 107, Gln 108, His 118, Trp 119, Glu 120, Glu 122, Leu 123, Gly 124, Lys 137, Arg 156, Gly 157, Met 158, Ser 231, Asp 232, Ile 233, Ser 234, Leu 235, Val 236, Asp 237, Tyr 238, Thr 239, Lys 240, and Lys 243 of SEQ ID NO: 2493. In some embodiments, the TL1A-binding antibody specifically binds to the TL1A sequence at 10 or more amino acid residues selected from Arg 103, Gln 104, Ser 234, Leu 235, Val 236, Asp 237, Tyr 238, Thr 239, and Lys 240 of SEQ ID NO: 2493. In some embodiments, the TL1A-binding protein is an antibody.

[0134] In some embodiments, the TL1A-binding protein specifically binds to the epitope of TL1A. In some embodiments, the TL1A-binding protein specifically binds to one of the following amino acid residues of the TL1A polypeptide, including SEQ ID NO: 2493: Val 102, Arg 103, Gln 104, Thr 105, Thr 107, Gln 108, His 118, Trp 119, Glu 120, Glu 122, Leu 123, Gly 124, Lys 137, Arg 156, Gly 157, Met 158, Ser 234, Tyr 238, and Thr 239. In some embodiments, the TL1A-binding protein specifically binds to the TL1A sequence at the amino acid residues Arg103, Gln104, Ser234, Leu235, Val236, Asp237, Tyr238, Thr239, and Lys240.

[0135] In some embodiments, TL1A-binding proteins that are antibodies are described herein, which specifically bind to the TL1A polypeptide containing SEQ ID NO: 2493 at any one of the following amino acid residues: Val 102, Arg 103, Gln 104, Thr 105, Thr 107, Gln 108, His 118, Trp 119, Glu 120, Glu 122, Leu 123, Gly 15 124, Lys 137, Arg 156, Gly 157, Met 158, Ser 234, Tyr 238, and Thr 239. In some embodiments, the TL1A-binding protein specifically binds to the TL1A sequence at the amino acid residues Val 102, Arg 103, Gln 104, Thr 105, Thr 107, Gln 108, His 118, Trp 119, Glu 120, Glu 122, Leu 123, Gly 124, Lys 137, Arg 156, Gly 157, Met 158, Ser 234, Tyr 238, and Thr 239.

[0136] In some embodiments, the TL1A-binding protein specifically binds to the TL1A sequence at all of at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, or 19 of the amino acid residues Val 102, Arg 103, Gln 104, Thr 105, Thr 107, Gln 108, His 118, Trp 119, Glu 120, Glu 122, Leu 123, Gly 124, Lys 137, Arg 156, Gly 157, Met 158, Ser 234, Tye 238, and Thr 239 of sequence number 2493.

[0137] In some embodiments, the TL1A-binding protein is the amino acid residue of SEQ ID NO: 2493, Val 101, Val 102, Arg 103, Gln 104, Thr 105, Pro 106, Thr 107, His 118, Trp 119, Glu 120, His 121, Glu 122, Leu 123, Gly 124, Tyr 134, Asn 136, Arg 156, Gly 157, Met 158, Thr 159, Ser 206, Asn 207, Ser 234, Leu 235, Val 236, Asp 237, Tyr 238, Thr 239, and Lys It specifically binds to at least 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, or all of the 240.

[0138] In some embodiments, the TL1A-binding protein is the amino acid residue of SEQ ID NO: 2493 relative to the TL1A sequence: Arg 103, Gln 104, Thr 105, Pro 106, Thr 107, Gln 108, His 109, Phe 110, Lys 111, Pro 115, Arg 156, Met 158, Thr 159, Ser 160, Glu 161, Ala 168, Gly 169, Arg 170, Pro 171, Lys 173, Asp 175, Gln 193, Ser 206, Asn 207, Ser 231, Asp 232, Ile 233, Ser 234, Leu 235, Val 236, Asp 237, Tyr It specifically binds to at least 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, or all of the following: 238, Thr 239, Lys 240, and Lys 243.

[0139] In some embodiments, the TL1A-binding protein is configured to bind to the amino acid residues of SEQ ID NO: 2493 relative to the TL1A sequence: Val 102, Arg 103, Gln 104, Thr 105, Pro 106, Thr 107, Gln 108, His 109, Asn 112, Pro 115, Leu 117, Arg 156, Gly 157, Met 158, Thr 159, Ser 160, Glu 161, Arg 170, Lys 173, Asp 175, Ser 176, Val 201, Ser 206, Asn 207, Trp 208, Phe 209, Asp 232, Ile 233, Ser 234, Leu 235, Val 236, Asp It specifically binds to at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 21, 22, or all of 237, Tyr 238, Thr 239, Lys 240, and Lys 243.

[0140] In some embodiments, the TL1A-binding protein specifically binds to the TL1A sequence at at least 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, or all of the amino acid residues Val 101, Val 102, Arg 103, Gln 104, His 118, Trp 119, Glu 120, His 121, Glu 122, Leu 123, Gly 124, Tyr 134, Thr 135, Lys 137, Tyr 188, Glu 190, Pro 191, Thr 192, Gln 193, Thr 239, Lys 240, Glu 241, and Asp 272 of sequence number 2493.

[0141] In some embodiments, the TL1A-binding protein specifically binds to the TL1A sequence at at least one, two, three, four, five, six, seven, eight, nine, ten, one, two, one

[0142] In some embodiments, the TL1A-binding protein specifically binds to the TL1A sequence at least one, two, three, four, five, six, seven, eight, nine, ten, one, or all of the amino acid residues Val 101, Val 102, Arg 103, Gln 104, Thr 105, Gln 108, Glu 120, Glu 122, Leu 123, Arg 156, Gly 157, Met 158, and Tyr 238 of SEQ ID NO: 2493.

[0143] In some embodiments, the TL1A-binding protein specifically binds to the TL1A sequence at at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or all of the amino acid residues Val 101, Val 102, Arg 103, Gln 104, Thr 105, Pro 106, His 118, Glu 120, Glu 122, Leu 123, Gly 124, Arg 156, Ser 234, Tyr 238, and Thr 239 of SEQ ID NO: 2493.

[0144] In some embodiments, the TL1A-binding protein is the amino acid residue of SEQ ID NO: 2493, Val 101, Val 102, Arg 103, Gln 104, Thr 105, Pro 106, Thr 107, Gln 108, His 109, Phe 110, Lys 111, Leu 117, His 118, Trp 119, Arg 156, Gly 157, Lys 173, Met 196, Ser 206, Ser 231, Asp 232, Ile 233, Ser 234, Leu 235, Val 236, Asp 237, Tyr 238, Thr 239, Lys 240, and Lys It specifically binds to at least 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or all of the 243.

[0145] In some embodiments, the TL1A-binding protein is the amino acid residue of SEQ ID NO: 2493, Val 101, Val 102, Arg 103, Gln 104, Thr 105, Pro 106, Thr 107, Gln 108, His 109, Phe 110, Lys 111, Gln 113, Pro 115, Leu 117, His 118, Trp 119, Arg 156, Lys 173, Ser 206, Asn 207, Ser 231, Asp 232, Ile 233, Ser 234, Leu 235, Val 236, Asp 237, Tyr 238, Thr 239, Lys 240, and Lys It specifically binds to at least 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, or all of the 243.

[0146] In some embodiments, the TL1A-binding protein is the amino acid residues of SEQ ID NO: 2493, Val 101, Val 102, Arg 103, Gln 104, Thr 105, Pro 106, Thr 107, Gln 108, His 109, Phe 110, Lys 111, Leu 117, His 118, Trp 119, Arg 156, Lys 173, Ser 231, Asp 232, Ile 233, Ser 234, Leu 235, Val 236, Asp 237, Tyr 238, Thr 239, Lys 240, and Lys It specifically binds to at least 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, or all of the 243.

[0147] In some embodiments, the TL1A-binding protein is the amino acid residue of SEQ ID NO: 2493 relative to the TL1A sequence: Thr 100, Val 101, Val 102, Arg 103, Gln 104, Thr 105, Pro 106, Thr 107, Gln 108, His 109, Phe 110, Lys 111, Gln 113, Pro 115, His 118, Trp 119, Glu 120, Arg 156, Asp 232, Ile 233, Ser 234, Leu 235, Val 236, Asp 237, Tyr 238, Thr 239, Lys 240, and Lys It specifically binds to at least 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, or all of the 243.

[0148] In some embodiments, amino acid residues of the TL1A epitope bind to the antibody paratope at distances of 6 angstroms or less, 5 angstroms or less, 4 angstroms or less, 3 angstroms or less, or 2 angstroms or less.

[0149] This specification describes a TL1A-binding protein comprising: a) a heavy chain variable region (VH) including (i) a CDR1 having the amino acid sequence described in SEQ ID NO: 1 or a CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 1, (ii) a CDR2 having the amino acid sequence described in SEQ ID NO: 11 or a CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 11, and (iii) a heavy chain variable region (VL) including (i) a CDR1 having the amino acid sequence described in SEQ ID NO: 31 or a CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 31, (ii) a CDR2 having the amino acid sequence described in SEQ ID NO: 41 or a CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 41, and (iii) a light chain variable region (VL) including a CDR3 having the amino acid sequence described in SEQ ID NO: 51 or a CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 51. In some embodiments, the TL1A-binding protein comprises a) a heavy chain variable region (VH) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 1, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 11, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 21, and b) a light chain variable region (VL) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 31, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 41, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 51. In some embodiments, the TL1A-binding protein comprises an immunoglobulin Fc domain. In some embodiments, the Fc domain comprises amino acid modified L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0150] This specification describes a TL1A-binding protein comprising: a) a heavy chain variable region (VH) including (i) a CDR1 having the amino acid sequence described in SEQ ID NO: 2 or a CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 2; (ii) a CDR2 having the amino acid sequence described in SEQ ID NO: 12 or a CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 12; and (iii) a light chain variable region (VL) including (i) a CDR1 having the amino acid sequence described in SEQ ID NO: 32 or a CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 32; (ii) a CDR2 having the amino acid sequence described in SEQ ID NO: 42 or a CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 42; and (iii) a CDR3 having the amino acid sequence described in SEQ ID NO: 52 or a CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 52. In some embodiments, the TL1A-binding protein includes a) a heavy chain variable region (VH) comprising (i) CDR1 having the amino acid sequence described in SEQ ID NO: 2, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 12, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 22, and b) a light chain variable region (VL) comprising (i) CDR1 having the amino acid sequence described in SEQ ID NO: 32, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 42, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 52. In some embodiments, the TL1A-binding protein includes an immunoglobulin Fc domain. In some embodiments, the Fc domain includes amino acid modified L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0151] A TL1A-binding protein is described herein, comprising a) a heavy chain variable region (VH) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 3 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 3, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 13 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 13, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 23 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 23; and a light chain variable region (VL) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 33 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 33, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 43 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 43, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 53 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 53. In some embodiments, the TL1A-binding protein comprises a) a heavy chain variable region (VH) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 3, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 13, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 23, and b) a light chain variable region (VL) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 33, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 43, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 53. In some embodiments, the TL1A-binding protein comprises an immunoglobulin Fc domain. In some embodiments, the Fc domain comprises amino acid modified L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0152] This specification describes a TL1A-binding protein comprising: a) a heavy chain variable region (VH) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 4 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 4; (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 14 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 14; and (iii) a light chain variable region (VL) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 34 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 34; (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 44 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 44; and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 54 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 54. In some embodiments, the TL1A-binding protein includes a) a heavy chain variable region (VH) comprising (i) CDR1 having the amino acid sequence described in SEQ ID NO: 4, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 14, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 24, and b) a light chain variable region (VL) comprising (i) CDR1 having the amino acid sequence described in SEQ ID NO: 34, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 44, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 54. In some embodiments, the TL1A-binding protein includes an immunoglobulin Fc domain. In some embodiments, the Fc domain includes amino acid modified L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0153] A TL1A-binding protein comprising a)(i) CDR1 having the amino acid sequence described in SEQ ID NO: 321 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 321, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 430 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 430, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 539 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 539, and (i) This specification describes TL1A-binding proteins comprising (ii) a light chain variable region (VL) including (ii) a CDR1 having the amino acid sequence described in SEQ ID NO: 648 or a CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 648, (ii) a CDR2 having the amino acid sequence described in SEQ ID NO: 757 or a CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 757, and (iii) a light chain variable region (VL) including a CDR3 having the amino acid sequence described in SEQ ID NO: 866 or a CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 866. In some embodiments, the TL1A-binding protein comprises a) a heavy chain variable region (VH) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 321, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 430, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 539, and b) a light chain variable region (VL) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 648, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 757, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 866. In some embodiments, the TL1A-binding protein comprises an immunoglobulin Fc domain. In some embodiments, the Fc domain comprises amino acid modified L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0154] A TL1A-binding protein comprising a)(i) a heavy chain variable region (VH) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 341 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 341, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 450 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 450, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 559 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 559, and b)(i This specification describes TL1A-binding proteins comprising (ii) a CDR1 having the amino acid sequence described in SEQ ID NO: 668 or a CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 668, (ii) a CDR2 having the amino acid sequence described in SEQ ID NO: 777 or a CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 777, and (iii) a light chain variable region (VL) comprising a CDR3 having the amino acid sequence described in SEQ ID NO: 886 or a CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 886. In some embodiments, the TL1A-binding protein comprises a) a heavy chain variable region (VH) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 341, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 450, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 559, and b) a light chain variable region (VL) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 668, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 777, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 886. In some embodiments, the TL1A-binding protein comprises an immunoglobulin Fc domain. In some embodiments, the Fc domain comprises amino acid modified L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0155] A TL1A-binding protein comprising a)(i) a heavy chain variable region (VH) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 345 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 345, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 454 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 454, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 563 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 563, and b)(i This specification describes TL1A-binding proteins comprising (ii) a CDR1 having the amino acid sequence described in SEQ ID NO: 672 or a CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 672, (ii) a CDR2 having the amino acid sequence described in SEQ ID NO: 781 or a CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 781, and (iii) a light chain variable region (VL) comprising a CDR3 having the amino acid sequence described in SEQ ID NO: 890 or a CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 890. In some embodiments, the TL1A-binding protein comprises a) a heavy chain variable region (VH) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 345, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 454, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 563, and b) a light chain variable region (VL) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 672, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 781, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 890. In some embodiments, the TL1A-binding protein comprises an immunoglobulin Fc domain. In some embodiments, the Fc domain comprises amino acid modified L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0156] A TL1A-binding protein comprising a)(i) a heavy chain variable region (VH) including (i) a CDR1 having the amino acid sequence described in SEQ ID NO: 349 or a CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 349, (ii) a CDR2 having the amino acid sequence described in SEQ ID NO: 458 or a CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 458, and (iii) a CDR3 having the amino acid sequence described in SEQ ID NO: 567 or a CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 567, and b)(i This specification describes a TL1A-binding protein comprising (ii) a CDR1 having the amino acid sequence described in SEQ ID NO: 676 or a CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 676, (ii) a CDR2 having the amino acid sequence described in SEQ ID NO: 785 or a CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 785, and (iii) a light chain variable region (VL) comprising a CDR3 having the amino acid sequence described in SEQ ID NO: 894 or a CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 894. In some embodiments, the TL1A-binding protein comprises a) a heavy chain variable region (VH) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 349, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 458, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 567, and b) a light chain variable region (VL) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 676, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 785, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 894. In some embodiments, the TL1A-binding protein comprises an immunoglobulin Fc domain. In some embodiments, the Fc domain comprises amino acid modified L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0157] A TL1A-binding protein comprising a)(i) a heavy chain variable region (VH) including (i) a CDR1 having the amino acid sequence described in SEQ ID NO: 351 or a CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 351, (ii) a CDR2 having the amino acid sequence described in SEQ ID NO: 460 or a CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 460, and (iii) a CDR3 having the amino acid sequence described in SEQ ID NO: 569 or a CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 569, and b)(i This specification describes TL1A-binding proteins comprising (ii) a CDR1 having the amino acid sequence described in SEQ ID NO: 678 or a CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 678, (ii) a CDR2 having the amino acid sequence described in SEQ ID NO: 787 or a CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 787, and (iii) a light chain variable region (VL) comprising a CDR3 having the amino acid sequence described in SEQ ID NO: 896 or a CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 896. In some embodiments, the TL1A-binding protein comprises a) a heavy chain variable region (VH) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 351, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 460, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 569, and b) a light chain variable region (VL) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 678, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 787, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 896. In some embodiments, the TL1A-binding protein comprises an immunoglobulin Fc domain. In some embodiments, the Fc domain comprises amino acid modified L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0158] A TL1A-binding protein comprising a)(i) a heavy chain variable region (VH) having the amino acid sequence described in SEQ ID NO: 354 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 354, (ii) a CDR2 having the amino acid sequence described in SEQ ID NO: 463 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 463, and (iii) a heavy chain variable region (VH) having the amino acid sequence described in SEQ ID NO: 572 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 572, and b)(i This specification describes TL1A-binding proteins comprising (ii) a CDR1 having the amino acid sequence described in SEQ ID NO: 681 or a CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 681, (ii) a CDR2 having the amino acid sequence described in SEQ ID NO: 790 or a CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 790, and (iii) a light chain variable region (VL) comprising a CDR3 having the amino acid sequence described in SEQ ID NO: 899 or a CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 899. In some embodiments, the TL1A-binding protein comprises a) a heavy chain variable region (VH) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 354, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 463, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 572, and b) a light chain variable region (VL) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 681, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 790, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 899. In some embodiments, the TL1A-binding protein comprises an immunoglobulin Fc domain. In some embodiments, the Fc domain comprises amino acid modified L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0159] A TL1A-binding protein comprising a)(i) a heavy chain variable region (VH) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 365 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 365, (ii) a CDR2 having the amino acid sequence described in SEQ ID NO: 474 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 474, and (iii) a heavy chain variable region (VH) including (i) This specification describes TL1A-binding proteins comprising (ii) a light chain variable region (VL) including (ii) a CDR1 having the amino acid sequence described in SEQ ID NO: 692 or a CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 692, (ii) a CDR2 having the amino acid sequence described in SEQ ID NO: 801 or a CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 801, and (iii) a CDR3 having the amino acid sequence described in SEQ ID NO: 910 or a CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 910. In some embodiments, the TL1A-binding protein comprises a) a heavy chain variable region (VH) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 365, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 474, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 583, and b) a light chain variable region (VL) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 692, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 801, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 910. In some embodiments, the TL1A-binding protein comprises an immunoglobulin Fc domain. In some embodiments, the Fc domain comprises amino acid modified L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0160] A TL1A-binding protein comprising a)(i) a heavy chain variable region (VH) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 371 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 371, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 480 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 480, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 589 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 589, and b)(i This specification describes TL1A-binding proteins comprising (ii) a CDR1 having the amino acid sequence described in SEQ ID NO: 698 or a CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 698, (ii) a CDR2 having the amino acid sequence described in SEQ ID NO: 807 or a CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 807, and (iii) a light chain variable region (VL) comprising a CDR3 having the amino acid sequence described in SEQ ID NO: 916 or a CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 916. In some embodiments, the TL1A-binding protein comprises a) a heavy chain variable region (VH) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 371, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 480, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 589, and b) a light chain variable region (VL) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 698, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 807, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 916. In some embodiments, the TL1A-binding protein comprises an immunoglobulin Fc domain. In some embodiments, the Fc domain comprises amino acid modified L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0161] A TL1A-binding protein comprising a)(i) CDR1 having the amino acid sequence described in SEQ ID NO: 372 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 372, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 481 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 481, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 590 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 590, and b)(i) SEQ ID NO: 69 9 CDR1 or SEQ ID NO: 69 having the amino acid sequence described above 9 This specification describes a TL1A-binding protein comprising a light chain variable region (VL) comprising (ii) CDR1 having one to two amino acid substitutions compared to the sequence of (ii) SEQ ID NO: 808, or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 808, and (iii) CDR3 having the amino acid sequence of (iii) SEQ ID NO: 917, or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 917. In some embodiments, the TL1A-binding protein comprises a) a heavy chain variable region (VH) comprising (i) CDR1 having the amino acid sequence of (ii) SEQ ID NO: 372, (ii) CDR2 having the amino acid sequence of (iii) CDR3 having the amino acid sequence of (iii) SEQ ID NO: 590, and b) (i) SEQ ID NO: 69 9 The TL1A-binding protein comprises a light chain variable region (VL) including (ii) CDR1 having the amino acid sequence described in (ii) 808, and (iii) CDR3 having the amino acid sequence described in 917. In some embodiments, the TL1A-binding protein comprises an immunoglobulin Fc domain. In some embodiments, the Fc domain comprises amino acid modified L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0162] A TL1A-binding protein comprising a)(i) a CDR1 having the amino acid sequence described in SEQ ID NO: 373 or a CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 373, (ii) a CDR2 having the amino acid sequence described in SEQ ID NO: 482 or a CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 482, and (iii) a heavy chain variable region (VH) having the amino acid sequence described in SEQ ID NO: 591 or a CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 591, and (i) This specification describes TL1A-binding proteins comprising (ii) a light chain variable region (VL) including (ii) a CDR1 having the amino acid sequence described in SEQ ID NO: 700 or a CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 700, (ii) a CDR2 having the amino acid sequence described in SEQ ID NO: 809 or a CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 809, and (iii) a CDR3 having the amino acid sequence described in SEQ ID NO: 918 or a CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 918. In some embodiments, the TL1A-binding protein comprises a) a heavy chain variable region (VH) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 373, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 482, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 591, and b) a light chain variable region (VL) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 700, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 809, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 918. In some embodiments, the TL1A-binding protein comprises an immunoglobulin Fc domain. In some embodiments, the Fc domain comprises amino acid modified L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0163] A TL1A-binding protein comprising a)(i) CDR1 having the amino acid sequence described in SEQ ID NO: 388 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 388, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 497 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 497, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 606 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 606, and (i) This specification describes TL1A-binding proteins comprising (ii) a light chain variable region (VL) including (ii) a CDR1 having the amino acid sequence described in SEQ ID NO: 715 or a CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 715, (ii) a CDR2 having the amino acid sequence described in SEQ ID NO: 824 or a CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 824, and (iii) a CDR3 having the amino acid sequence described in SEQ ID NO: 933 or a CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 933. In some embodiments, the TL1A-binding protein comprises a) a heavy chain variable region (VH) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 388, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 497, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 606, and b) a light chain variable region (VL) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 715, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 824, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 933. In some embodiments, the TL1A-binding protein comprises an immunoglobulin Fc domain. In some embodiments, the Fc domain comprises amino acid modified L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0164] A TL1A-binding protein comprising a)(i) a heavy chain variable region (VH) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 394 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 394, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 503 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 503, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 612 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 612, and b)(i This specification describes TL1A-binding proteins comprising (ii) a CDR1 having the amino acid sequence described in SEQ ID NO: 721 or a CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 721, (ii) a CDR2 having the amino acid sequence described in SEQ ID NO: 830 or a CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 830, and (iii) a light chain variable region (VL) comprising a CDR3 having the amino acid sequence described in SEQ ID NO: 939 or a CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 939. In some embodiments, the TL1A-binding protein comprises a) a heavy chain variable region (VH) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 394, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 503, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 612, and b) a light chain variable region (VL) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 721, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 830, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 939. In some embodiments, the TL1A-binding protein comprises an immunoglobulin Fc domain. In some embodiments, the Fc domain comprises amino acid modified L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0165] A TL1A-binding protein comprising a)(i) a heavy chain variable region (VH) including (i) a CDR1 having the amino acid sequence described in SEQ ID NO: 400 or a CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 400, (ii) a CDR2 having the amino acid sequence described in SEQ ID NO: 509 or a CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 509, and (iii) a CDR3 having the amino acid sequence described in SEQ ID NO: 618 or a CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 618, and b)(i This specification describes TL1A-binding proteins comprising (ii) a CDR1 having the amino acid sequence described in SEQ ID NO: 727 or a CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 727, (ii) a CDR2 having the amino acid sequence described in SEQ ID NO: 836 or a CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 836, and (iii) a light chain variable region (VL) comprising a CDR3 having the amino acid sequence described in SEQ ID NO: 945 or a CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 945. In some embodiments, the TL1A-binding protein comprises a) a heavy chain variable region (VH) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 400, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 509, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 618, and b) a light chain variable region (VL) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 727, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 836, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 945. In some embodiments, the TL1A-binding protein comprises an immunoglobulin Fc domain. In some embodiments, the Fc domain comprises amino acid modified L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0166] In some embodiments, a TL1A-binding protein comprising a heavy chain variable region (VH) including (i) CDR1 having the amino acid sequence described in any one of SEQ ID NOs: 1-10 and 313-421, or having one to two amino acid substitutions compared to any one of SEQ ID NOs: 1-10 and 313-421, (ii) CDR2 having the amino acid sequence described in any one of SEQ ID NOs: 11-20 and 422-530, or having one to two amino acid substitutions compared to any one of SEQ ID NOs: 11-20 and 422-530, and (iii) CDR3 having the amino acid sequence described in any one of SEQ ID NOs: 21-30 and 531-639, or having one to two amino acid substitutions compared to any one of SEQ ID NOs: 21-30 and 531-639, b)TL1A-binding proteins are described herein that include a light chain variable region (VL) comprising (i) CDR1 having the amino acid sequence described in any one of SEQ ID NOs. 31-40 and 640-748, or having one to two amino acid substitutions compared to any one of SEQ ID NOs. 31-40 and 640-748; (ii) CDR2 having the amino acid sequence described in any one of SEQ ID NOs. 41-50 and 749-857, or having one to two amino acid substitutions compared to any one of SEQ ID NOs. 41-50 and 749-857; and (iii) CDR3 having the amino acid sequence described in any one of SEQ ID NOs. 51-60 and 858-966, or having one to two amino acid substitutions compared to any one of SEQ ID NOs. 51-60 and 858-966.

[0167] In some embodiments, TL1A-binding proteins are described herein, comprising a) a heavy chain variable region (VH) including (i) a CDR1 having the amino acid sequence described in any one of SEQ ID NOs: 1-10 and 313-421, (ii) a CDR2 having the amino acid sequence described in any one of SEQ ID NOs: 11-20 and 422-530, and (iii) a CDR3 having the amino acid sequence described in any one of SEQ ID NOs: 21-30 and 531-639, and b) a light chain variable region (VL) including (i) a CDR1 having the amino acid sequence described in any one of SEQ ID NOs: 31-40 and 640-748, (ii) a CDR2 having the amino acid sequence described in any one of SEQ ID NOs: 41-50 and 749-857, and (iii) a CDR3 having the amino acid sequence described in any one of SEQ ID NOs: 51-60 and 858-966.

[0168] In some embodiments, a) a heavy chain variable region (VH) comprising (i) CDR1 having the amino acid sequence described in any one of the CDRH1 sequences listed in Table 1.1A, Table 1.1B, and Table 1.1C, (ii) CDR2 having the amino acid sequence described in any one of the CDRH2 sequences listed in Table 1.1A, Table 1.1B, and Table 1.1C, and (iii) CDR3 having the amino acid sequence described in any one of the CDRH3 sequences listed in Table 1.1A, Table 1.1B, and Table 1.1C, and b) (i) Table 1. This specification describes a TL1A-binding protein comprising (ii) a CDR1 having the amino acid sequence described in any one of the CDRL1 sequences listed in Table 1A, Table 1.1B, and Table 1.1C, (ii) a CDR2 having the amino acid sequence described in any one of the CDRL2 sequences listed in Table 1.1A, Table 1.1B, and Table 1.1C, and (iii) a light chain variable region (VL) including a CDR3 having the amino acid sequence described in any one of the CDRL3 sequences listed in Table 1.1A, Table 1.1B, and Table 1.1C.

[0169] In some embodiments, a TL1A-binding protein comprising a) a heavy chain variable region (VH) including (i) CDR1 having the amino acid sequence described in any one of SEQ ID NOs: 1-10 and 313-421, (ii) CDR2 having the amino acid sequence described in any one of SEQ ID NOs: 11-20 and 422-530, and (iii) CDR3 having the amino acid sequence described in any one of SEQ ID NOs: 21-30 and 531-639, and b) (i) any one of SEQ ID NOs: 31-40 and 640-748 A TL1A-binding protein is further described herein, comprising a light chain variable region (VL) including (ii) a CDR1 having the amino acid sequence described in any one of SEQ ID NOs: 41-50 and 749-857, and (iii) a CDR3 having the amino acid sequence described in any one of SEQ ID NOs: 51-60 and 858-966, and c) a modified Fc that extends the half-life of the TL1A-binding protein compared to a TL1A-binding protein without the modified Fc.

[0170] In some embodiments, a TL1A-binding protein is provided that specifically binds to a TL1A polypeptide containing SEQ ID NO: 2493 or 2494. In some embodiments, an antibody is provided that binds to a TL1A polypeptide containing SEQ ID NO: 2493 at one of the amino acid residues in Table 13 or Table 14. In some embodiments, an antibody is provided that binds to the TL1A polypeptide containing SEQ ID NO: 2493 at any one of the amino acid residues Lys243, Lys240, Thr239, Tyr238, Asp237, Val236, Leu235, Ser234, Ile233, Asp232, Met158, Arg156, Trp119, His118, Lys111, Phe110, His109, Gln108, Thr107, Pro106, Thr105, Gln104, Arg103, Val102, and Val101. In some embodiments, an antibody is provided that binds to the TL1A polypeptide containing SEQ ID NO: 2493 at any one of the following amino acid residues: Lys240, Thr239, Tyr238, Asp237, Val236, Leu235, Ser234, Gln104, and Arg103, Val102, and Val101.

[0171] In some embodiments, the TL1A-binding protein comprises a) a heavy chain variable region (VH) including (i) CDR1 having the amino acid sequence described in any one of the CDRH1 sequences listed in Tables 1.1A, 1.1B, and 1.1C, (ii) CDR2 having the amino acid sequence described in any one of the CDRH2 sequences listed in Tables 1.1A, 1.1B, and 1.1C, and (iii) CDR3 having the amino acid sequence described in any one of the CDRH3 sequences listed in Tables 1.1A, 1.1B, and 1.1C, and b) (i) listed in Tables 1.1A, 1.1B, and 1.1C (ii) a light chain variable region (VL) comprising CDR1 having the amino acid sequence described in any one of the listed CDRL1 sequences, CDR2 having the amino acid sequence described in any one of the CDRL2 sequences listed in Table 1.1A, Table 1.1B, and Table 1.1C, and (iii) a light chain variable region (VL) comprising CDR3 having the amino acid sequence described in any one of the CDRL3 sequences listed in Table 1.1A, Table 1.1B, and Table 1.1C, and c) a modified Fc which extends the half-life of the TL1A-binding protein compared to a TL1A-binding protein that does not contain the modified Fc.

[0172] In some embodiments, a TL1A-binding protein comprising a) a heavy chain variable region (VH) including (i) CDR1 having the amino acid sequence described in any one of the CDRH1 sequences listed in Table 1.2A, Table 1.2B, and Table 1.2C, (ii) CDR2 having the amino acid sequence described in any one of the CDRH2 sequences listed in Table 1.2A, Table 1.2B, and Table 1.2C, and (iii) CDR3 having the amino acid sequence described in any one of the CDRH3 sequences listed in Table 1.2A, Table 1.2B, and Table 1.2C The TL1A-binding proteins described herein include (i) a CDR1 having the amino acid sequence described in any one of the CDRL1 sequences listed in Tables 1.2A, 1.2B, and 1.2C, (ii) a CDR2 having the amino acid sequence described in any one of the CDRL2 sequences listed in Tables 1.2A, 1.2B, and 1.2C, and (iii) a light chain variable region (VL) containing a CDR3 having the amino acid sequence described in any one of the CDRL3 sequences listed in Tables 1.2A, 1.2B, and 1.2C.

[0173] In some embodiments, a TL1A-binding protein comprising a heavy chain variable region (VH) including (i) CDR1 having the amino acid sequence described in any one of the CDRH1 sequences listed in Table 1.2A, Table 1.2B, and Table 1.2C, (ii) CDR2 having the amino acid sequence described in any one of the CDRH2 sequences listed in Table 1.2A, Table 1.2B, and Table 1.2C, and (iii) CDR3 having the amino acid sequence described in any one of the CDRH3 sequences listed in Table 1.2A, Table 1.2B, and Table 1.2C, and b) (i) CDRL1 sequence listed in Table 1.2A, Table 1.2B, and Table 1.2C A TL1A-binding protein comprising a light chain variable region (VL) including (ii) a CDR1 having the amino acid sequence described in any one of the following, (ii) a CDR2 having the amino acid sequence described in any one of the CDRL2 sequences listed in Table 1.2A, Table 1.2B, and Table 1.2C, and (iii) a CDR3 having the amino acid sequence described in any one of the CDRL3 sequences listed in Table 1.2A, Table 1.2B, and Table 1.2C, and c) a modified Fc which extends the half-life of the TL1A-binding protein compared to a TL1A-binding protein that does not contain the modified Fc, is further described herein.

[0174] In some embodiments, provided herein is a TL1A-binding protein, comprising: a) a heavy chain variable region (VH), wherein the VH comprises (i) a CDR1 having the amino acid sequence set forth in any one of the CDRH1 sequences listed in Tables 1.3A, 1.3B, and 1.3C, (ii) a CDR2 having the amino acid sequence set forth in any one of the CDRH2 sequences listed in Tables 1.3A, 1.3B, and 1.3C, and (iii) a CDR3 having the amino acid sequence set forth in any one of the CDRH3 sequences listed in Tables 1.3A, 1.3B, and 1.3C; and b) a light chain variable region (VL), wherein the VL comprises (i) a CDR1 having the amino acid sequence set forth in any one of the CDRL1 sequences listed in Tables 1.3A, 1.3B, and 1.3C, (ii) a CDR2 having the amino acid sequence set forth in any one of the CDRL2 sequences listed in Tables 1.3A, 1.3B, and 1.3C, and (iii) a CDR3 having the amino acid sequence set forth in any one of the CDRL3 sequences listed in Tables 1.3A, 1.3B, and 1.3C.

[0175] In some embodiments, a TL1A-binding protein comprising a heavy chain variable region (VH) including (i) CDR1 having the amino acid sequence described in any one of the CDRH1 sequences listed in Table 1.3A, Table 1.3B, and Table 1.3C, (ii) CDR2 having the amino acid sequence described in any one of the CDRH2 sequences listed in Table 1.3A, Table 1.3B, and Table 1.3C, and (iii) CDR3 having the amino acid sequence described in any one of the CDRH3 sequences listed in Table 1.3A, Table 1.3B, and Table 1.3C, and b) (i) CDRL1 sequence listed in Table 1.3A, Table 1.3B, and Table 1.3C A TL1A-binding protein comprising a light chain variable region (VL) including (ii) a CDR1 having the amino acid sequence described in any one of the following, (ii) a CDR2 having the amino acid sequence described in any one of the CDRL2 sequences listed in Table 1.3A, Table 1.3B, and Table 1.3C, and (iii) a CDR3 having the amino acid sequence described in any one of the CDRL3 sequences listed in Table 1.3A, Table 1.3B, and Table 1.3C, and c) a modified Fc which extends the half-life of the TL1A-binding protein compared to a TL1A-binding protein that does not contain the modified Fc, is further described herein.

[0176] In some embodiments, TL1A-binding proteins are described herein that include a VH containing a sequence having at least 80% sequence identity to any one of the VH sequences listed in Tables 2.1 and 2.2, and a VL containing a sequence having at least 80% sequence identity to any one of the VL sequences listed in Tables 2.1 and 2.2. In some embodiments, the TL1A-binding protein includes a VH containing a sequence having at least 85% sequence identity to any one of the VH sequences listed in Tables 2.1 and 2.2, and a VL containing a sequence having at least 85% sequence identity to any one of the VL sequences listed in Tables 2.1 and 2.2. In some embodiments, the TL1A-binding protein includes a VH containing a sequence having at least 90% sequence identity to one of the VH sequences listed in Tables 2.1 and 2.2, and a VL containing a sequence having at least 90% sequence identity to one of the VL sequences listed in Tables 2.1 and 2.2. In some embodiments, the TL1A-binding protein includes a VH containing a sequence having at least 95% sequence identity to one of the VH sequences listed in Tables 2.1 and 2.2, and a VL containing a sequence having at least 95% sequence identity to one of the VL sequences listed in Tables 2.1 and 2.2. In some embodiments, the TL1A-binding protein includes a VH containing a sequence having at least 96% sequence identity to one of the VH sequences listed in Tables 2.1 and 2.2, and a VL containing a sequence having at least 96% sequence identity to one of the VL sequences listed in Tables 2.1 and 2.2. In some embodiments, the TL1A-binding protein includes a VH containing a sequence having at least 97% sequence identity to one of the VH sequences listed in Tables 2.1 and 2.2, and a VL containing a sequence having at least 97% sequence identity to one of the VL sequences listed in Tables 2.1 and 2.2.In some embodiments, the TL1A-binding protein comprises a VH comprising a sequence having at least 98% sequence identity to the amino acid sequence of any one of the VH sequences listed in Tables 2.1 and 2.2, and a VL comprising a sequence having at least 98% sequence identity to the amino acid sequence of any one of the VL sequences listed in Tables 2.1 and 2.2. In some embodiments, the TL1A-binding protein comprises a VH comprising a sequence having at least 99% sequence identity to the amino acid sequence of any one of the VH sequences listed in Tables 2.1 and 2.2, and a VL comprising a sequence having at least 99% sequence identity to the amino acid sequence of any one of the VL sequences listed in Tables 2.1 and 2.2.

[0177] In some embodiments, the TL1A-binding protein comprises an Fc domain. In some embodiments, the Fc domain is an IgG1, IgG2 or IgG4 immunoglobulin Fc domain. In some embodiments, the Fc domain is an IgG1 immunoglobulin Fc domain. In some embodiments, the Fc domain is an IgG2 immunoglobulin Fc domain. In some embodiments, the Fc domain is an IgG4 immunoglobulin Fc domain. In some embodiments, the Fc domain amino acids comprise the amino acid modifications L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE). In some embodiments, the TL1A-binding protein is a TL1A-binding antibody.

[0178] Further described herein are TL1A-binding antibodies that specifically bind to an epitope of TL1A and comprise an Fc domain comprising the amino acid modifications L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0179] In some embodiments, a TL1A-binding protein is described herein, comprising a heavy chain variable region (VH) comprising a)(i) CDR1 having the amino acid sequence listed in the CDRH1 sequence listed in Table 1.1A, (ii) CDR2 having the amino acid sequence listed in the CDRH2 sequence listed in Table 1.1A, and (iii) CDR3 having the amino acid sequence listed in the CDRH3 sequence listed in Table 1.1A, and b) a light chain variable region (VL) comprising a CDR1 having the amino acid sequence listed in the CDRL1 sequence listed in Table 1.1A, (ii) CDR2 having the amino acid sequence listed in the CDRL2 sequence listed in Table 1.1A, and (iii) CDR3 having the amino acid sequence listed in the CDRL3 sequence listed in Table 1.1A. In some embodiments, the VH comprises a sequence having at least 80% sequence identity to any one of the VH sequences listed in Table 2.2, and the VL comprises a sequence having at least 80% sequence identity to any one of the VL sequences listed in Table 2.2. In some embodiments, the TL1A-binding protein includes an amino acid-modified L234A / L235A(LALA) and / or an Fc domain containing M252Y, S254T, and T256E(YTE).

[0180] In some embodiments, a TL1A-binding protein is described herein, comprising a heavy chain variable region (VH) comprising (i) a CDR1 having the amino acid sequence described in the CDRH1 sequence listed in Table 1.2A, (ii) a CDR2 having the amino acid sequence described in the CDRH2 sequence listed in Table 1.2A, and (iii) a CDR3 having the amino acid sequence described in the CDRH3 sequence listed in Table 1.2A, and b) a light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence described in the CDRL1 sequence listed in Table 1.2A, (ii) a CDR2 having the amino acid sequence described in the CDRL2 sequence listed in Table 1.2A, and (iii) a CDR3 having the amino acid sequence described in the CDRL3 sequence listed in Table 1.2A. In some embodiments, the VH comprises a sequence having at least 80% sequence identity to any one of the VH sequences listed in Table 2.2, and the VL comprises a sequence having at least 80% sequence identity to any one of the VL sequences listed in Table 2.2. In some embodiments, the TL1A-binding protein includes an amino acid-modified L234A / L235A(LALA) and / or an Fc domain containing M252Y, S254T, and T256E(YTE).

[0181] In some embodiments, a TL1A-binding protein is described herein, comprising a heavy chain variable region (VH) including a)(i) CDR1 having the amino acid sequence listed in the CDRH1 sequence listed in Table 1.3A, (ii) CDR2 having the amino acid sequence listed in the CDRH2 sequence listed in Table 1.3A, and (iii) CDR3 having the amino acid sequence listed in the CDRH3 sequence listed in Table 1.3A, and b) a light chain variable region (VL) including a CDR1 having the amino acid sequence listed in the CDRL1 sequence listed in Table 1.3A, (ii) CDR2 having the amino acid sequence listed in the CDRL2 sequence listed in Table 1.3A, and (iii) CDR3 having the amino acid sequence listed in the CDRL3 sequence listed in Table 1.3A. In some embodiments, the VH includes a sequence having at least 80% sequence identity to any one of the VH sequences listed in Table 2.2, and the VL includes a sequence having at least 80% sequence identity to any one of the VL sequences listed in Table 2.2. In some embodiments, the TL1A-binding protein includes an amino acid-modified L234A / L235A(LALA) and / or an Fc domain containing M252Y, S254T, and T256E(YTE).

[0182] In some embodiments, a TL1A-binding protein is described herein, comprising a heavy chain variable region (VH) including a)(i) CDR1 having the amino acid sequence listed in the CDRH1 sequence listed in Table 1.1B, (ii) CDR2 having the amino acid sequence listed in the CDRH2 sequence listed in Table 1.1B, and (iii) CDR3 having the amino acid sequence listed in the CDRH3 sequence listed in Table 1.1B, and b) a light chain variable region (VL) including a CDR1 having the amino acid sequence listed in the CDRL1 sequence listed in Table 1.1B, (ii) CDR2 having the amino acid sequence listed in the CDRL2 sequence listed in Table 1.1B, and (iii) CDR3 having the amino acid sequence listed in the CDRL3 sequence listed in Table 1.1B. In some embodiments, the VH includes a sequence having at least 80% sequence identity to any one of the VH sequences listed in Table 2.2, and the VL includes a sequence having at least 80% sequence identity to any one of the VL sequences listed in Table 2.1. In some embodiments, the TL1A-binding protein includes an amino acid-modified L234A / L235A(LALA) and / or an Fc domain containing M252Y, S254T, and T256E(YTE).

[0183] In some embodiments, a TL1A-binding protein is described herein, comprising a heavy chain variable region (VH) comprising a)(i) CDR1 having the amino acid sequence listed in the CDRH1 sequence listed in Table 1.2B, (ii) CDR2 having the amino acid sequence listed in the CDRH2 sequence listed in Table 1.2B, and (iii) CDR3 having the amino acid sequence listed in the CDRH3 sequence listed in Table 1.2B, and b) a light chain variable region (VL) comprising a CDR1 having the amino acid sequence listed in the CDRL1 sequence listed in Table 1.2B, (ii) CDR2 having the amino acid sequence listed in the CDRL2 sequence listed in Table 1.2B, and (iii) CDR3 having the amino acid sequence listed in the CDRL3 sequence listed in Table 1.2B. In some embodiments, the VH comprises a sequence having at least 80% sequence identity to any one of the VH sequences listed in Table 2.2, and the VL comprises a sequence having at least 80% sequence identity to any one of the VL sequences listed in Table 2.1. In some embodiments, the TL1A-binding protein includes an amino acid-modified L234A / L235A(LALA) and / or an Fc domain containing M252Y, S254T, and T256E(YTE).

[0184] In some embodiments, a TL1A-binding protein is described herein, comprising a heavy chain variable region (VH) including a)(i) CDR1 having the amino acid sequence listed in the CDRH1 sequence listed in Table 1.3B, (ii) CDR2 having the amino acid sequence listed in the CDRH2 sequence listed in Table 1.3B, and (iii) CDR3 having the amino acid sequence listed in the CDRH3 sequence listed in Table 1.3B, and b) a light chain variable region (VL) including a CDR1 having the amino acid sequence listed in the CDRL1 sequence listed in Table 1.3B, (ii) CDR2 having the amino acid sequence listed in the CDRL2 sequence listed in Table 1.3B, and (iii) CDR3 having the amino acid sequence listed in the CDRL3 sequence listed in Table 1.3B. In some embodiments, the VH includes a sequence having at least 80% sequence identity to any one of the VH sequences listed in Table 2.2, and the VL includes a sequence having at least 80% sequence identity to any one of the VL sequences listed in Table 2.1. In some embodiments, the TL1A-binding protein includes an amino acid-modified L234A / L235A(LALA) and / or an Fc domain containing M252Y, S254T, and T256E(YTE).

[0185] In some embodiments, a TL1A-binding protein is described herein, comprising a heavy chain variable region (VH) including a)(i) CDR1 having the amino acid sequence listed in the CDRH1 sequence listed in Table 1.1C, (ii) CDR2 having the amino acid sequence listed in the CDRH2 sequence listed in Table 1.1C, and (iii) CDR3 having the amino acid sequence listed in the CDRH3 sequence listed in Table 1.1C, and b) a light chain variable region (VL) including a CDR1 having the amino acid sequence listed in the CDRL1 sequence listed in Table 1.1C, (ii) CDR2 having the amino acid sequence listed in the CDRL2 sequence listed in Table 1.1C, and (iii) CDR3 having the amino acid sequence listed in the CDRL3 sequence listed in Table 1.1C. In some embodiments, the VH includes a sequence having at least 80% sequence identity to any one of the VH sequences listed in Table 2.2, and the VL includes a sequence having at least 80% sequence identity to any one of the VL sequences listed in Table 2.2. In some embodiments, the TL1A-binding protein includes an amino acid-modified L234A / L235A(LALA) and / or an Fc domain containing M252Y, S254T, and T256E(YTE).

[0186] In some embodiments, a TL1A-binding protein is described herein, comprising a heavy chain variable region (VH) comprising (i) a CDR1 having the amino acid sequence described in the CDRH1 sequence listed in Table 1.2C, (ii) a CDR2 having the amino acid sequence described in the CDRH2 sequence listed in Table 1.2C, and (iii) a CDR3 having the amino acid sequence described in the CDRH3 sequence listed in Table 1.2C, and b) a light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence described in the CDRL1 sequence listed in Table 1.2C, (ii) a CDR2 having the amino acid sequence described in the CDRL2 sequence listed in Table 1.2C, and (iii) a CDR3 having the amino acid sequence described in the CDRL3 sequence listed in Table 1.2C. In some embodiments, the VH comprises a sequence having at least 80% sequence identity to any one of the VH sequences listed in Table 2.2, and the VL comprises a sequence having at least 80% sequence identity to any one of the VL sequences listed in Table 2.2. In some embodiments, the TL1A-binding protein includes an amino acid-modified L234A / L235A(LALA) and / or an Fc domain containing M252Y, S254T, and T256E(YTE).

[0187] In some embodiments, a TL1A-binding protein is described herein, comprising a heavy chain variable region (VH) comprising a)(i) CDR1 having the amino acid sequence listed in the CDRH1 sequence listed in Table 1.3C, (ii) CDR2 having the amino acid sequence listed in the CDRH2 sequence listed in Table 1.3C, and (iii) CDR3 having the amino acid sequence listed in the CDRH3 sequence listed in Table 1.3C, and b) a light chain variable region (VL) comprising a CDR1 having the amino acid sequence listed in the CDRL1 sequence listed in Table 1.3C, (ii) CDR2 having the amino acid sequence listed in the CDRL2 sequence listed in Table 1.3C, and (iii) CDR3 having the amino acid sequence listed in the CDRL3 sequence listed in Table 1.3C. In some embodiments, the VH comprises a sequence having at least 80% sequence identity to any one of the VH sequences listed in Table 2.2, and the VL comprises a sequence having at least 80% sequence identity to any one of the VL sequences listed in Table 2.2. In some embodiments, the TL1A-binding protein includes an amino acid-modified L234A / L235A(LALA) and / or an Fc domain containing M252Y, S254T, and T256E(YTE).

[0188] In some embodiments, a) a heavy chain variable region (VH) comprising (i) CDR1 having the amino acid sequence described in any one of the CDRH1 sequences listed in Table 1.1A, Table 1.1B, and Table 1.1C, (ii) CDR2 having the amino acid sequence described in any one of the CDRH2 sequences listed in Table 1.1A, Table 1.1B, and Table 1.1C, and (iii) CDR3 having the amino acid sequence described in any one of the CDRH3 sequences listed in Table 1.1A, Table 1.1B, and Table 1.1C, and b) (i) any of the CDRL1 sequences listed in Table 1.1A, Table 1.1B, and Table 1.1C This specification describes a TL1A-binding protein comprising a light chain variable region (VL) having a CDR1 having one of the amino acid sequences described herein, a CDR2 having one of the amino acid sequences described in any one of the CDRL2 sequences listed in Tables 1.1A, 1.1B, and 1.1C, and a CDR3 having one of the amino acid sequences described in any one of the CDRL3 sequences listed in Tables 1.1A, 1.1B, and 1.1C, and a modified Fc which extends the half-life of the TL1A-binding protein compared to a TL1A-binding protein that does not contain the modified Fc.

[0189] In some embodiments, TL1A-binding proteins are described herein that specifically bind to the epitope of TL1A and include Fc domains comprising amino acid modifications L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE). In some embodiments, the TL1A-binding protein binds to TL1A at a concentration of less than approximately 0.5 nanomolar (nM) of K D It binds to TL1A. In some embodiments, the TL1A-binding protein is connected to TL1A at a K concentration of less than approximately 0.4 nanomolar (nM). DBinding occurs via [method]. In some embodiments, the TL1A-binding protein has a binding affinity for TL1A that is at least twice as high as the binding affinity of the control antibody to TL1A. In some embodiments, the TL1A-binding protein is a TL1A-binding antibody. In some embodiments, the TL1A-binding protein reduces TL1A-induced apoptosis by at least twice as much as the control antibody.

[0190] In some embodiments, the TL1A-binding protein specifically binds to a TL1A polypeptide containing SEQ ID NO: 2493 or 2494.

[0191] In some embodiments, the TL1A-binding protein specifically binds to the TL1A epitope. In some embodiments, the TL1A-binding protein specifically binds to the TL1A polypeptide containing SEQ ID NO: 2493 at one of the amino acid residues in Table 12. In some embodiments, the TL1A-binding protein specifically binds to the TL1A polypeptide containing SEQ ID NO: 2493 at one of the amino acid residues in Table 13. In some embodiments, the TL1A-binding protein specifically binds to the TL1A polypeptide containing SEQ ID NO: 2493 at one of the amino acid residues in Table 14. In some embodiments, the TL1A antigen-binding protein is an antibody.

[0192] In some embodiments, the TL1A-binding protein specifically binds to the TL1A polypeptide at at least two or more amino acid residues from Table 12. In some embodiments, the TL1A-binding protein specifically binds to the TL1A polypeptide, including SEQ ID NO: 2493, at at least two or more amino acid residues from Val 101, Val 102, Arg 103, Gln 104, Thr 105, Pro 106, Gln 108, His 118, Glu 120, Glu 122, Leu 123, Gly 124, Asn 136, Lys 137, Arg 156, Gly 157, Met 158, Ser 234, Tyr 238, and Thr 239. In some embodiments, the TL1A-binding protein specifically binds to the TL1A polypeptide containing SEQ ID NO: 2493 at at least two or more amino acid residues of Val 102, Arg 103, Gln 104, Glu 120, Glu 122, Leu 123, and Arg 156. In some embodiments, the TL1A-binding protein specifically binds to the TL1A polypeptide containing SEQ ID NO: 2493 at at least two or more amino acid residues of Val 102, Arg 103, Gln 104, Glu 120, Glu 122, Leu 123, Arg 156, and Tyr 238.

[0193] In some embodiments, the TL1A-binding protein specifically binds to the TL1A polypeptide containing SEQ ID NO: 2493 at at least two or more amino acid residues from Table 13. In some embodiments, the TL1A-binding protein specifically binds to the TL1A polypeptide containing SEQ ID NO: 2493 at at least two or more amino acid residues from Table 14. In some embodiments, the TL1A-binding protein specifically binds to the TL1A polypeptide containing SEQ ID NO: 2493 at at least two or more amino acid residues from among Val 101, Val 102, Arg 103, Gln 104, Thr 105, Pro 106, Thr 107, Gln 108, His 109, Phe 110, Lys 111, Leu 117, His 118, Trp 119, Arg 156, Asp 232, Ile 233, Ser 234, Leu 235, Val 236, Asp 237, Tyr 238, Thr 239, and Lys 240. In some embodiments, the TL1A-binding protein specifically binds to the TL1A polypeptide containing SEQ ID NO: 2493 at at least two or more amino acid residues from among Table 14. In some embodiments, the TL1A-binding protein specifically binds to the TL1A polypeptide, including SEQ ID NO: 2493, at least two or more amino acid residues among Arg103, Gln104, Arg 156, Ser234, Leu235, Val236, Asp237, Tyr238, Thr239, and Lys240.

[0194] In some embodiments, amino acid residues of the TL1A epitope bind to the antibody paratope at distances of 6 angstroms or less, 5 angstroms or less, 4 angstroms or less, 3 angstroms or less, or 2 angstroms or less. [Table 1] [Table 1.1A] Table 1.2A Table 1.3A Table 1.1B Table 1.2B Table 1.3B Table 1.1C-1

Table 1.1C-2

Table 1.1C-3

Table 1.1C-4

Table 1.1C-5

Table 1.1C-6

Table 1.1C-7

Table 1.1C-8

Table 1.1C-9

Table 1.2C-1

Table 1.2C-2

Table 1.2C-3

Table 1.2C-4

Table 1.2C-5

Table 1.2C-6

Table 1.3C-1

Table 1.3C-2

Table 1.3C-3

Table 1.3C-4

Table 1.3C-5

Table 1.3C-6

[0195] In some embodiments, the TL1A-binding protein includes a heavy chain variable region comprising CDR1, CDR2, and CDR3 as listed in Tables 1.1A, 1.1B, 1.1C, 1.2A, 1.2B, 1.2C, 1.3A, 1.3B, and 1.3C. In some embodiments, the TL1A-binding protein includes a heavy chain variable region comprising (i) CDR1 having the amino acid sequence described in any one of the CDRH1 sequences listed in Tables 1.1A, 1.1B, and 1.1C; (ii) CDR2 having the amino acid sequence described in any one of the CDRH2 sequences listed in Tables 1.1A, 1.1B, and 1.1C; and (iii) CDR3 having the amino acid sequence described in any one of the CDRH3 sequences listed in Tables 1.1A, 1.1B, and 1.1C. In some embodiments, the TL1A-binding protein includes a heavy chain variable region comprising (i) CDR1 having the amino acid sequence described in any one of SEQ ID NOs: 1-10 and 313-421, (ii) CDR2 having the amino acid sequence described in any one of SEQ ID NOs: 11-20 and 422-530, and (iii) CDR3 having the amino acid sequence described in any one of SEQ ID NOs: 21-30 and 531-639.

[0196] In some embodiments, the TL1A-binding protein includes a light chain variable region comprising CDR1, CDR2, and CDR3 as listed in Tables 1.1A, 1.1B, 1.1C, 1.2A, 1.2B, 1.2C, 1.3A, 1.3B, and 1.3C. In some embodiments, the TL1A-binding protein includes a light chain variable region comprising (i) CDR1 having the amino acid sequence described in any one of the CDRL1 sequences listed in Tables 1.1A, 1.1B, and 1.1C; (ii) CDR2 having the amino acid sequence described in any one of the CDRL2 sequences listed in Tables 1.1A, 1.1B, and 1.1C; and (iii) CDR3 having the amino acid sequence described in any one of the CDRL3 sequences listed in Tables 1.1A, 1.1B, and 1.1C. In some embodiments, the TL1A-binding protein includes a light chain variable region comprising (i) CDR1 having the amino acid sequence described in any one of SEQ ID NOs. 31-40 and 640-748, (ii) CDR2 having the amino acid sequence described in any one of SEQ ID NOs. 41-50 and 749-857, and (iii) CDR3 having the amino acid sequence described in any one of SEQ ID NOs. 51-60 and 858-966.

[0197] In some embodiments, the TL1A-binding protein comprises a) a heavy chain variable region (VH) including (i) a CDR1 having the amino acid sequence described in any one of SEQ ID NOs: 1-10 and 313-421, (ii) a CDR2 having the amino acid sequence described in any one of SEQ ID NOs: 11-20 and 422-530, and (iii) a CDR3 having the amino acid sequence described in any one of SEQ ID NOs: 21-30 and 531-639, and b) a light chain variable region (VL) including (i) a CDR1 having the amino acid sequence described in any one of SEQ ID NOs: 31-40 and 640-748, (ii) a CDR2 having the amino acid sequence described in any one of SEQ ID NOs: 41-50 and 749-857, and (iii) a CDR3 having the amino acid sequence described in any one of SEQ ID NOs: 51-60 and 858-966. In some embodiments, the TL1A-binding protein comprises a) (i) CDR1 having the amino acid sequence described in any one of the CDRH1 sequences listed in Tables 1.1A, 1.1B, and 1.1C; (ii) CDR2 having the amino acid sequence described in any one of the CDRH2 sequences listed in Tables 1.1A, 1.1B, and 1.1C; and (iii) CDR3 having the amino acid sequence described in any one of the CDRH3 sequences listed in Tables 1.1A, 1.1B, and 1.1C. The light chain variable region (VL) comprises a chain variable region (VH) and a light chain variable region (VL) including (i) CDR1 having the amino acid sequence described in any one of the CDRL1 sequences listed in Tables 1.1A, 1.1B, and 1.1C, (ii) CDR2 having the amino acid sequence described in any one of the CDRL2 sequences listed in Tables 1.1A, 1.1B, and 1.1C, and (iii) CDR3 having the amino acid sequence described in any one of the CDRL3 sequences listed in Tables 1.1A, 1.1B, and 1.1C.In some embodiments, the TL1A-binding protein described herein includes a sequence in which VH has at least 80% sequence identity to any one of the amino acid sequences listed in Tables 2.1 and 2.2, and VL has at least 80% sequence identity to any one of the amino acid sequences listed in Tables 2.1 and 2.2.

[0198] In some embodiments, the TL1A-binding protein includes a heavy chain variable region comprising (i) CDR1 having the amino acid sequence described in any one of SEQ ID NOs. 61-70 and 967-1075, (ii) CDR2 having the amino acid sequence described in any one of SEQ ID NOs. 71-80 and 1076-1184, and (iii) CDR3 having the amino acid sequence described in any one of SEQ ID NOs. 81-90 and 1185-1293.

[0199] In some embodiments, the TL1A-binding protein includes a light chain variable region comprising (i) CDR1 having the amino acid sequence described in any one of SEQ ID NOs: 91-100 and 1294-1402, (ii) CDR2 having the amino acid sequence described in any one of the CDRL2 sequences listed in Tables 1.2A, 1.2B, and 1.2C, and (iii) CDR3 having the amino acid sequence described in any one of SEQ ID NOs: 111-120 and 1512-1620.

[0200] In some embodiments, the TL1A-binding protein comprises a) a heavy chain variable region including i) a CDR1 having the amino acid sequence described in any one of SEQ ID NOs. 61-70 and 967-1075, (ii) a CDR2 having the amino acid sequence described in any one of SEQ ID NOs. 71-80 and 1076-1184, and (iii) a CDR3 having the amino acid sequence described in any one of SEQ ID NOs. 81-90 and 1185-1293, and b) a light chain variable region including (i) a CDR1 having the amino acid sequence described in any one of SEQ ID NOs. 91-100 and 1294-1402, (ii) a CDR2 having the amino acid sequence described in any one of the CDRL2 sequences listed in Tables 1.2A, 1.2B, and 1.2C, and (iii) a CDR3 having the amino acid sequence described in any one of SEQ ID NOs. 111-120 and 1512-1620.

[0201] In some embodiments, the TL1A-binding protein includes a heavy chain variable region comprising (i) CDR1 having the amino acid sequence described in any one of SEQ ID NOs: 121-130 and 1621-1729, (ii) CDR2 having the amino acid sequence described in any one of SEQ ID NOs: 131-140 and 1730-1838, and (iii) CDR3 having the amino acid sequence described in any one of SEQ ID NOs: 141-150 and 1839-1947.

[0202] In some embodiments, the TL1A-binding protein includes a light chain variable region comprising (i) CDR1 having the amino acid sequence described in any one of SEQ ID NOs. 151-160 and 1948-2056, (ii) CDR2 having the amino acid sequence described in any one of the CDRL2 sequences listed in Tables 1.3A, 1.3B, and 1.3C, and (iii) CDR3 having the amino acid sequence described in any one of SEQ ID NOs. 171-180 and 2166-2274.

[0203] In some embodiments, the TL1A-binding protein comprises a) a heavy chain variable region including (i) a CDR1 having the amino acid sequence described in any one of SEQ ID NOs: 121-130 and 1621-1729, (ii) a CDR2 having the amino acid sequence described in any one of SEQ ID NOs: 131-140 and 1730-1838, and (iii) a CDR3 having the amino acid sequence described in any one of SEQ ID NOs: 141-150 and 1839-1947; and b) a light chain variable region including (i) a CDR1 having the amino acid sequence described in any one of SEQ ID NOs: 151-160 and 1948-2056, (ii) a CDR2 having the amino acid sequence described in any one of the CDRL2 sequences listed in Tables 1.3A, 1.3B, and 1.3C, and (iii) a CDR3 having the amino acid sequence described in any one of SEQ ID NOs: 171-180 and 2166-2274.

[0204] In some embodiments, the TL1A-binding protein comprises a) a heavy chain variable region (VH) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 1, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 11, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 21, and b) a light chain variable region (VL) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 31, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 41, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 51.

[0205] In some embodiments, the TL1A-binding protein includes a) a heavy chain variable region (VH) comprising (i) CDR1 having the amino acid sequence described in SEQ ID NO: 2, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 12, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 22, and b) a light chain variable region (VL) comprising (i) CDR1 having the amino acid sequence described in SEQ ID NO: 32, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 42, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 52.

[0206] In some embodiments, the TL1A-binding protein comprises a) a heavy chain variable region (VH) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 3, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 13, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 23, and b) a light chain variable region (VL) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 33, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 43, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 53.

[0207] In some embodiments, the TL1A-binding protein comprises a) a heavy chain variable region (VH) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 4, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 14, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 24, and b) a light chain variable region (VL) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 34, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 44, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 54.

[0208] In some embodiments, the TL1A-binding protein comprises a) a heavy chain variable region (VH) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 5, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 15, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 25, and b) a light chain variable region (VL) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 35, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 45, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 55.

[0209] In some embodiments, the TL1A-binding protein comprises a) a heavy chain variable region (VH) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 6, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 16, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 26, and b) a light chain variable region (VL) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 36, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 46, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 56.

[0210] In some embodiments, the TL1A-binding protein comprises a) a heavy chain variable region (VH) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 7, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 17, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 27, and b) a light chain variable region (VL) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 37, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 47, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 57.

[0211] In some embodiments, the TL1A-binding protein comprises a) a heavy chain variable region (VH) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 8, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 18, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 28, and b) a light chain variable region (VL) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 38, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 48, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 58.

[0212] In some embodiments, the TL1A-binding protein comprises a) a heavy chain variable region (VH) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 9, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 19, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 29, and b) a light chain variable region (VL) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 39, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 49, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 59.

[0213] In some embodiments, the TL1A-binding protein comprises a) a heavy chain variable region (VH) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 10, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 20, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 30, and b) a light chain variable region (VL) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 40, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 50, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 60.

[0214] In some embodiments, the TL1A-binding protein comprises a) a heavy chain variable region (VH) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 321, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 430, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 539, and b) a light chain variable region (VL) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 648, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 757, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 866.

[0215] In some embodiments, the TL1A-binding protein comprises a) a heavy chain variable region (VH) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 341, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 450, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 559, and b) a light chain variable region (VL) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 668, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 777, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 886.

[0216] In some embodiments, the TL1A-binding protein comprises a) a heavy chain variable region (VH) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 345, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 454, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 563, and b) a light chain variable region (VL) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 672, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 781, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 890.

[0217] In some embodiments, the TL1A-binding protein comprises a) a heavy chain variable region (VH) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 349, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 458, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 567, and b) a light chain variable region (VL) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 676, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 785, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 894.

[0218] In some embodiments, the TL1A-binding protein comprises a) a heavy chain variable region (VH) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 351, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 460, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 569, and b) a light chain variable region (VL) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 678, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 787, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 896.

[0219] In some embodiments, the TL1A-binding protein comprises a) a heavy chain variable region (VH) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 354, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 463, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 572, and b) a light chain variable region (VL) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 681, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 790, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 899.

[0220] In some embodiments, the TL1A-binding protein comprises a) a heavy chain variable region (VH) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 365, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 474, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 583, and b) a light chain variable region (VL) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 692, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 801, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 910.

[0221] In some embodiments, the TL1A-binding protein comprises a) a heavy chain variable region (VH) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 371, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 480, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 589, and b) a light chain variable region (VL) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 698, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 807, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 916.

[0222] In some embodiments, the TL1A-binding protein comprises a) a heavy chain variable region (VH) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 372, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 481, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 590, and b) (i) SEQ ID NO: 69 9 (ii) a light chain variable region (VL) comprising CDR1 having the amino acid sequence described in (ii) 808, and CDR2 having the amino acid sequence described in (iii) 917.

[0223] In some embodiments, the TL1A-binding protein comprises a) a heavy chain variable region (VH) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 373, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 482, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 591, and b) a light chain variable region (VL) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 700, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 809, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 918.

[0224] In some embodiments, the TL1A-binding protein comprises a) a heavy chain variable region (VH) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 388, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 497, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 606, and b) a light chain variable region (VL) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 715, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 824, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 933.

[0225] In some embodiments, the TL1A-binding protein comprises a) a heavy chain variable region (VH) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 394, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 503, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 612, and b) a light chain variable region (VL) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 721, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 830, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 939.

[0226] In some embodiments, the TL1A-binding protein comprises a) a heavy chain variable region (VH) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 400, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 509, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 618, and b) a light chain variable region (VL) including (i) CDR1 having the amino acid sequence described in SEQ ID NO: 727, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 836, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 945.

[0227] Exemplary amino acid sequences of the heavy chain variable region (VH) and light chain variable region (VL) of TL1A-binding proteins are shown in Tables 2.1 and 2.2. [Table 2.1-1] Table 2.1-2 Table 2.2-1 Table 2.2-2 Table 2.2-3 Table 2.2-4 Table 2.2-5 Table 2.2-6 Table 2.2-7 Table 2.2-8 Table 2.2-9 Table 2.2-10 Table 2.2-11 Table 2.2-12 Table 2.2-13 Table 2.2-14 Table 2.2-15 Table 2.2-16

[0228] In some embodiments, the TL1A-binding protein includes a VH having at least 80% sequence identity with the amino acid sequence described in any one of the heavy chain variable region (VH) sequences listed in Tables 2.1 and 2.2. In some embodiments, the TL1A-binding protein includes a VH having at least 85% sequence identity with the amino acid sequence described in any one of the heavy chain variable region (VH) sequences (SEQ ID NOs. 181-190 and 2275-2383) listed in Tables 2.1 and 2.2. In some embodiments, the TL1A-binding protein includes a VH having at least 90% sequence identity with the amino acid sequence described in any one of the heavy chain variable region (VH) sequences listed in Tables 2.1 and 2.2. In some embodiments, the TL1A-binding protein includes a VH having at least 95% sequence identity with the amino acid sequence described in any one of the heavy chain variable region (VH) sequences listed in Tables 2.1 and 2.2. In some embodiments, the TL1A-binding protein includes a VH containing an amino acid sequence having at least 96% sequence identity to the amino acid sequence described in any one of the heavy chain variable region (VH) sequences listed in Tables 2.1 and 2.2. In some embodiments, the TL1A-binding protein includes a VH containing an amino acid sequence having at least 97% sequence identity to the amino acid sequence described in any one of the heavy chain variable region (VH) sequences listed in Tables 2.1 and 2.2. In some embodiments, the TL1A-binding protein includes a VH containing an amino acid sequence having at least 98% sequence identity to the amino acid sequence described in any one of the heavy chain variable region (VH) sequences listed in Tables 2.1 and 2.2. In some embodiments, the TL1A-binding protein includes a VH containing an amino acid sequence having at least 99% sequence identity to the amino acid sequence described in any one of the heavy chain variable region (VH) sequences listed in Tables 2.1 and 2.2.In some embodiments, the TL1A-binding protein includes a VH comprising the amino acid sequence described in any one of the heavy chain variable region (VH) sequences listed in Tables 2.1 and 2.2.

[0229] In some embodiments, the TL1A-binding protein includes a VL containing an amino acid sequence having at least 80% sequence identity to the amino acid sequence described in any one of the light chain variable region (VL) sequences (SEQ ID NOs. 191-200 and 2384-2492) listed in Tables 2.1 and 2.2. In some embodiments, the TL1A-binding protein includes a VL containing an amino acid sequence having at least 85% sequence identity to the amino acid sequence described in any one of the light chain variable region (VL) sequences listed in Tables 2.1 and 2.2. In some embodiments, the TL1A-binding protein includes a VL containing an amino acid sequence having at least 90% sequence identity to the amino acid sequence described in any one of the light chain variable region (VL) sequences listed in Tables 2.1 and 2.2. In some embodiments, the TL1A-binding protein includes a VL containing an amino acid sequence having at least 95% sequence identity to the amino acid sequence described in any one of the light chain variable region (VL) sequences listed in Tables 2.1 and 2.2. In some embodiments, the TL1A-binding protein includes a VL containing an amino acid sequence having at least 96% sequence identity to the amino acid sequence described in any one of the light chain variable region (VL) sequences listed in Tables 2.1 and 2.2. In some embodiments, the TL1A-binding protein includes a VL containing an amino acid sequence having at least 97% sequence identity to the amino acid sequence described in any one of the light chain variable region (VL) sequences listed in Tables 2.1 and 2.2. In some embodiments, the TL1A-binding protein includes a VL containing an amino acid sequence having at least 98% sequence identity to the amino acid sequence described in any one of the light chain variable region (VL) sequences listed in Tables 2.1 and 2.2. In some embodiments, the TL1A-binding protein includes a VL containing an amino acid sequence having at least 99% sequence identity to the amino acid sequence described in any one of the light chain variable region (VL) sequences listed in Tables 2.1 and 2.2.In some embodiments, the TL1A-binding protein includes a VL containing the amino acid sequence described in any one of the light chain variable region (VL) sequences listed in Tables 2.1 and 2.2.

[0230] In some embodiments, the TL1A-binding protein contains an amino acid sequence that is at least 60% (e.g., at least 70%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the heavy chain variable region (VH) of the TL1A-binding proteins disclosed in Tables 2.1 and 2.2. The protein comprises a chain variable region (VH) and a light chain variable region (VL) having an amino acid sequence that is at least 60% (e.g., at least 70%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%) identical to the light chain variable region (VL) of the TL1A-binding proteins disclosed in Tables 2.1 and 2.2.

[0231] In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 80% sequence identity with the amino acid sequence described in any one of the VH sequences (SEQ ID NOs. 181-190 and 2275-2383) listed in Tables 2.1 and 2.2, and a light chain variable region containing an amino acid sequence having at least 80% sequence identity with the amino acid sequence described in any one of the VL sequences (SEQ ID NOs. 191-200 and 2384-2492) listed in Tables 2.1 and 2.2. In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 85% sequence identity with the amino acid sequence described in any one of the VH sequences (SEQ ID NOs. 181-190 and 2275-2383) listed in Tables 2.1 and 2.2, and a light chain variable region containing an amino acid sequence having at least 85% sequence identity with the amino acid sequence described in any one of the VL sequences (SEQ ID NOs. 191-200 and 2384-2492) listed in Tables 2.1 and 2.2. In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 90% sequence identity with the amino acid sequence described in any one of the VH sequences (SEQ ID NOs. 181-190 and 2275-2383) listed in Tables 2.1 and 2.2, and a light chain variable region containing an amino acid sequence having at least 90% sequence identity with the amino acid sequence described in any one of the VL sequences (SEQ ID NOs. 191-200 and 2384-2492) listed in Tables 2.1 and 2.2. In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 95% sequence identity to the amino acid sequence described in any one of the VH sequences (SEQ ID NOs. 181-190 and 2275-2383) listed in Tables 2.1 and 2.2, and a light chain variable region containing an amino acid sequence having at least 95% sequence identity to the amino acid sequence described in any one of the VL sequences (SEQ ID NOs. 191-200 and 2384-2492) listed in Tables 2.1 and 2.2.In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 96% sequence identity with the amino acid sequence described in any one of the VH sequences (SEQ ID NOs. 181-190 and 2275-2383) listed in Tables 2.1 and 2.2, and a light chain variable region containing an amino acid sequence having at least 96% sequence identity with the amino acid sequence described in any one of the VL sequences (SEQ ID NOs. 191-200 and 2384-2492) listed in Tables 2.1 and 2.2. In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 97% sequence identity with the amino acid sequence described in any one of the VH sequences (SEQ ID NOs. 181-190 and 2275-2383) listed in Tables 2.1 and 2.2, and a light chain variable region containing an amino acid sequence having at least 97% sequence identity with the amino acid sequence described in any one of the VL sequences (SEQ ID NOs. 191-200 and 2384-2492) listed in Tables 2.1 and 2.2. In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 98% sequence identity with the amino acid sequence described in any one of the VH sequences (SEQ ID NOs. 181-190 and 2275-2383) listed in Tables 2.1 and 2.2, and a light chain variable region containing an amino acid sequence having at least 98% sequence identity with the amino acid sequence described in any one of the VL sequences (SEQ ID NOs. 191-200 and 2384-2492) listed in Tables 2.1 and 2.2. In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 99% sequence identity with the amino acid sequence described in any one of the VH sequences (SEQ ID NOs. 181-190 and 2275-2383) listed in Tables 2.1 and 2.2, and a light chain variable region containing an amino acid sequence having at least 99% sequence identity with the amino acid sequence described in any one of the VL sequences (SEQ ID NOs. 191-200 and 2384-2492) listed in Tables 2.1 and 2.2.In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence described in any one of the VH sequences (SEQ ID NOs. 181-190 and 2275-2383) listed in Tables 2.1 and 2.2, and a light chain variable region containing an amino acid sequence described in any one of the VL sequences (SEQ ID NOs. 191-200 and 2384-2492) listed in Tables 2.1 and 2.2.

[0232] In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 80% sequence identity with the amino acid sequences listed in Table 2.1, and a light chain variable region containing an amino acid sequence having at least 80% sequence identity with the amino acid sequences listed in Table 2.1. In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 85% sequence identity with the amino acid sequences listed in Table 2.1, and a light chain variable region containing an amino acid sequence having at least 85% sequence identity with the amino acid sequences listed in Table 2.1. In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 90% sequence identity with the amino acid sequences listed in Table 2.1, and a light chain variable region containing an amino acid sequence having at least 90% sequence identity with the amino acid sequences listed in Table 2.1. In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 95% sequence identity with the amino acid sequences listed in Table 2.1, and a light chain variable region containing an amino acid sequence having at least 95% sequence identity with the amino acid sequences listed in Table 2.1. In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 96% sequence identity with the amino acid sequences listed in Table 2.1, and a light chain variable region containing an amino acid sequence having at least 96% sequence identity with the amino acid sequences listed in Table 2.1. In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 97% sequence identity with the amino acid sequences listed in Table 2.1, and a light chain variable region containing an amino acid sequence having at least 97% sequence identity with the amino acid sequences listed in Table 2.1. In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 98% sequence identity with the amino acid sequences listed in Table 2.1, and a light chain variable region containing an amino acid sequence having at least 98% sequence identity with the amino acid sequences listed in Table 2.1.In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 99% sequence identity with the amino acid sequences listed in Table 2.1, and a light chain variable region containing an amino acid sequence having at least 99% sequence identity with the amino acid sequences listed in Table 2.1.

[0233] In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 80% sequence identity with the amino acid sequences listed in Table 2.2, and a light chain variable region containing an amino acid sequence having at least 80% sequence identity with the amino acid sequences listed in Table 2.2. In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 85% sequence identity with the amino acid sequences listed in Table 2.2, and a light chain variable region containing an amino acid sequence having at least 85% sequence identity with the amino acid sequences listed in Table 2.2. In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 90% sequence identity with the amino acid sequences listed in Table 2.2, and a light chain variable region containing an amino acid sequence having at least 90% sequence identity with the amino acid sequences listed in Table 2.2. In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 95% sequence identity with the amino acid sequences listed in Table 2.2, and a light chain variable region containing an amino acid sequence having at least 95% sequence identity with the amino acid sequences listed in Table 2.2. In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 96% sequence identity with the amino acid sequences listed in Table 2.2, and a light chain variable region containing an amino acid sequence having at least 96% sequence identity with the amino acid sequences listed in Table 2.2. In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 97% sequence identity with the amino acid sequences listed in Table 2.2, and a light chain variable region containing an amino acid sequence having at least 97% sequence identity with the amino acid sequences listed in Table 2.2. In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 98% sequence identity with the amino acid sequences listed in Table 2.2, and a light chain variable region containing an amino acid sequence having at least 98% sequence identity with the amino acid sequences listed in Table 2.2.In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 99% sequence identity with the amino acid sequences listed in Table 2.2, and a light chain variable region containing an amino acid sequence having at least 99% sequence identity with the amino acid sequences listed in Table 2.2.

[0234] In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 80% sequence identity with the amino acid sequence described in SEQ ID NO: 181, and a light chain variable region containing an amino acid sequence having at least 80% sequence identity with the amino acid sequence described in SEQ ID NO: 191. In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 85% sequence identity with the amino acid sequence described in SEQ ID NO: 181, and a light chain variable region containing an amino acid sequence having at least 85% sequence identity with the amino acid sequence described in SEQ ID NO: 191. In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 90% sequence identity with the amino acid sequence described in SEQ ID NO: 181, and a light chain variable region containing an amino acid sequence having at least 90% sequence identity with the amino acid sequence described in SEQ ID NO: 191. In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 95% sequence identity with the amino acid sequence described in SEQ ID NO: 181, and a light chain variable region containing an amino acid sequence having at least 95% sequence identity with the amino acid sequence described in SEQ ID NO: 191. In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 96% sequence identity with the amino acid sequence described in SEQ ID NO: 181, and a light chain variable region containing an amino acid sequence having at least 96% sequence identity with the amino acid sequence described in SEQ ID NO: 191. In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 97% sequence identity with the amino acid sequence described in SEQ ID NO: 181, and a light chain variable region containing an amino acid sequence having at least 97% sequence identity with the amino acid sequence described in SEQ ID NO: 191. In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 98% sequence identity with the amino acid sequence described in SEQ ID NO: 181, and a light chain variable region containing an amino acid sequence having at least 98% sequence identity with the amino acid sequence described in SEQ ID NO: 191.In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 99% sequence identity with the amino acid sequence described in SEQ ID NO: 181, and a light chain variable region containing an amino acid sequence having at least 99% sequence identity with the amino acid sequence described in SEQ ID NO: 191. In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing the amino acid sequence described in SEQ ID NO: 181, and a light chain variable region containing the amino acid sequence described in SEQ ID NO: 191.

[0235] In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 80% sequence identity with the amino acid sequence described in SEQ ID NO: 182, and a light chain variable region containing an amino acid sequence having at least 80% sequence identity with the amino acid sequence described in SEQ ID NO: 192. In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 85% sequence identity with the amino acid sequence described in SEQ ID NO: 182, and a light chain variable region containing an amino acid sequence having at least 85% sequence identity with the amino acid sequence described in SEQ ID NO: 192. In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 90% sequence identity with the amino acid sequence described in SEQ ID NO: 182, and a light chain variable region containing an amino acid sequence having at least 90% sequence identity with the amino acid sequence described in SEQ ID NO: 192. In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 95% sequence identity with the amino acid sequence described in SEQ ID NO: 182, and a light chain variable region containing an amino acid sequence having at least 95% sequence identity with the amino acid sequence described in SEQ ID NO: 192. In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 96% sequence identity with the amino acid sequence described in SEQ ID NO: 182, and a light chain variable region containing an amino acid sequence having at least 96% sequence identity with the amino acid sequence described in SEQ ID NO: 192. In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 97% sequence identity with the amino acid sequence described in SEQ ID NO: 182, and a light chain variable region containing an amino acid sequence having at least 97% sequence identity with the amino acid sequence described in SEQ ID NO: 192. In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 98% sequence identity with the amino acid sequence described in SEQ ID NO: 182, and a light chain variable region containing an amino acid sequence having at least 98% sequence identity with the amino acid sequence described in SEQ ID NO: 192.In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 99% sequence identity with the amino acid sequence described in SEQ ID NO: 182, and a light chain variable region containing an amino acid sequence having at least 99% sequence identity with the amino acid sequence described in SEQ ID NO: 192. In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing the amino acid sequence described in SEQ ID NO: 182, and a light chain variable region containing the amino acid sequence described in SEQ ID NO: 192.

[0236] In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 80% sequence identity with the amino acid sequence described in SEQ ID NO: 183, and a light chain variable region containing an amino acid sequence having at least 80% sequence identity with the amino acid sequence described in SEQ ID NO: 193. In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 85% sequence identity with the amino acid sequence described in SEQ ID NO: 183, and a light chain variable region containing an amino acid sequence having at least 85% sequence identity with the amino acid sequence described in SEQ ID NO: 193. In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 90% sequence identity with the amino acid sequence described in SEQ ID NO: 183, and a light chain variable region containing an amino acid sequence having at least 90% sequence identity with the amino acid sequence described in SEQ ID NO: 193. In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 95% sequence identity with the amino acid sequence described in SEQ ID NO: 183, and a light chain variable region containing an amino acid sequence having at least 95% sequence identity with the amino acid sequence described in SEQ ID NO: 193. In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 96% sequence identity with the amino acid sequence described in SEQ ID NO: 183, and a light chain variable region containing an amino acid sequence having at least 96% sequence identity with the amino acid sequence described in SEQ ID NO: 193. In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 97% sequence identity with the amino acid sequence described in SEQ ID NO: 183, and a light chain variable region containing an amino acid sequence having at least 97% sequence identity with the amino acid sequence described in SEQ ID NO: 193. In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 98% sequence identity with the amino acid sequence described in SEQ ID NO: 183, and a light chain variable region containing an amino acid sequence having at least 98% sequence identity with the amino acid sequence described in SEQ ID NO: 193.In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 99% sequence identity with the amino acid sequence described in SEQ ID NO: 183, and a light chain variable region containing an amino acid sequence having at least 99% sequence identity with the amino acid sequence described in SEQ ID NO: 193. In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing the amino acid sequence described in SEQ ID NO: 183, and a light chain variable region containing the amino acid sequence described in SEQ ID NO: 193.

[0237] In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 80% sequence identity with the amino acid sequence described in SEQ ID NO: 184, and a light chain variable region containing an amino acid sequence having at least 80% sequence identity with the amino acid sequence described in SEQ ID NO: 194. In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 85% sequence identity with the amino acid sequence described in SEQ ID NO: 184, and a light chain variable region containing an amino acid sequence having at least 85% sequence identity with the amino acid sequence described in SEQ ID NO: 194. In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 90% sequence identity with the amino acid sequence described in SEQ ID NO: 184, and a light chain variable region containing an amino acid sequence having at least 90% sequence identity with the amino acid sequence described in SEQ ID NO: 194. In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 95% sequence identity with the amino acid sequence described in SEQ ID NO: 184, and a light chain variable region containing an amino acid sequence having at least 95% sequence identity with the amino acid sequence described in SEQ ID NO: 194. In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 96% sequence identity with the amino acid sequence described in SEQ ID NO: 184, and a light chain variable region containing an amino acid sequence having at least 96% sequence identity with the amino acid sequence described in SEQ ID NO: 194. In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 97% sequence identity with the amino acid sequence described in SEQ ID NO: 184, and a light chain variable region containing an amino acid sequence having at least 97% sequence identity with the amino acid sequence described in SEQ ID NO: 194. In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 98% sequence identity with the amino acid sequence described in SEQ ID NO: 184, and a light chain variable region containing an amino acid sequence having at least 98% sequence identity with the amino acid sequence described in SEQ ID NO: 194.In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 99% sequence identity with the amino acid sequence described in SEQ ID NO: 184, and a light chain variable region containing an amino acid sequence having at least 99% sequence identity with the amino acid sequence described in SEQ ID NO: 194. In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing the amino acid sequence described in SEQ ID NO: 184, and a light chain variable region containing the amino acid sequence described in SEQ ID NO: 194.

[0238] In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 80% sequence identity with the amino acid sequence described in SEQ ID NO: 185, and a light chain variable region containing an amino acid sequence having at least 80% sequence identity with the amino acid sequence described in SEQ ID NO: 195. In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 85% sequence identity with the amino acid sequence described in SEQ ID NO: 185, and a light chain variable region containing an amino acid sequence having at least 85% sequence identity with the amino acid sequence described in SEQ ID NO: 195. In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 90% sequence identity with the amino acid sequence described in SEQ ID NO: 185, and a light chain variable region containing an amino acid sequence having at least 90% sequence identity with the amino acid sequence described in SEQ ID NO: 195. In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 95% sequence identity with the amino acid sequence described in SEQ ID NO: 185, and a light chain variable region containing an amino acid sequence having at least 95% sequence identity with the amino acid sequence described in SEQ ID NO: 195. In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 96% sequence identity with the amino acid sequence described in SEQ ID NO: 185, and a light chain variable region containing an amino acid sequence having at least 96% sequence identity with the amino acid sequence described in SEQ ID NO: 195. In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 97% sequence identity with the amino acid sequence described in SEQ ID NO: 185, and a light chain variable region containing an amino acid sequence having at least 97% sequence identity with the amino acid sequence described in SEQ ID NO: 195. In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 98% sequence identity with the amino acid sequence described in SEQ ID NO: 185, and a light chain variable region containing an amino acid sequence having at least 98% sequence identity with the amino acid sequence described in SEQ ID NO: 195.In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 99% sequence identity with the amino acid sequence described in SEQ ID NO: 185, and a light chain variable region containing an amino acid sequence having at least 99% sequence identity with the amino acid sequence described in SEQ ID NO: 195.

[0239] In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 80% sequence identity with the amino acid sequence described in SEQ ID NO: 186, and a light chain variable region containing an amino acid sequence having at least 80% sequence identity with the amino acid sequence described in SEQ ID NO: 196. In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 85% sequence identity with the amino acid sequence described in SEQ ID NO: 186, and a light chain variable region containing an amino acid sequence having at least 85% sequence identity with the amino acid sequence described in SEQ ID NO: 196. In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 90% sequence identity with the amino acid sequence described in SEQ ID NO: 186, and a light chain variable region containing an amino acid sequence having at least 90% sequence identity with the amino acid sequence described in SEQ ID NO: 196. In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 95% sequence identity with the amino acid sequence described in SEQ ID NO: 186, and a light chain variable region containing an amino acid sequence having at least 95% sequence identity with the amino acid sequence described in SEQ ID NO: 196. In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 96% sequence identity with the amino acid sequence described in SEQ ID NO: 186, and a light chain variable region containing an amino acid sequence having at least 96% sequence identity with the amino acid sequence described in SEQ ID NO: 196. In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 97% sequence identity with the amino acid sequence described in SEQ ID NO: 186, and a light chain variable region containing an amino acid sequence having at least 97% sequence identity with the amino acid sequence described in SEQ ID NO: 196. In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 98% sequence identity with the amino acid sequence described in SEQ ID NO: 186, and a light chain variable region containing an amino acid sequence having at least 98% sequence identity with the amino acid sequence described in SEQ ID NO: 196.In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 99% sequence identity with the amino acid sequence described in SEQ ID NO: 186, and a light chain variable region containing an amino acid sequence having at least 99% sequence identity with the amino acid sequence described in SEQ ID NO: 196.

[0240] In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 80% sequence identity with the amino acid sequence described in SEQ ID NO: 187, and a light chain variable region containing an amino acid sequence having at least 80% sequence identity with the amino acid sequence described in SEQ ID NO: 197. In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 85% sequence identity with the amino acid sequence described in SEQ ID NO: 187, and a light chain variable region containing an amino acid sequence having at least 85% sequence identity with the amino acid sequence described in SEQ ID NO: 197. In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 90% sequence identity with the amino acid sequence described in SEQ ID NO: 187, and a light chain variable region containing an amino acid sequence having at least 90% sequence identity with the amino acid sequence described in SEQ ID NO: 197. In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 95% sequence identity with the amino acid sequence described in SEQ ID NO: 187, and a light chain variable region containing an amino acid sequence having at least 95% sequence identity with the amino acid sequence described in SEQ ID NO: 197. In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 96% sequence identity with the amino acid sequence described in SEQ ID NO: 187, and a light chain variable region containing an amino acid sequence having at least 96% sequence identity with the amino acid sequence described in SEQ ID NO: 197. In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 97% sequence identity with the amino acid sequence described in SEQ ID NO: 187, and a light chain variable region containing an amino acid sequence having at least 97% sequence identity with the amino acid sequence described in SEQ ID NO: 197. In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 98% sequence identity with the amino acid sequence described in SEQ ID NO: 187, and a light chain variable region containing an amino acid sequence having at least 98% sequence identity with the amino acid sequence described in SEQ ID NO: 197.In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 99% sequence identity with the amino acid sequence described in SEQ ID NO: 187, and a light chain variable region containing an amino acid sequence having at least 99% sequence identity with the amino acid sequence described in SEQ ID NO: 197. In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing the amino acid sequence described in SEQ ID NO: 187, and a light chain variable region containing the amino acid sequence described in SEQ ID NO: 197.

[0241] In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 80% sequence identity with the amino acid sequence described in SEQ ID NO: 188, and a light chain variable region containing an amino acid sequence having at least 80% sequence identity with the amino acid sequence described in SEQ ID NO: 198. In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 85% sequence identity with the amino acid sequence described in SEQ ID NO: 188, and a light chain variable region containing an amino acid sequence having at least 85% sequence identity with the amino acid sequence described in SEQ ID NO: 198. In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 90% sequence identity with the amino acid sequence described in SEQ ID NO: 188, and a light chain variable region containing an amino acid sequence having at least 90% sequence identity with the amino acid sequence described in SEQ ID NO: 198. In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 95% sequence identity with the amino acid sequence described in SEQ ID NO: 188, and a light chain variable region containing an amino acid sequence having at least 95% sequence identity with the amino acid sequence described in SEQ ID NO: 198. In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 96% sequence identity with the amino acid sequence described in SEQ ID NO: 188, and a light chain variable region containing an amino acid sequence having at least 96% sequence identity with the amino acid sequence described in SEQ ID NO: 198. In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 97% sequence identity with the amino acid sequence described in SEQ ID NO: 188, and a light chain variable region containing an amino acid sequence having at least 97% sequence identity with the amino acid sequence described in SEQ ID NO: 198. In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 98% sequence identity with the amino acid sequence described in SEQ ID NO: 188, and a light chain variable region containing an amino acid sequence having at least 98% sequence identity with the amino acid sequence described in SEQ ID NO: 198.In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 99% sequence identity with the amino acid sequence described in SEQ ID NO: 188, and a light chain variable region containing an amino acid sequence having at least 99% sequence identity with the amino acid sequence described in SEQ ID NO: 198. In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing the amino acid sequence described in SEQ ID NO: 188, and a light chain variable region containing the amino acid sequence described in SEQ ID NO: 198.

[0242] In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 80% sequence identity with the amino acid sequence described in SEQ ID NO: 189, and a light chain variable region containing an amino acid sequence having at least 80% sequence identity with the amino acid sequence described in SEQ ID NO: 199. In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 85% sequence identity with the amino acid sequence described in SEQ ID NO: 189, and a light chain variable region containing an amino acid sequence having at least 85% sequence identity with the amino acid sequence described in SEQ ID NO: 199. In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 90% sequence identity with the amino acid sequence described in SEQ ID NO: 189, and a light chain variable region containing an amino acid sequence having at least 90% sequence identity with the amino acid sequence described in SEQ ID NO: 199. In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 95% sequence identity with the amino acid sequence described in SEQ ID NO: 189, and a light chain variable region containing an amino acid sequence having at least 95% sequence identity with the amino acid sequence described in SEQ ID NO: 199. In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 96% sequence identity with the amino acid sequence described in SEQ ID NO: 189, and a light chain variable region containing an amino acid sequence having at least 96% sequence identity with the amino acid sequence described in SEQ ID NO: 199. In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 97% sequence identity with the amino acid sequence described in SEQ ID NO: 189, and a light chain variable region containing an amino acid sequence having at least 97% sequence identity with the amino acid sequence described in SEQ ID NO: 199. In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 98% sequence identity with the amino acid sequence described in SEQ ID NO: 189, and a light chain variable region containing an amino acid sequence having at least 98% sequence identity with the amino acid sequence described in SEQ ID NO: 199.In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 99% sequence identity with the amino acid sequence described in SEQ ID NO: 189, and a light chain variable region containing an amino acid sequence having at least 99% sequence identity with the amino acid sequence described in SEQ ID NO: 199. In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing the amino acid sequence described in SEQ ID NO: 189, and a light chain variable region containing the amino acid sequence described in SEQ ID NO: 199.

[0243] In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 80% sequence identity with the amino acid sequence described in SEQ ID NO: 190, and a light chain variable region containing an amino acid sequence having at least 80% sequence identity with the amino acid sequence described in SEQ ID NO: 200. In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 85% sequence identity with the amino acid sequence described in SEQ ID NO: 190, and a light chain variable region containing an amino acid sequence having at least 85% sequence identity with the amino acid sequence described in SEQ ID NO: 200. In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 90% sequence identity with the amino acid sequence described in SEQ ID NO: 190, and a light chain variable region containing an amino acid sequence having at least 90% sequence identity with the amino acid sequence described in SEQ ID NO: 200. In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 95% sequence identity with the amino acid sequence described in SEQ ID NO: 190, and a light chain variable region containing an amino acid sequence having at least 95% sequence identity with the amino acid sequence described in SEQ ID NO: 200. In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 96% sequence identity with the amino acid sequence described in SEQ ID NO: 190, and a light chain variable region containing an amino acid sequence having at least 96% sequence identity with the amino acid sequence described in SEQ ID NO: 200. In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 97% sequence identity with the amino acid sequence described in SEQ ID NO: 190, and a light chain variable region containing an amino acid sequence having at least 97% sequence identity with the amino acid sequence described in SEQ ID NO: 200. In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 98% sequence identity with the amino acid sequence described in SEQ ID NO: 190, and a light chain variable region containing an amino acid sequence having at least 98% sequence identity with the amino acid sequence described in SEQ ID NO: 200.In some embodiments, the TL1A-binding protein includes a heavy chain variable region containing an amino acid sequence having at least 99% sequence identity with the amino acid sequence described in SEQ ID NO: 190, and a light chain variable region containing an amino acid sequence having at least 99% sequence identity with the amino acid sequence described in SEQ ID NO: 200.

[0244] In some embodiments, the TL1A-binding protein has a K concentration of 10 nanomolars (nM), 9nM, 8nM, 7nM, 6nM, 5nM, 4nM, 3nM, 2nM, 1nM, 0.9nM, 0.8nM, 0.7nM, 0.6nM, 0.5nM, 0.4nM, 0.3nM, 0.2nM, 0.1nM, 90pM, 80pM, 70pM, 60pM, 50pM, 40pM, 30pM, 20pM, or less than or equal to 10pM. D It binds to TL1A. In some embodiments, the TL1A-binding protein is approximately 10 pM to 1 nM, approximately 10 pM to 0.9 nM, approximately 10 pM to 0.8 nM, approximately 10 pM to 0.7 nM, approximately 10 pM to 0.6 nM, approximately 10 pM to 0.5 nM, approximately 10 pM to 0.4 nM, approximately 10 pM to 0.3 nM, approximately 10 pM to 0.2 nM, approximately 10 pM to 0.1 nM, approximately 10pM to about 50pM, 0.1nM to about 10nM, about 0.1nM to about 9nM, about 0.1nM to about 8nM, about 0.1nM to about 7nM, about 0.1nM to about 6nM, about 0.1n K in the range of M ~ about 5 nM, about 0.1 nM to about 4 nM, about 0.1 nM to about 3 nM, about 0.1 nM to about 2 nM, about 0.1 nM to about 1 nM, or about 0.1 nM to about 0.5 nM D It binds to TL1A. In some embodiments, the TL1A-binding protein is K at a concentration of less than approximately 1 nanomolar (nM). D It binds to TL1A. In some embodiments, the TL1A-binding protein is K at a concentration of less than approximately 0.9 nanomolars (nM). D It binds to TL1A. In some embodiments, the TL1A-binding protein has a K concentration of less than approximately 0.8 nanomolars (nM). Dbinds to TL1A. In some embodiments, the TL1A-binding protein has a K of less than about 0.7 nanomolar (nM) D binds to TL1A. In some embodiments, the TL1A-binding protein has a K of less than about 0.6 nanomolar (nM) D binds to TL1A. In some embodiments, the TL1A-binding protein has a K of less than about 0.5 nanomolar (nM) D binds to TL1A. In some embodiments, the TL1A-binding protein has a K of less than about 0.4 nanomolar (nM) D binds to TL1A. In some embodiments, the TL1A-binding protein has a K of less than about 0.3 nanomolar (nM) D binds to TL1A. In some embodiments, the TL1A-binding protein has a K of less than about 0.2 nanomolar (nM) D binds to TL1A. In some embodiments, the TL1A-binding protein has a K of less than about 0.1 nanomolar (nM) D binds to TL1A. In some embodiments, K D is measured by surface plasmon resonance (SPR). In some embodiments, K D is measured by Biolayer Interferometry (BLI).

[0245] In some embodiments, the TL1A-binding protein has a binding affinity to TL1A that is at least 1.5 times, 2 times, 3 times, 4 times, 5 times, 6 times, 7 times, 8 times, 9 times, 10 times, 15 times, or 20 times higher than the binding affinity of the comparison antibody to TL1A. In some embodiments, the TL1A-binding protein has a binding affinity to TL1A that is at least 1.5 times higher than the binding affinity of the comparison antibody to TL1A. In some embodiments, the TL1A-binding protein has a binding affinity to TL1A that is at least 2 times higher than the binding affinity of the comparison antibody to TL1A. In some embodiments, the TL1A-binding protein has a binding affinity to TL1A that is at least 3 times higher than the binding affinity of the comparison antibody to TL1A. In some embodiments, the TL1A-binding protein has a binding affinity to TL1A that is at least 4 times higher than the binding affinity of the comparison antibody to TL1A. In some embodiments, the TL1A-binding protein has a binding affinity to TL1A that is at least 5 times higher than the binding affinity of the comparison antibody to TL1A. In some embodiments, the TL1A-binding protein has a binding affinity to TL1A that is at least 6 times higher than the binding affinity of the comparison antibody to TL1A. In some embodiments, the TL1A-binding protein has a binding affinity to TL1A that is at least 7 times higher than the binding affinity of the comparison antibody to TL1A. In some embodiments, the TL1A-binding protein has a binding affinity to TL1A that is at least 8 times higher than the binding affinity of the comparison antibody to TL1A. In some embodiments, the TL1A-binding protein has a binding affinity to TL1A that is at least 9 times higher than the binding affinity of the comparison antibody to TL1A. In some embodiments, the TL1A-binding protein has a binding affinity to TL1A that is at least 10 times higher than the binding affinity of the comparison antibody to TL1A.

[0246] In some embodiments, the TL1A-binding protein inhibits the binding of receptors (e.g., death receptor 3 (DR3) and decoy receptor 3 (DcR3)) to TL1A at least 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, or 20 times more strongly than a comparator antibody against TL1A. In some embodiments, the TL1A-binding protein inhibits the binding of receptors to TL1A at least 1.5 times more strongly than a comparator antibody against TL1A. In some embodiments, the TL1A-binding protein inhibits the binding of receptors to TL1A at least 2 times more strongly than a comparator antibody against TL1A. In some embodiments, the TL1A-binding protein inhibits the binding of receptors to TL1A at least 3 times more strongly than a comparator antibody against TL1A. In some embodiments, the TL1A-binding protein inhibits the binding of receptors to TL1A at least 4 times more strongly than a comparator antibody against TL1A. In some embodiments, the TL1A-binding protein inhibits the binding of the receptor to TL1A at least 5 times more strongly than a comparator antibody against TL1A. In some embodiments, the TL1A-binding protein inhibits the binding of the receptor to TL1A at least 6 times more strongly than a comparator antibody against TL1A. In some embodiments, the TL1A-binding protein inhibits the binding of the receptor to TL1A at least 7 times more strongly than a comparator antibody against TL1A. In some embodiments, the TL1A-binding protein inhibits the binding of the receptor to TL1A at least 8 times more strongly than a comparator antibody against TL1A. In some embodiments, the TL1A-binding protein inhibits the binding of the receptor to TL1A at least 9 times more strongly than a comparator antibody against TL1A. In some embodiments, the TL1A-binding protein inhibits the binding of the receptor to TL1A at least 10 times more strongly than a comparator antibody against TL1A.

[0247] In some embodiments, the TL1A-binding protein reduces TL1A-induced apoptosis by at least 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, or 20 times compared to the binding affinity of the comparison antibody to TL1A. In some embodiments, the TL1A-binding protein reduces TL1A-induced apoptosis by at least 1.5 times compared to the binding affinity of the comparison antibody to TL1A. In some embodiments, the TL1A-binding protein reduces TL1A-induced apoptosis by at least 2 times compared to the binding affinity of the comparison antibody to TL1A. In some embodiments, the TL1A-binding protein reduces TL1A-induced apoptosis by at least 3 times compared to the binding affinity of the comparison antibody to TL1A. In some embodiments, the TL1A-binding protein reduces TL1A-induced apoptosis by at least 4 times compared to the binding affinity of the comparison antibody to TL1A. In some embodiments, the TL1A-binding protein reduces TL1A-induced apoptosis by at least 5 times compared to the binding affinity of the comparison antibody to TL1A. In some embodiments, the TL1A-binding protein reduces TL1A-induced apoptosis by at least 6 times compared to the binding affinity of the comparison antibody to TL1A. In some embodiments, the TL1A-binding protein reduces TL1A-induced apoptosis by at least 7 times compared to the binding affinity of the comparison antibody to TL1A. In some embodiments, the TL1A-binding protein reduces TL1A-induced apoptosis by at least 8 times compared to the binding affinity of the comparison antibody to TL1A. In some embodiments, the TL1A-binding protein reduces TL1A-induced apoptosis by at least 9 times compared to the binding affinity of the comparison antibody to TL1A. In some embodiments, the TL1A-binding protein reduces TL1A-induced apoptosis by at least 10 times compared to the binding affinity of the comparison antibody to TL1A.

[0248] In some embodiments, the TL1A-binding protein exhibits improved solubility and / or development suitability. In some embodiments, the TL1A-binding protein is formulated at high concentrations. In some embodiments, the TL1A-binding protein is formulated at high concentrations for subcutaneous administration (e.g., by an autoinjector). In some embodiments, the TL1A-binding protein is formulated at concentrations of at least about 75, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, or 300 milligrams / milliliter (mg / mL) or greater than 300 mg / mL. In some embodiments, the TL1A-binding protein is formulated at concentrations ranging from approximately 50 to approximately 300, approximately 50 to approximately 200, approximately 50 to approximately 150, approximately 50 to approximately 100, approximately 75 to approximately 300, approximately 75 to approximately 200, approximately 75 to approximately 150, approximately 75 to approximately 100, approximately 100 to approximately 200, approximately 100 to approximately 150, or approximately 150 to approximately 200 mg / mL.

[0249] In some embodiments, the TL1A-binding protein is formulated to a pH range of about 5 to about 7. In some embodiments, the TL1A-binding protein is formulated to a pH range of about 5.5 to about 6.5. In some embodiments, the TL1A-binding protein is formulated to a pH range of about 4, 4.5, 5, 5.5, 6, 6.5, 7, or 7.5. In some embodiments, the TL1A-binding protein is formulated to a pH range of about 4 to 4.5, 4.5 to 5, 5 to 5.5, 5.5 to 6, 6 to 6.5, 6.5 to 7, or 7 to 7.5. FC modification

[0250] Compositions, systems, and methods comprising TL1A-binding proteins containing a modified Fc region are provided herein. Unless otherwise specified herein, the numbering of amino acid residues in the Fc region or constant region follows the EU numbering scheme. The EU numbering scheme, also known as the EU index, is described in Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD, 1991.

[0251] In some embodiments, the TL1A-binding protein includes a modified Fc containing one or more modifications. In some embodiments, one or more modifications are located on an Fc derived from IgG1 (e.g., human IgG1 (hIgG1)). In some embodiments, one or more modifications are located on an Fc derived from IgG4 (e.g., human IgG4 (hIgG4)). In some embodiments, one or more modifications are located on an Fc derived from IgG2. In some embodiments, one or more modifications promote selective binding of the Fc-gamma receptor.

[0252] Table 3 shows an example of the amino acid sequence of an Fc sequence. [Table 3-1] [Table 3-2] [Table 3-3] [Table 3-4] [Table 3-5] [Table 3-6] Table 3-7 Table 3-8 Table 3-9 Table 3-10 Table 3-11 Table 3-12 Table 3-13 Table 3-14 Table 3-15 Table 3-16 Table 3-17 Table 3-18 Table 3-19 Table 3-20 Table 3-21 Table 3-22 Table 3-23 Table 3-24 Table 3-25 Table 3-26 Table 3-27 Table 3-28 Table 3-29 Table 3-30 Table 3-31 Table 3-32 Table 3-33 Table 3-34

[0253] In some embodiments, Fc includes an amino acid sequence having at least 80% sequence identity with any one of the amino acid sequences listed in Table 3. In some embodiments, Fc includes an amino acid sequence having at least 85% sequence identity with any one of the amino acid sequences listed in Table 3. In some embodiments, Fc includes an amino acid sequence having at least 90% sequence identity with any one of the amino acid sequences listed in Table 3. In some embodiments, Fc includes an amino acid sequence having at least 95% sequence identity with any one of the amino acid sequences listed in Table 3. In some embodiments, Fc includes an amino acid sequence having at least 96% sequence identity with any one of the amino acid sequences listed in Table 3. In some embodiments, Fc includes an amino acid sequence having at least 97% sequence identity with any one of the amino acid sequences listed in Table 3. In some embodiments, Fc includes an amino acid sequence having at least 98% sequence identity with any one of the amino acid sequences listed in Table 3. In some embodiments, Fc includes an amino acid sequence having at least 99% sequence identity with any one of the amino acid sequences listed in Table 3. In some embodiments, Fc includes an amino acid sequence described in any one of the amino acid sequences listed in Table 3.

[0254] In some embodiments, the TL1A-binding protein includes an Fc containing one or more modifications of SEQ ID NO: 201. In some embodiments, the TL1A-binding protein includes an Fc containing one or more modifications of SEQ ID NO: 202. In some embodiments, the TL1A-binding protein includes an Fc containing one or more modifications of SEQ ID NO: 203. In some embodiments, the Fc includes an amino acid sequence having at least 80% sequence identity to the amino acid sequence described in any one of SEQ ID NOs. 201 to 203. In some embodiments, the Fc includes an amino acid sequence having at least 85% sequence identity to the amino acid sequence described in any one of SEQ ID NOs. 201 to 203. In some embodiments, the Fc includes an amino acid sequence having at least 90% sequence identity to the amino acid sequence described in any one of SEQ ID NOs. 201 to 203. In some embodiments, the Fc includes an amino acid sequence having at least 95% sequence identity to the amino acid sequence described in any one of SEQ ID NOs. 201 to 203. In some embodiments, Fc includes an amino acid sequence having at least 96% sequence identity with the amino acid sequence described in any one of SEQ ID NOs. 201 to 203. In some embodiments, Fc includes an amino acid sequence having at least 97% sequence identity with the amino acid sequence described in any one of SEQ ID NOs. 201 to 203. In some embodiments, Fc includes an amino acid sequence having at least 98% sequence identity with the amino acid sequence described in any one of SEQ ID NOs. 201 to 203. In some embodiments, Fc includes an amino acid sequence having at least 99% sequence identity with the amino acid sequence described in any one of SEQ ID NOs. 201 to 203. In some embodiments, Fc includes an amino acid sequence described in any one of SEQ ID NOs. 201 to 203.

[0255] In some embodiments, one or more modifications in the modified Fc are selected from the group consisting of S298A, E333A, K334A, K326A, F243L, R292P, Y300L, V305I, P396L, F243L, R292P, Y300L, L235V, P396L, F243L, S239D, I332E, A330L, S267E, L328F, D265S, S239E, K326A, A327H, G237F, K326E, G236A, D270L, H268D, S324T, L234F, N325L, V266L, and S267D. In some embodiments, one or more modifications in the modified Fc are selected from the group consisting of S228P, M252Y, S254T, T256E, T256D, T250Q, H285D, T307A, T307Q, T307R, T307W, L309D, Q411H, Q311V, A378V, E380A, M428L, N434A, N434S, N297A, D265A, L234A, L235A, and N434W.

[0256] In some embodiments, the modified Fc includes specific combinations of amino acid substitutions selected from the group consisting of L234A / L235A, V234A / G237A, L235A / G237A / E318A, S228P / L236E, H268Q / V309L / A330S / A331S, C220S / C226S / C229S / P238S, C226S / C229S / E3233P / L235V / L235A, L234F / L235E / P331S, C226S / P230S, L234A / G237A, L234A / L235A / G237A, Q311R / M428L, and L234A / L235A / P329G.

[0257] M428L / N434S (LS); M252Y / S254T / T256E (YTE); T250Q / M428L; T307A / E380A / N434A; T256D / T307Q (DQ); T256D / T307W (DW); M252Y / T256D (YD); T307Q / Q311V / A378V (QVV); T256D / H285D / T307R / Q311V / A378V (DDRVV); L309D / Q311H / N434S (DHS); S228P / L235E (SPLE); L234A / L235A (LALA); M428L / N434A (LA); L234A / G237A (LAGA); L234A / L235A / G237A (LAGAGA); L234A / L235A / P329G (LALAPG); N297A / YTE; D265A / YTE; LALA / YTE; LAGA / YTE; LALAGA / YTE; LALAPG / YTE; N297A / LS; D265A / LS; LALA / LS; LAGA / LS; LALAGA / LS; LALAPG / LS; N297A / DHS; D265A / DHS; LALA / DHS; LAGA / DHS; LALAGA / DHS; LALAPG / DHS; SP / YTE; SPLE / YTE; SP / LS; SPLE / LS; SP / DHS; SPLE / DHS; N297A / LA; D265A / LA; LALA / LA; LEAVE / NOT; INSTALL / NOT; LALAPG / LA; N297A / N434A; D265A / N434A; LALA / N434A; LAGA / N434A; LALAGA / N434A; LALAPG / N434A; N297A / N434W; D265A / N434W; LALA / N434W; LAGA / N434W; LALAGA / N434W; LALAPG / N434W; N297A / DQ; D265A / DQ; LALA / DQ; LAGA / DQ; LALAGA / DQ; LALAPG / DQ; N297A / DW; D265A / DW; LALA / DW; LAGA / DW; LALAGA / DW; LALAPG / DW; N297A / YD; D265A / YD; LALA / YD; LAGA / YD; LALAGA / YD;LALAPG / YD; N297A / QVV; D265A / QVV; LALA / QVV; LAGA / QVV, LALAGA / QVV; LALAPG / QVV; N297A / DDRVV; D265A / DDRVV; LALA / DDRVV; LAGA / DDRVV; LALAGA / DDRVV; SP / Q311R / M428L; SPLE / Q311R / M428L; N297A / Q311R / M428L; D265A / Q311R / M428L; LALA / Q311R / M428L; LAGA / Q311R / M428L; The modified Fc includes specific combinations of amino acid substitutions selected from the group consisting of LALAGA / Q311R / M428L and LALAPG / Q311R / M428L. In some embodiments, the modified Fc includes specific combinations of amino acid substitutions selected from the group consisting of M428L / N434S(LS) and M252Y / S254T / T256E(YTE). In some embodiments, the modified Fc includes modifications of M428L / N434S(LS) (e.g., SEQ ID NO: 219, SEQ ID NO: 236, SEQ ID NO: 243). In some embodiments, the modified Fc includes modifications of M252Y / S254T / T256E(YTE) (e.g., SEQ ID NO: 212, SEQ ID NO: 233, SEQ ID NO: 242).

[0258] In some embodiments, the TL1A-binding proteins described herein include modifications that improve their ability to mediate effector function. Such modifications are known in the art and include defucosylation or engineering of the affinity of Fc to activating receptors, primarily to FCGR3a in relation to antibody-dependent cell-mediated cytotoxicity (ADCC) and to C1q in relation to complement-dependent cell-mediated cytotoxicity (CDC).

[0259] In some embodiments, the antibodies pro...

Claims

1. A TL1A-binding protein, (i) CDR1 having the amino acid sequence described in SEQ ID NO: 5 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 5, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 15 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 15, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 25 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 25, (i) CDR1 having the amino acid sequence described in SEQ ID NO: 35 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 35, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 45 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 45, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 55 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 55; or (i) CDR1 having the amino acid sequence described in SEQ ID NO: 6 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 6, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 16 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 16, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 26 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 26, (i) CDR1 having the amino acid sequence described in SEQ ID NO: 36 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 36, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 46 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 46, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 56 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 56; or (i) CDR1 having the amino acid sequence described in SEQ ID NO: 7 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 7, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 17 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 17, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 27 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 27, (i) CDR1 having the amino acid sequence described in SEQ ID NO: 37 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 37, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 47 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 47, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 57 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 57; or (i) CDR1 having the amino acid sequence described in SEQ ID NO: 8 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 8, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 18 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 18, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 28 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 28, (i) CDR1 having the amino acid sequence described in SEQ ID NO: 38 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 38, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 48 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 48, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 58 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 58; or (i) CDR1 having the amino acid sequence described in SEQ ID NO: 9 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 9, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 19 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 19, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 29 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 29, (i) CDR1 having the amino acid sequence described in SEQ ID NO: 39 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 39, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 49 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 49, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 59 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 59; or (i) CDR1 having the amino acid sequence described in SEQ ID NO: 10 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 10, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 20 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 20, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 30 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 30, (i) CDR1 having the amino acid sequence described in SEQ ID NO: 40 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 40, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 50 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 50, and (iii) a light chain variable region (VL) comprising CDR3 having the amino acid sequence described in SEQ ID NO: 60 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 60; or (i) CDR1 having the amino acid sequence described in SEQ ID NO: 1 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 1, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 11 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 11, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 21 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 21, (i) CDR1 having the amino acid sequence described in SEQ ID NO: 31 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 31, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 41 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 41, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 51 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 51; or (i) CDR1 having the amino acid sequence described in SEQ ID NO: 2 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 2, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 12 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 12, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 22 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 22, (i) CDR1 having the amino acid sequence described in SEQ ID NO: 32 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 32; (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 42 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 42; and (iii) a light chain variable region (VL) comprising CDR3 having the amino acid sequence described in SEQ ID NO: 52 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 52; or (i) CDR1 having the amino acid sequence described in SEQ ID NO: 3 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 3, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 13 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 13, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 23 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 23, (i) CDR1 having the amino acid sequence described in SEQ ID NO: 33 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 33, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 43 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 43, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 53 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 53; or (i) CDR1 having the amino acid sequence described in SEQ ID NO: 4 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 4, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 14 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 14, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 24 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 24, (i) CDR1 having the amino acid sequence described in SEQ ID NO: 34 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 34, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 44 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 44, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 54 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 54; or (i) CDR1 having the amino acid sequence described in SEQ ID NO: 321 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 321, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 430 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 430, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 539 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 539, (i) CDR1 having the amino acid sequence described in SEQ ID NO: 648 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 648, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 757 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 757, and (iii) a light chain variable region (VL) comprising CDR3 having the amino acid sequence described in SEQ ID NO: 866 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 866; or (i) CDR1 having the amino acid sequence described in SEQ ID NO: 341 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 341, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 450 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 450, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 559 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 559, (i) CDR1 having the amino acid sequence described in SEQ ID NO: 668 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 668, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 777 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 777, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 886 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 886; or (i) CDR1 having the amino acid sequence described in SEQ ID NO: 345 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 345, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 454 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 454, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 563 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 563, (i) CDR1 having the amino acid sequence described in SEQ ID NO: 672 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 672, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 781 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 781, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 890 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 890; or (i) CDR1 having the amino acid sequence described in SEQ ID NO: 349 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 349, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 458 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 458, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 567 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 567, (i) CDR1 having the amino acid sequence described in SEQ ID NO: 676 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 676, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 785 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 785, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 894 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 894; or (i) CDR1 having the amino acid sequence described in SEQ ID NO: 351 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 351, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 460 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 460, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 569 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 569, (i) CDR1 having the amino acid sequence described in SEQ ID NO: 678 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 678, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 787 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 787, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 896 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 896; or (i) CDR1 having the amino acid sequence described in SEQ ID NO: 354 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 354, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 463 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 463, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 572 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 572, (i) CDR1 having the amino acid sequence described in SEQ ID NO: 681 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 681, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 790 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 790, and (iii) a light chain variable region (VL) comprising CDR3 having the amino acid sequence described in SEQ ID NO: 899 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 899; or (i) CDR1 having the amino acid sequence described in SEQ ID NO: 365 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 365, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 474 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 474, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 583 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 583, (i) CDR1 having the amino acid sequence described in SEQ ID NO: 692 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 692, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 801 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 801, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 910 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 910; or (i) CDR1 having the amino acid sequence described in SEQ ID NO: 371 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 371, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 480 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 480, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 589 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 589, (i) CDR1 having the amino acid sequence described in SEQ ID NO: 698 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 698, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 807 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 807, and (iii) a light chain variable region (VL) comprising CDR3 having the amino acid sequence described in SEQ ID NO: 916 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 916; or (i) CDR1 having the amino acid sequence described in SEQ ID NO: 372 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 372, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 481 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 481, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 590 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 590, (i) CDR1 having the amino acid sequence described in SEQ ID NO: 699 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 699, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 808 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 808, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 917 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 917; or (i) CDR1 having the amino acid sequence described in SEQ ID NO: 373 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 373, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 482 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 482, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 591 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 591, (i) CDR1 having the amino acid sequence described in SEQ ID NO: 700 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 700, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 809 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 809, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 918 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 918; or (i) CDR1 having the amino acid sequence described in SEQ ID NO: 388 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 388, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 497 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 497, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 606 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 606, (i) CDR1 having the amino acid sequence described in SEQ ID NO: 715 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 715, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 824 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 824, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 933 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 933; or (i) CDR1 having the amino acid sequence described in SEQ ID NO: 394 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 394, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 503 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 503, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 612 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 612, (i) CDR1 having the amino acid sequence described in SEQ ID NO: 721 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 721, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 830 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 830, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 939 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 939; or (i) CDR1 having the amino acid sequence described in SEQ ID NO: 400 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 400, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 509 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 509, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 618 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 618, (i) CDR1 having the amino acid sequence described in SEQ ID NO: 727 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 727, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 836 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 836, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 945 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 945, and A TL1A-binding protein containing [this protein].

2. (i) CDR1 having the amino acid sequence described in SEQ ID NO: 5, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 15, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 25, a heavy chain variable region (VH) (i) a light chain variable region (VL) comprising CDR1 having the amino acid sequence described in SEQ ID NO: 35, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 45, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 55; or (i) CDR1 having the amino acid sequence described in SEQ ID NO: 6, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 16, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 26, a heavy chain variable region (VH) (i) a light chain variable region (VL) comprising CDR1 having the amino acid sequence described in SEQ ID NO: 36, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 46, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 56; or (i) CDR1 having the amino acid sequence described in SEQ ID NO: 7, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 17, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 27, a heavy chain variable region (VH) (i) a light chain variable region (VL) comprising CDR1 having the amino acid sequence described in SEQ ID NO: 37, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 47, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 57; or (i) CDR1 having the amino acid sequence described in SEQ ID NO: 8, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 18, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 28, a heavy chain variable region (VH) (i) a light chain variable region (VL) comprising CDR1 having the amino acid sequence described in SEQ ID NO: 38, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 48, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 58; or (i) CDR1 having the amino acid sequence described in SEQ ID NO: 9, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 19, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 29, a heavy chain variable region (VH) (i) a light chain variable region (VL) comprising CDR1 having the amino acid sequence described in SEQ ID NO: 39, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 49, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 59; or (i) CDR1 having the amino acid sequence described in SEQ ID NO: 10, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 20, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 30, a heavy chain variable region (VH) (i) a light chain variable region (VL) comprising CDR1 having the amino acid sequence described in SEQ ID NO: 40, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 50, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 60; or (i) CDR1 having the amino acid sequence described in SEQ ID NO: 1, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 11, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 21, a heavy chain variable region (VH) (i) a light chain variable region (VL) comprising CDR1 having the amino acid sequence described in SEQ ID NO: 31, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 41, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 51; or (i) CDR1 having the amino acid sequence described in SEQ ID NO: 2, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 12, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 22, a heavy chain variable region (VH) (i) a light chain variable region (VL) comprising CDR1 having the amino acid sequence described in SEQ ID NO: 32, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 42, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 52; or (i) a heavy chain variable region (VH) comprising CDR1 having the amino acid sequence described in SEQ ID NO: 3, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 13, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 23, (i) a light chain variable region (VL) comprising CDR1 having the amino acid sequence described in SEQ ID NO: 33, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 43, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 53; or (i) CDR1 having the amino acid sequence described in SEQ ID NO: 4, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 14, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 24, a heavy chain variable region (VH) (i) a light chain variable region (VL) comprising CDR1 having the amino acid sequence described in SEQ ID NO: 34, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 44, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 54; or (i) CDR1 having the amino acid sequence described in SEQ ID NO: 321, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 430, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 539, a heavy chain variable region (VH) (i) a light chain variable region (VL) comprising CDR1 having the amino acid sequence described in SEQ ID NO: 648, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 757, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 866; or (i) CDR1 having the amino acid sequence described in SEQ ID NO: 341, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 450, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 559, a heavy chain variable region (VH) (i) a light chain variable region (VL) comprising CDR1 having the amino acid sequence described in SEQ ID NO: 668, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 777, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 886; or (i) CDR1 having the amino acid sequence described in SEQ ID NO: 345, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 454, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 563, a heavy chain variable region (VH) (i) a light chain variable region (VL) comprising CDR1 having the amino acid sequence described in SEQ ID NO: 672, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 781, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 890; or (i) CDR1 having the amino acid sequence described in SEQ ID NO: 349, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 458, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 567, a heavy chain variable region (VH) (i) a light chain variable region (VL) comprising CDR1 having the amino acid sequence described in SEQ ID NO: 676, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 785, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 894; or (i) CDR1 having the amino acid sequence described in SEQ ID NO: 351, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 460, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 569, a heavy chain variable region (VH) (i) a light chain variable region (VL) comprising CDR1 having the amino acid sequence described in SEQ ID NO: 678, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 787, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 896; or (i) CDR1 having the amino acid sequence described in SEQ ID NO: 354, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 463, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 572, a heavy chain variable region (VH) (i) a light chain variable region (VL) comprising CDR1 having the amino acid sequence described in SEQ ID NO: 681, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 790, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 899; or (i) CDR1 having the amino acid sequence described in SEQ ID NO: 365, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 474, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 583, a heavy chain variable region (VH) (i) a light chain variable region (VL) comprising CDR1 having the amino acid sequence described in SEQ ID NO: 692, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 801, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 910; or (i) CDR1 having the amino acid sequence described in SEQ ID NO: 371, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 480, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 589, a heavy chain variable region (VH) (i) a light chain variable region (VL) comprising CDR1 having the amino acid sequence described in SEQ ID NO: 698, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 807, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 916; or (i) CDR1 having the amino acid sequence described in SEQ ID NO: 372, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 481, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 590, a heavy chain variable region (VH) (i) a light chain variable region (VL) comprising CDR1 having the amino acid sequence described in SEQ ID NO: 699, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 808, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 917; or (i) CDR1 having the amino acid sequence described in SEQ ID NO: 373, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 482, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 591, a heavy chain variable region (VH) (i) a light chain variable region (VL) comprising CDR1 having the amino acid sequence described in SEQ ID NO: 700, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 809, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 918; or (i) CDR1 having the amino acid sequence described in SEQ ID NO: 388, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 497, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 606, a heavy chain variable region (VH) (i) a light chain variable region (VL) comprising CDR1 having the amino acid sequence described in SEQ ID NO: 715, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 824, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 933; or (i) CDR1 having the amino acid sequence described in SEQ ID NO: 394, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 503, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 612, a heavy chain variable region (VH) (i) a light chain variable region (VL) comprising CDR1 having the amino acid sequence described in SEQ ID NO: 721, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 830, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 939; or (i) CDR1 having the amino acid sequence described in SEQ ID NO: 400, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 509, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 618, a heavy chain variable region (VH) (i) CDR1 having the amino acid sequence described in SEQ ID NO: 727, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 836, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 945, comprising a light chain variable region (VL) A TL1A-binding protein according to claim 1, comprising:

3. A TL1A-binding protein according to claim 1 or claim 2, comprising an immunoglobulin Fc domain.

4. (a) A heavy chain variable region (VH) comprising (i) CDR1 having an amino acid sequence described in any one of SEQ ID NOs. 5 to 10, or an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NOs. 5 to 10, (ii) CDR2 having an amino acid sequence described in any one of SEQ ID NOs. 15 to 20, or an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NOs. 15 to 20, and (iii) CDR3 having an amino acid sequence described in any one of SEQ ID NOs. 25 to 30, or an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NOs. 25 to 30, (b) A light chain variable region (VL) comprising (i) CDR1 having an amino acid sequence described in any one of SEQ ID NOs. 35 to 40, or an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NOs. 35 to 40, (ii) CDR2 having an amino acid sequence described in any one of SEQ ID NOs. 45 to 50, or an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NOs. 45 to 50, and (iii) CDR3 having an amino acid sequence described in any one of SEQ ID NOs. 55 to 60, or an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NOs. 55 to 60. A TL1A-binding protein containing this protein.

5. The TL1A-binding protein according to claim 4, wherein VH comprises a sequence having at least 80% sequence identity with any one amino acid sequence of SEQ ID NOs. 185 to 190, and VL comprises a sequence having at least 80% sequence identity with any one amino acid sequence of SEQ ID NOs. 195 to 200.

6. The VH contains a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 185, and the VL contains a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO:

195. The VH contains a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 186, and the VL contains a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO:

196. The VH contains a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 187, and the VL contains a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO:

197. The VH comprises a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 188, and the VL comprises a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO:

198. The VH contains a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 189, and the VL contains a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 199, or The VH contains a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 190, and the VL contains a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO:

200. The TL1A-binding protein according to claim 4 or claim 5.

7. A TL1A-binding protein, (i) CDR1 having the amino acid sequence described in SEQ ID NO: 5 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 5, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 15 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 15, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 25 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 25, (i) CDR1 having the amino acid sequence described in SEQ ID NO: 35 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 35, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 45 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 45, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 55 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 55; or (i) CDR1 having the amino acid sequence described in SEQ ID NO: 6 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 6, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 16 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 16, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 26 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 26, (i) CDR1 having the amino acid sequence described in SEQ ID NO: 36 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 36, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 46 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 46, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 56 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 56; or (i) CDR1 having the amino acid sequence described in SEQ ID NO: 7 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 7, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 17 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 17, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 27 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 27, (i) CDR1 having the amino acid sequence described in SEQ ID NO: 37 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 37, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 47 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 47, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 57 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 57; or (i) CDR1 having the amino acid sequence described in SEQ ID NO: 8 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 8, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 18 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 18, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 28 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 28, (i) CDR1 having the amino acid sequence described in SEQ ID NO: 38 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 38, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 48 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 48, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 58 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 58; or (i) CDR1 having the amino acid sequence described in SEQ ID NO: 9 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 9, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 19 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 19, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 29 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 29, (i) CDR1 having the amino acid sequence described in SEQ ID NO: 39 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 39, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 49 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 49, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 59 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 59; or (i) CDR1 having the amino acid sequence described in SEQ ID NO: 10 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 10, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 20 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 20, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 30 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 30, (i) CDR1 having the amino acid sequence described in SEQ ID NO: 40 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 40, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 50 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 50, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 60 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 60, and A TL1A-binding protein containing [this protein].

8. (i) CDR1 having the amino acid sequence described in SEQ ID NO: 5, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 15, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 25, a heavy chain variable region (VH) (i) a light chain variable region (VL) comprising CDR1 having the amino acid sequence described in SEQ ID NO: 35, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 45, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 55; or (i) CDR1 having the amino acid sequence described in SEQ ID NO: 6, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 16, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 26, a heavy chain variable region (VH) (i) a light chain variable region (VL) comprising CDR1 having the amino acid sequence described in SEQ ID NO: 36, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 46, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 56; or (i) CDR1 having the amino acid sequence described in SEQ ID NO: 7, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 17, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 27, a heavy chain variable region (VH) (i) a light chain variable region (VL) comprising CDR1 having the amino acid sequence described in SEQ ID NO: 37, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 47, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 57; or (i) CDR1 having the amino acid sequence described in SEQ ID NO: 8, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 18, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 28, a heavy chain variable region (VH) (i) a light chain variable region (VL) comprising CDR1 having the amino acid sequence described in SEQ ID NO: 38, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 48, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 58; or (i) CDR1 having the amino acid sequence described in SEQ ID NO: 9, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 19, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 29, a heavy chain variable region (VH) (i) a light chain variable region (VL) comprising CDR1 having the amino acid sequence described in SEQ ID NO: 39, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 49, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 59; or (i) CDR1 having the amino acid sequence described in SEQ ID NO: 10, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 20, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 30, a heavy chain variable region (VH) (i) CDR1 having the amino acid sequence described in SEQ ID NO: 40, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 50, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 60, and a light chain variable region (VL) The TL1A-binding protein according to claim 7, comprising:

9. (i) CDR1 having an amino acid sequence described in any one of SEQ ID NOs. 5 to 10, or an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NOs. 5 to 10; (ii) CDR2 having an amino acid sequence described in any one of SEQ ID NOs: 15 to 20, or an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NOs: 15 to 20; and (iii) CDR3 having an amino acid sequence described in any one of SEQ ID NOs. 25-30, or having an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NOs. 25-30. A TL1A-binding protein containing a heavy chain variable region (VH).

10. (i) CDR1 having an amino acid sequence described in any one of SEQ ID NOs: 35 to 40, or an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NOs: 35 to 40; (ii) CDR2 having an amino acid sequence described in any one of SEQ ID NOs. 45 to 50, or an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NOs. 45 to 50; and (iii) CDR3 having an amino acid sequence described in any one of SEQ ID NOs. 55 to 60, or having an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NOs. 55 to 60. A TL1A-binding protein containing a light chain variable region (VL) that includes [specific component].

11. A TL1A-binding protein according to any one of claims 1 to 8, which is an antibody having an IgG1, IgG2, or IgG4 immunoglobulin Fc domain.

12. The TL1A-binding protein according to claim 11, wherein the Fc domain is a modified Fc that extends the half-life of the TL1A-binding protein compared to a TL1A-binding protein that does not contain the modified Fc domain.

13. The TL1A-binding protein according to claim 11 or claim 12, wherein the Fc domain comprises amino acid-modified L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

14. A TL1A-binding antibody that specifically binds to one of the following amino acid residues—Val 102, Arg 103, Glun 104, Glu 120, Glu 122, Leu 123, and Arg 156—on the TL1A polypeptide containing SEQ ID NO: 2493.

15. A TL1A-binding antibody according to claim 14, which specifically binds to the TL1A sequence at the amino acid residues Val 102, Arg 103, Glun 104, Glu 120, Glu 122, Leu 123, and Arg 156.

16. The TL1A-binding protein is present in TL1A at a K concentration of less than approximately 0.5 nanomolar (nM). Ｄ A TL1A-binding protein or TL1A-binding antibody according to any one of claims 1 to 15, which binds to the TL1A-binding antibody.

17. a) A heavy chain variable region (VH) comprising (i) CDR1 having an amino acid sequence described in any one of SEQ ID NOs: 1-4 and 313-421, or an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NOs: 1-4 and 313-421; (ii) CDR2 having an amino acid sequence described in any one of SEQ ID NOs: 11-14 and 422-530, or an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NOs: 11-14 and 422-530; and (iii) CDR3 having an amino acid sequence described in any one of SEQ ID NOs: 21-24 and 531-639, or an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NOs: 21-24 and 531-639; b) A light chain variable region (VL) comprising (i) CDR1 having an amino acid sequence described in any one of SEQ ID NOs: 31-34 and 640-748, or an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NOs: 1-4 and 313-421; (ii) CDR2 having an amino acid sequence described in any one of SEQ ID NOs: 41-44 and 749-857, or an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NOs: 41-44 and 749-857; and (iii) CDR3 having an amino acid sequence described in any one of SEQ ID NOs: 51-54 and 858-966, or an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NOs: 51-54 and 858-966. A TL1A-binding protein containing this protein.

18. The TL1A-binding protein according to claim 17, wherein the VH comprises a sequence having at least 80% sequence identity with respect to any one amino acid sequence of sequence numbers 181-184 and 2275-2383, and the VL comprises a sequence having at least 80% sequence identity with respect to any one amino acid sequence of sequence numbers 191-194 and 2384-2492.

19. The VH comprises a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 181, and the VL comprises a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 191; The VH comprises a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 182, and the VL comprises a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 192; The VH comprises a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 183, and the VL comprises a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 193; The VH comprises a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 184, and the VL comprises a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 194; The VH comprises a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2283, and the VL comprises a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2392; The VH comprises a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2303, and the VL comprises a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2412; The VH comprises a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2307, and the VL comprises a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2416; The VH comprises a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2311, and the VL comprises a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2420; The VH comprises a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2313, and the VL comprises a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2422; The VH comprises a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2316, and the VL comprises a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2425; The VH comprises a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2327, and the VL comprises a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2436; The VH comprises a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2333, and the VL comprises a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2442; The VH comprises a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2334, and the VL comprises a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2443; The VH comprises a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2335, and the VL comprises a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2444; The VH comprises a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2350, and the VL comprises a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2459; The VH comprises a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2356, and the VL comprises a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2465; or The VH comprises a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2362, and the VL comprises a sequence having at least 80% sequence identity with SEQ ID NO: 2471. The TL1A-binding protein according to claim 17 or claim 18.

20. (i) CDR1 having the amino acid sequence described in SEQ ID NO: 1 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 1, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 11 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 11, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 21 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 21, (i) CDR1 having the amino acid sequence described in SEQ ID NO: 31 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 31, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 41 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 41, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 51 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 51; or (i) CDR1 having the amino acid sequence described in SEQ ID NO: 2 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 2, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 12 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 12, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 22 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 22, (i) CDR1 having the amino acid sequence described in SEQ ID NO: 32 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 32; (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 42 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 42; and (iii) a light chain variable region (VL) comprising CDR3 having the amino acid sequence described in SEQ ID NO: 52 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 52; or (i) CDR1 having the amino acid sequence described in SEQ ID NO: 3 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 3, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 13 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 13, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 23 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 23, (i) CDR1 having the amino acid sequence described in SEQ ID NO: 33 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 33, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 43 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 43, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 53 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 53; or (i) CDR1 having the amino acid sequence described in SEQ ID NO: 4 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 4, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 14 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 14, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 24 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 24, (i) CDR1 having the amino acid sequence described in SEQ ID NO: 34 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 34, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 44 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 44, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 54 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 54; or (i) CDR1 having the amino acid sequence described in SEQ ID NO: 321 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 321, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 430 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 430, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 539 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 539, (i) CDR1 having the amino acid sequence described in SEQ ID NO: 648 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 648, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 757 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 757, and (iii) a light chain variable region (VL) comprising CDR3 having the amino acid sequence described in SEQ ID NO: 866 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 866; or (i) CDR1 having the amino acid sequence described in SEQ ID NO: 341 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 341, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 450 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 450, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 559 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 559, (i) CDR1 having the amino acid sequence described in SEQ ID NO: 668 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 668, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 777 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 777, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 886 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 886; or (i) CDR1 having the amino acid sequence described in SEQ ID NO: 345 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 345, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 454 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 454, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 563 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 563, (i) CDR1 having the amino acid sequence described in SEQ ID NO: 672 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 672, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 781 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 781, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 890 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 890; or (i) CDR1 having the amino acid sequence described in SEQ ID NO: 349 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 349, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 458 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 458, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 567 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 567, (i) CDR1 having the amino acid sequence described in SEQ ID NO: 676 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 676, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 785 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 785, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 894 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 894; or (i) CDR1 having the amino acid sequence described in SEQ ID NO: 351 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 351, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 460 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 460, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 569 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 569, (i) CDR1 having the amino acid sequence described in SEQ ID NO: 678 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 678, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 787 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 787, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 896 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 896; or (i) CDR1 having the amino acid sequence described in SEQ ID NO: 354 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 354, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 463 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 463, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 572 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 572, (i) CDR1 having the amino acid sequence described in SEQ ID NO: 681 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 681, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 790 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 790, and (iii) a light chain variable region (VL) comprising CDR3 having the amino acid sequence described in SEQ ID NO: 899 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 899; or (i) CDR1 having the amino acid sequence described in SEQ ID NO: 365 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 365, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 474 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 474, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 583 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 583, (i) CDR1 having the amino acid sequence described in SEQ ID NO: 692 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 692, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 801 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 801, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 910 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 910; or (i) CDR1 having the amino acid sequence described in SEQ ID NO: 371 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 371, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 480 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 480, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 589 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 589, (i) CDR1 having the amino acid sequence described in SEQ ID NO: 698 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 698, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 807 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 807, and (iii) a light chain variable region (VL) comprising CDR3 having the amino acid sequence described in SEQ ID NO: 916 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 916; or (i) CDR1 having the amino acid sequence described in SEQ ID NO: 372 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 372, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 481 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 481, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 590 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 590, (i) CDR1 having the amino acid sequence described in SEQ ID NO: 699 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 699, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 808 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 808, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 917 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 917; or (i) CDR1 having the amino acid sequence described in SEQ ID NO: 373 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 373, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 482 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 482, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 591 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 591, (i) CDR1 having the amino acid sequence described in SEQ ID NO: 700 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 700, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 809 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 809, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 918 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 918; or (i) CDR1 having the amino acid sequence described in SEQ ID NO: 388 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 388, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 497 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 497, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 606 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 606, (i) CDR1 having the amino acid sequence described in SEQ ID NO: 715 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 715, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 824 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 824, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 933 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 933; or (i) CDR1 having the amino acid sequence described in SEQ ID NO: 394 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 394, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 503 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 503, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 612 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 612, (i) CDR1 having the amino acid sequence described in SEQ ID NO: 721 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 721, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 830 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 830, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 939 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 939; or (i) CDR1 having the amino acid sequence described in SEQ ID NO: 400 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 400, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 509 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 509, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 618 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 618, (i) CDR1 having the amino acid sequence described in SEQ ID NO: 727 or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 727, (ii) CDR2 having the amino acid sequence described in SEQ ID NO: 836 or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 836, and (iii) CDR3 having the amino acid sequence described in SEQ ID NO: 945 or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 945, and A TL1A-binding protein containing this protein.

21. (i) CDR1 having an amino acid sequence described in any one of SEQ ID NOs: 1-4 and 313-421, or an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NOs: 1-4 and 313-421; (ii) CDR2 having an amino acid sequence described in any one of SEQ ID NOs: 11-14 and 422-530, or an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NOs: 11-14 and 422-530; and (iii) CDR3 having an amino acid sequence described in any one of SEQ ID NOs. 21-24 and 531-639, or an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NOs. 21-24 and 531-639. A TL1A-binding protein containing a heavy chain variable region (VH).

22. (i) CDR1 having an amino acid sequence described in any one of SEQ ID NOs: 31-34 and 640-748, or an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NOs: 31-34 and 640-748; (ii) CDR2 having an amino acid sequence described in any one of SEQ ID NOs: 41-44 and 749-857, or an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NOs: 41-44 and 749-857; and (iii) CDR3 having an amino acid sequence described in any one of SEQ ID NOs. 51-54 and 858-966, or an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NOs. 51-54 and 858-966. A TL1A-binding protein containing a light chain variable region (VL) that includes [specific component].

23. A TL1A-binding protein according to any one of claims 17 to 20, which is an antibody comprising an IgG1, IgG2, or IgG4 immunoglobulin Fc domain.

24. The TL1A-binding protein according to claim 23, wherein the Fc domain is a modified Fc that extends the half-life of the TL1A-binding protein compared to a TL1A-binding protein that does not contain the modified Fc domain.

25. The TL1A-binding protein according to claim 24, wherein the modified Fc domain comprises amino acid modified L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

26. A TL1A-binding antibody that specifically binds to one of the following amino acid residues, Lys243, Lys240, Thr239, Tyr238, Asp237, Val236, Leu235, Ser234, Ile233, Asp232, Met158, Arg156, Trp119, His118, Lys111, Phe110, His109, Gln108, Thr107, Pro106, Thr105, Gln104, Arg103, Val102, and Val101, to the TL1A polypeptide containing SEQ ID NO: 2493.

27. A TL1A-binding antibody that specifically binds to one of the following amino acid residues, Lys240, Thr239, Tyr238, Asp237, Val236, Leu235, Ser234, Glun104, and Arg103, for the TL1A polypeptide containing SEQ ID NO: 2493.

28. TL1A contains K at a concentration of less than approximately 0.5 nanomolars (nM). Ｄ A TL1A-binding protein according to any one of claims 17 to 27, which binds to the TL1A.

29. A method for treating an inflammatory disease in a patient requiring treatment for an inflammatory disease, A TL1A-binding protein according to any one of claims 1 to 28, or A TL1A-binding antibody that specifically binds to one of the amino acid residues Lys240, Thr239, Tyr238, Asp237, Val236, Leu235, Ser234, Glun104, and Arg103 of the TL1A polypeptide containing SEQ ID NO: 2493, or A TL1A-binding antibody that specifically binds to the TL1A polypeptide containing SEQ ID NO: 2493 at one of the following amino acid residues: Val 102, Arg 103, Glun 104, Glu 120, Glu 122, Leu 123, and Arg 156. A method comprising the step of subcutaneously or intravenously administering an effective amount of to the patient.

30. The method according to claim 29, wherein the inflammatory disease is an inflammatory disease of the gastrointestinal tract or inflammatory bowel disease.

31. The method according to claim 30, wherein the inflammatory bowel disease is Crohn's disease.

32. The method according to claim 31, wherein the inflammatory bowel disease is ulcerative colitis.

33. The method according to claim 32, wherein the inflammatory disease is psoriasis, psoriatic arthritis, or hidradenitis suppurativa.

34. The method according to any one of claims 29 to 33, wherein the administration of the TL1A-binding protein is by subcutaneous administration.

35. The method according to any one of claims 29 to 33, wherein the administration of the TL1A-binding protein is intravenous.

36. The method according to any one of claims 29 to 33, comprising the step of administering the TL1A-binding protein to the patient two or more times at intervals of about two weeks to about twelve weeks or longer.

37. A composition comprising a TL1A-binding protein according to any one of claims 1 to 28 and a pharmaceutically acceptable carrier.

38. A liquid composition for injection comprising a TL1A-binding protein and a pharmaceutically acceptable carrier as described in any one of claims 1 to 28.

39. An isolated nucleic acid encoding a TL1A-binding protein according to any one of claims 1 to 28.

40. Recombinant host cells comprising isolated nucleic acids as described in claim 39.

41. A method for producing a TL1A-binding protein that specifically binds to a TL1A polypeptide containing SEQ ID NO: 2493 at one of the amino acid residues in Table 12, 13, or 14, wherein the TL1A antigen-binding protein is an antibody.

42. The method according to claim 41, wherein the TL1A-binding antibody specifically binds to one of the amino acid residues Lys240, Thr239, Tyr238, Asp237, Val236, Leu235, Ser234, Glun104, and Arg103 of the TL1A polypeptide containing SEQ ID NO: 2493.

43. The method according to claim 41, wherein the TL1A-binding antibody specifically binds to one of the amino acid residues Val 102, Arg 103, Glun 104, Glu 120, Glu 122, Leu 123, and Arg 156 of the TL1A polypeptide containing SEQ ID NO: 2493.

44. A method for obtaining an antibody that specifically binds to a particular epitope portion of a TL1A sequence containing SEQ ID NO: 2493 or SEQ ID NO: 2494, a) A step of evaluating whether the antibody specifically binds to a certain epitope portion, wherein the certain epitope portion is i) Recognized by an antibody according to any one of claims 1 to 28; or ii) Having the amino acid residues Val 102, Arg 103, Glun 104, Glu 120, Glu 122, Leu 123, and Arg 156 of SEQ ID NO: 2493, or iii) Steps comprising having the amino acid residues Lys240, Thr239, Tyr238, Asp237, Val236, Leu235, Ser234, Glun104, and Arg103 of Sequence ID No. 2493, b) The step of isolating or selecting an antibody that binds to a specific epitope region. Methods that include...

Images